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ABSTRACT OF DISSERTATION 
ISOPRENOID ANALOGS AS CHEMICAL GENETIC TOOLS TO PROVIDE INSIGHTS 
INTO FARNESYL TRANSFERASE TARGET SELECTION AND CELLULAR ACTIVITY 
 
Protein farnesylation is an essential post-translational modification required for 
the function of numerous cellular proteins including the oncoprotein Ras. The farnesyl 
transferase (FTase) catalyzed reaction is unique because farnesyl diphosphate (FPP), 
the farnesyl group donor for the reaction, forms a significant portion of a target protein 
binding site. The major goal of this research was to exploit this unique property of the 
FTase reaction and determine if changing the structure of the farnesyl donor group 
would affect FTase protein targeting. A small library of structural analogues of FPP was 
synthesized. Michelis-Menten steady-state kinetic analyses and competition reactions 
were used to determine the effect of these structural modifications on FTase targeting. 
We found that the analogues did affect FTase protein selectivity and that this could be 
exploited to induce unnatural target selectivity into the enzyme. 
The second goal of this research was to determine the effect of FPP analogues 
on the function of FTase target proteins. To test the effect of these analogues we 
determined whether the unnatural lipid could ablate oncogenic H-Ras biological function 
in a Xenopus laevis model system. Several analogues were able to disrupt oncogenic 
H-Ras function while others mimicked the activity of FPP. These results indicated that 
some of the FPP analogues may act a prenyl group function inhibitors that could lead to 
an important new class of anti-cancer therapeutics.  
Another major goal of this research was to use the FPP analogues as unnatural 
probes for the endogenous cellular activity of FTase target proteins. We developed 
antibodies to two of the unnatural FPP analogues to study their activity in cell 
cultureUtilizing these antibodies we found that alcohol prodrugs of the FPP analogues 
could be incorporated into cellular proteins in an FTase dependent manner. The ability 
of cell permeant analogues to be incorporated into live cells enhances the chances that 
such a molecule could be used to modify oncogenic cellular proteins with a prenyl group 
function inhibitor.  
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CHAPTER 1 BACKGROUND AND OBJECTIVES 
Background 
Membranes and Lipid Anchoring in Cell Biology  
Biological membranes are uniquely organized arrays of lipids and proteins that 
constitute the boundaries of cells and intracellular organelles [1, 2]. They provide a 
surface for many important biological processes to take place, and contain proteins that 
mediate the transport of metabolites, macromolecules and ions. Important biological 
processes ranging from electron transport to muscle contraction all depend on 
membranes and membrane proteins. Proteins are the “workhorses” of a cell and often 
require membrane localization to exert their cellular function. Proteins can interact with 
membranes in a variety of ways. Peripherally bound membrane proteins interact with 
polar groups on the membrane surface, through electrostatic interactions; integrally 
membrane bound proteins are molecules with large hydrophobic regions embedded into 
lipid bilayers; and a third class of proteins associate with membranes via small lipid 
groups attached to the protein. Four different types of lipid anchoring motifs have been 
identified to date (Figure 1-1): amide linked myristoyl anchors, thioester linked fatty acyl 
anchors, thioether linked prenyl anchors, and amide linked glycosyl phosphatidylinositol 
(GPI) anchors[3-6].  
 
1 
 
Figure 1-1 Lipid Anchoring Motifs 
 
Note: GPI anchored proteins have variable length hydrophobic chains 
 
2 
 
Prenyl anchors are made up of isoprenoids, which are molecules derived from 
the mevalonate biosynthetic pathway (Figure 1-2) [6-9]. Isoprenoids are formed through 
a head to tail condensation of isopentyl diphosphate and dimethylallyl diphosphate to 
give the precursor molecule geranyl diphosphate 1(GPP) [10-12]. Sequential additions 
of the isopentyl diphosphate to geranyl diphosphate leads to elongation of the 
isoprenoid chain to 3 and 4 isoprene units to give farnesyl diphosphate 2 (FPP) and 
geranylgeranyl diphosphate 3 (GGPP), respectively. FPP can be divided into three 
isoprene units the first (α) isoprene which is the isoprene unit closest to the 
diphosphate, then the β-isoprene which is the middle isoprene unit, and the third 
isoprene which is often referred to as the terminal or ω-isoprene unit. The farnesyl and 
geranylgeranyl groups of FPP and GGPP are post-translationally added to proteins in a 
reaction catalyzed by protein prenyltransferase enzymes. The mevalonate biosynthetic 
pathway is essential for the production of FPP and GGPP as well as other biomolecules 
including cholesterol, numerous steroid hormones, ubiquinone and dolichol [6]. 
 
3 
 
Figure 1-2 Mevalonate Pathway 
 
 
Note: FPP isoprene unit designation (α, β and ω). 
 
 
4 
 
Prenylated proteins have received a great deal of attention in recent years due to 
the fact that the protein product of the ras oncogene requires post-translational 
attachment of a prenyl group in order to function [13-18]. The ras oncogene is present in 
10-30% of all human cancers and has become a major target of anti-cancer 
therapeutics [19]. Ras proteins are small molecular weight GTPases (Enzymes that bind 
and hydrolyze Guanosine Triphosphate or GTP) that act as molecular “on/off” switches 
that control cellular signaling cascades leading to cell proliferation and cell growth [19]. 
The Ras switching mechanism occurs through the cycling of the protein between a GTP 
bound “on” state, to a Guanosine diphosphate (GDP) bound “off” state. Ras proteins 
must be localized to membranes to carryout this crucial molecular switching function, 
and membrane association requires the attachment of an isoprenoid group. The best 
characterized Ras signaling pathway is control of the Mitogen Activated Protein Kinase 
(MAPK) signaling cascade (Figure 1-3) [20-23]. The MAPK signaling cascade can be 
activated by the binding of an external cellular signal to a Receptor Tyrosine Kinase 
(RTK) leading to receptor autophosphorylation. Autophosphorylation of the RTK recruits 
Guanine Nucleotide Exchange Factors (GEFs) to the membrane of a cell [19, 24-27]. 
GEF proteins assist the exchange of GDP for GTP and activate membrane localized 
Ras proteins [28-31]. GTP bound Ras then signals the initiation of cell proliferation 
through effector proteins such as Raf [32-36]. The signal then progresses through a 
series of phosphorylation events that eventually results in the activation of transcription 
factors essential for cell division. The Ras proteins are essential to cell survival making 
them an excellent model protein for studying prenylated protein function. In addition, 
inhibiting the activity of Ras proteins may be a key mechanism for the inhibition of 
cancer cell proliferation.  
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Figure 1-3 Ras Signaling 
This is a simple Ras signaling network leading to cell proliferation via binding of 
epidermal growth factor (EGF) to a receptor tyrosine kinase (RTK). The Figure 
highlights the molecular switching function of Ras from a GDP bound on state to a GTP 
bound off state. Switching between the two states requires guanine nucleotide 
exchange factors (GEF), and GTPase activating proteins (GAP). 
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There are at least four hypothesized roles for the prenyl modification of a protein 
(Figure 1-4) [37-40]. The best understood is the direct interaction of the isoprenoid 
group with the lipid bilayer of a cell. However, small isoprenoid anchors such as the 15 
carbon farnesyl isoprenoid poorly partition into membranes as evidenced by a 5-40 µM 
half-maximal binding to liposomes relative to 0.2-0.8 µM binding of a 20 carbon 
geranylgeranyl isoprenoid moiety [41]. Another potential role of an isoprenoid protein 
modification may be for the lipid moiety to directly interact with hydrophobic regions of 
other proteins such as chaperones. One example of this type of activity is the interaction 
between the small molecular weight GTPase Rac and the Rho GDP dissociation 
inhibitor (RhoGDI) [42]. Rac proteins are important in cytoskeleton formation, and are 
prenylated with a 20 carbon geranylgeranyl moiety. The geranylgeranyl moiety inserts 
directly into a hydrophobic groove in the RhoGDI protein and mediates the interaction 
between the two proteins. RhoGDI is thought to act as a carrier or transport protein that 
masks the hydrophobic prenyl group from the cytosolic aqueous environment, and 
delivers Rac to specific target membrane locations. The lipid groups attached to 
proteins may also interact with membranes through a mixed lipid:lipid and lipid:protein 
interaction. Another potential role for prenyl protein modifications may be to induce 
conformational changes in the modified protein. Such changes in the structure of a 
protein may lead to new protein:protein interactions with binding partners that would not 
otherwise interact with the unmodified protein [39]. Other types of protein modifications 
including phosphorylation and glycosylation have been shown to affect protein structure 
and folding, and it is possible that prenyl group modification may also support changes 
in the folding of a modified protein [43, 44]. The different roles of prenyl protein 
modification may be important for the function and cellular localization of a variety of 
proteins, and the role of the prenyl modification may differ depending on the protein 
modified.  
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Figure 1-4 Models for Isoprenoid Function 
Four models for prenyl group function on modified protein.  
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Protein Prenylation and Processing 
The protein prenyltransferases farnesyltransferase (FTase), geranylgeranyl 
transferase type I (GGTaseI) and geranylgeranyl transferase type II (GGTaseII) are 
heterodimeric zinc metalloenzymes that catalyze the prenylation of proteins. FTase and 
GGTaseI catalyze the transfer of FPP 2 or GGPP 3 to a conserved cysteine residue 
four amino acids from the C-terminus of target proteins (Figure 1-5) [45-48]. Protein 
substrates of both FTase and GGTaseI contain a Ca1a2X group at their C-terminus, 
where C is a conserved cysteine residue, a1 and a2 are often aliphatic amino acids and 
X is frequently methionine, glutamine or serine for FTase and leucine or phenylalanine 
for GGTaseI [49, 50]. However, there are overlapping Ca1a2X substrate specificities for 
the prenyltransferases, where some canonical GGTaseI substrates can be farnesylated 
by FTase, and visa versa [49, 51-53]. The Ca1a2X motif alone is all that is required for 
FTase and GGTaseI protein recognition and small Ca1a2X peptides often mimic the 
reactivity of full length proteins [54, 55]. The sequence of the Ca1a2X motif is also often 
unique to a single protein or subsets of proteins, and the reactivity of different Ca1a2X 
sequences varies from one sequence to another [56]. 
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Figure 1-5 Prenyltransferase Reaction and Downstream Processing 
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Protein prenylation directs an ordered series of processing events (Figure 1-5) to 
further increase hydrophobicity leading to the eventual localization of a modified protein 
to cell membranes [57-60]. Through a currently unidentified mode of transport, a target 
protein is prenylated then directed to the endoplasmic reticulum (ER). At the ER the 
protein undergoes two additional processing events. The first of these events is the 
cleavage of the a1a2X residues of the Ca1a2X sequence motif. The endoproteolysis of 
the protein is catalyzed by the integrally membrane bound Ras converting enzyme, 
RCE1 [58, 61-64]. Following the Ca1a2X cleavage reaction the now prenylated C-
terminal cysteine residue remains associated with the ER. The carboxyl terminus is then 
methylated by a second ER bound enzyme Isoprenylcysteine carboxymethyl 
transferase (ICMT) [59, 60, 65, 66]. The ICMT enzyme donates a methyl group from S-
adenosyl methionine (Ado-Met) to the carboxyl terminal residue. The reaction results in 
the formation of the hydrophobic methylated carboxyl terminus and adenosyl 
homocysteine (AdoHCy). A prenylated Ca1a2X motif is the minimum requirement for 
recognition by RCE1, and a prenylated cysteine residue is the minimum requirement for 
protein recognition by ICMT. Once the protein has been methylated it is then 
transported to cell membranes. Carboxyl group methylation and endoproteolysis of the 
protein is thought to increase the hydrophobicity of the C-terminus to enhance direct 
lipid:lipid interactions with membranes or hydrophobic interactions with protein 
chaperones. Once an isoprenylated protein has reached the target membrane it may 
undergo further post-translational lipid modification reactions [67-70]. Acyl transferases 
can attach palmitoyl hydrocarbon chains to further increase the protein hydrophobicity, 
but this modification is not essential for the membrane localization of all isoprenylated 
proteins.  
Protein Prenyltransferase Reaction Mechanism 
FTase and GGTaseI appear to have similar unexpectedly complex reaction 
mechanisms (Figure 1-6) [51, 55, 71-82]. Using steady-state kinetic analyses FTase 
was initially identified to follow a random ordered binding of the isoprenoid and Ca1a2X 
substrates where both FPP and the Ca1a2X substrate could bind to the free FTase 
enzyme [55]. However, the FTase reaction showed significant substrate inhibition by the 
Ca1a2X substrate making the standard Michaelis-Menten interpretations of the enzyme 
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activity difficult. Later using isotope trapping experiments, the reaction mechanism was 
found to progress preferentially with FPP binding first to the free enzyme (E?E•FPP) 
followed by the Ca1a2X substrate (E•FPP?E•CaaX) [72]. In these experiments an 
E•FPP complex was formed by mixing FTase and tritiated FPP at stoichiometric 
concentrations. Excess Ca1a2X peptide and a large excess of unlabeled FPP were then 
added to the “hot” E•FPP complex. The incorporation of radiolabel into product was then 
measured, and nearly the entire reaction product (>90%) was tritiated. To test the ability 
of the E•CaaX complex to form product a biotinylated Ca1a2X peptide was mixed 
stoichiometricly with FTase. The E•CaaX complex was then treated with tritiated FPP 
and a large excess of unbiotinylated Ca1a2X peptide. In these reactions very little of the 
tritiated product was biotinylated (<5%). These results suggested that the E•CaaX 
complex was unreactive, or at the very least dissociated rapidly allowing FPP to bind to 
the free enzyme followed by the excess unbiotinylated peptide. The preferred reaction 
pathway was therefore, through FPP binding first to the enzyme followed by the Ca1a2X 
substrate.   
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 Figure 1-6 FTase Mechanism 
a) FTase kinetic pathway where E is the FTase enzyme, E•FPP is the FTase•FPP 
complex, E•FPP•CaaX is the FTase•FPP•CaaX peptide complex, E•Product is the 
FTase bound product complex, E•Product•FPP is the FTase bound to both FPP and 
the reaction product, and E•CaaX is the peptide bound FTase inhibitory complex. b) 
Crystal structures published by Long et al. [80] of the individual steps along the FTase 
reaction pathway. Only substrates are shown other than the free E complex with 
individual kinetic constants provided for each step of the pathway. The kinetic constants 
are for a CVIM peptide and FPP as the isoprenoid donor.  
a) 
E-FPP E-ProductE-FPP-CaaX
E-Product-FPP
[CaaX]
[FProduct]
E
E-CaaX
[FPP]
[FPP]
 
 
b) 
 
Note: crystal structure diagram from Long et al. [80]  
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FPP was later found to have a much higher affinity for the free FTase enzyme 
(Kd=5nM) than a Ca1a2X peptide (Kd=4µM GCVLS) [54]. FTase and GGTaseI are α,β 
heterodimers with identical α subunits, but vary in the amino acid composition of the β 
subunit. FPP binds along one side of a hydrophobic cavity on the FTase β-subunit 
made up of the highly conserved aromatic residues Trp303β, Tyr251β, Trp102β, 
Tyr205β and Tyr200α [83-85]. When FPP was replaced with a non-hydrolyzable analog 
(Figure 1-7, 4) and mixed with FTase to form a non-reactive E•FPP complex, the analog 
bound to the same region of the FTase enzyme [83-85]. Surprisingly, the affinity for the 
Ca1a2X peptide to the E•FPP complex was increased up to 70 fold (Kd=58nM) relative 
to the free enzyme [76]. These results indicated that the isoprenoid directly interacted 
with the peptide target of the FTase reaction, and the isoprenoid increased the peptide 
binding affinity. Later, Beese et al. solved the crystal structure of a ternary complex 
containing FTase, a non-hydrolyzable FPP analog and a Ca1a2X peptide (E•FPP•CaaX) 
[49, 86]. The non-hydrolyzable analog bound to the enzyme with the same configuration 
as found in the crystal structure of the E•FPP complex. In the E•FPP•CaaX crystal 
structure the isoprenoid formed a significant portion of the binding site for the target 
protein Ca1a2X sequence (Figure 1-6). Interestingly, a similar interaction was found for 
the GGTaseI enzyme, with a non-hydrolyzable GGPP analog and a canonical GGTaseI 
target Ca1a2X sequence [49, 87]. 
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Figure 1-7 Inhibitors of FTase, RCE1 and ICMT 
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 FTase and GGTaseI have identical α subunits (48 kDa), but differ in the 
composition of the β-subunit (25% identity, 46 and 43 kDa respectively) [88]. To 
determine the structural parameters that affect Ca1a2X sequence binding, the crystal 
structures of different Ca1a2X sequences bound to an E•4•CaaX complex were solved 
(4 was the non-hydrolyzable FPP analog in Figure 1-7 and was extended by one 
isoprene unit for GGTaseI) [49]. FTase to GGTaseI Ca1a2X discrimination was highly 
dependent on the identity of the Ca1a2X sequence X residue. The X residue binds to 
what is referred to as the specificity pocket of the protein prenyltransferase enzymes. 
The specificity pocket is made up primarily of the β-subunit residues Ala98β, Ser99β, 
Trp102β, His149β, Ala151β, and Pro152β of FTase and Thr49β, His121β, Ala123β, 
Phe174β of GGTaseI. Interestingly, the X binding site of the GGTaseI enzyme also 
included the 4th isoprene of GGPP. A second X residue binding site was found for 
FTase with Ca1a2X sequences that are normally considered substrates for GGTaseI. 
The second binding site in FTase was made up of Leu92β, Ser99β, Trp102β, Ala151β, 
the third isoprene of FPP, and the Ca1a2X sequence a2 residue. This second binding 
site in FTase allowed for some of the overlap in the binding specificity of the two 
enzymes. The a2 binding site of both FTase and GGTaseI accept the same Ca1a2X 
sequence a2 residues. The a2 residue binding site in FTase was made up of the ω-
isoprene of FPP and the aromatic residues Trp102β, Trp106β and Tyr361β. The a2 
residue binding site of GGTaseI was made up of the 3rd and 4th isoprenes of GGPP, 
Thr49β, Phe53β and Leu320β. The peptide binding sites of both prenyltransferase 
enzymes were made up of the terminal isoprene units of FPP and GGPP interacting 
directly with the terminal Ca1a2X residues of the prenylation target. 
The chemical step of the FTase reaction is thought to primarily proceed through 
an SN2 addition of the zinc activated thiol to the C1 atom of the isoprenoid donor [89, 
90]. However, there is some evidence suggesting dissociative character in the 
isoprenoid diphosphate suggesting at least a partial SN1 contribution [91]. Crystal 
structures have been solved representing the E•4•CaaX and E•product complexes of 
both FTase and GGTaseI (Figure 1-6, FTase) [80, 87]. These structures suggest that 
the α-isoprene and β-isoprene unit of FPP and GGPP undergo a significant 
repositioning in the active site to place the C1 atom in close proximity to the zinc 
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activated thiol of the target Ca1a2X sequence. Interestingly, the ω-isoprene of FPP and 
GGPP is in the same position throughout the prenyltransferase reaction. 
The overall rate of the prenyltransferase reactions are dependent on the rate of 
product release from the enzyme [72]. After the chemical step of the reaction the 
resulting product remains bound to the enzyme active site. An unusual feature of the 
protein prenyltransferase reaction mechanism is that, in order for product to be released 
from the enzyme, a new substrate molecule must bind to displace it [74]. Studies have 
shown that both FPP and a Ca1a2X peptide can stimulate product release from FTase. 
However, FPP stimulated release is faster than peptide stimulated, and the general 
consensus is that FPP stimulated product release is the pathway primarily responsible 
for product dissociation from the enzyme. A crystal structure of FTase bound to both a 
farnesylated peptide and an FPP molecule (Figure 1-6) has revealed that the prenyl 
chain of the product is displaced from the active site onto a hydrophobic groove on the 
outer surface of the protein (“exit groove”) [80]. The new FPP binds to the active site in 
the same position previously occupied by the farnesyl moiety of the product in the 
E•product complex. The hypothesized consequence of FPP stimulated product release 
is that the free enzyme does not form after the first turnover of the reaction. Instead, the 
E•FPP complex is formed as a direct consequence of product release [74].  
Farnesyl Transferase Inhibitors 
The importance of oncogenic Ras proteins and other prenylated proteins in 
cancer biology has led to the development of numerous farnesyl transferase inhibitors 
(FTI) to block prenylated protein membrane localization and activity [13, 14, 92-98]. 
Several of these inhibitors are currently undergoing phase I, II, and III clinical trials as 
anti-neoplastic agents [15, 99].  The FTI Tipifarnib 5 (Figure 1-7) has been evaluated in 
phase III clinical trials and shows promise in the treatment of blood and breast 
malignancies [15, 94, 100-102]. Crystal structures of Tipifarnib and other FTIs 
(Lonafarnib 6) bound to FTase show a similar binding pattern. The molecules bind as a 
ternary complex with FPP already bound to the enzyme [102-105]. Extensive Van der 
Waals contacts are made between the FTI and the FPP lipid indicating an ordered 
binding inhibition mechanism where the inhibitor binds to the E•FPP complex not the 
free enzyme. The inhibition mechanism was therefore exactly analogous to the ordered 
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binding mechanism of the FTase enzyme substrates. Six potent FTIs bound to FTase 
have been crystallized and are positioned in such a way that the aromatic rings of the 
inhibitor interact directly with the a2 binding site of the enzyme. The inhibitors form face-
on-face or edge-on-face stacking interactions with one or more of the aromatic a2 
binding site residues. These aromatic stacking interactions are thought to provide the 
binding energy required for the non-peptidomimetic inhibitors to efficiently bind and 
inhibit the FTase enzyme. 
 FTIs have shown considerable activity in a number of clinical trials. However, the 
overall response in patients has been less than hoped for [106-108]. One possible 
explanation for the lack of FTI clinical efficacy is the process of alternative prenylation 
where some FTase substrates can become alternatively prenylated by GGTaseI [107]. 
Proteins such as K-Ras can be substrates for either FTase or GGTaseI. K-Ras is the 
most prevalent mutated Ras isoform found in human cancers, yet FTIs are ineffective at 
blocking the proliferation of cells transformed by oncogenic K-Ras. Alternative K-Ras 
geranylgeranylation is thought to be responsible for the proteins ability to evade the 
effects of an FTI. FTIs also do not appear to function solely by blocking farnesylation of 
Ras proteins. A number of pre-clinical studies have shown that FTI sensitivity does not 
correlate with the presence of constitutively active Ras; thus, FTIs must also target 
other, unknown FTase substrate(s) [109-111]. 
Recently the use of FTIs have shown promise for the treatment of numerous 
other important disease states including hepatitis δ,[112-114] African sleeping 
sickness[115] and malaria [116-118]. Each of these disease states are dependent upon 
the farnesylation of a protein essential for the development of the disease. For example, 
the hepatitis δ virus (HDV) causes chronic and acute liver disease in patients infected 
with both HDV and the hepatitis B virus. HDV viral assembly is dependent on the 
farnesylation of the HDV large antigen protein. Preclinical studies have shown that 
treatment of HDV infected mice with an FTI is highly effective in clearing HDV viremia 
[119-121]. 
Downstream Processing Inhibition 
Recently the farnesylated protein processing enzymes have become increasingly 
popular targets for the inhibition of prenylated protein function in transformed cells [60, 
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122-124]. Targeting the downstream enzymes rather than FTase may avoid issues 
related to alternative prenylation of proteins such as K-Ras by targeting post-prenylation 
processing. In cells deletion of RCE1 induces mislocalization of Ras, but the affect on 
oncogenic transformation of cells has been less pronounced relative to FTI treatment 
[58]. Elimination of RCE1 does however markedly increase the sensitivity of cells to an 
FTI [58]. In contrast to the effects induced by elimination of RCE1, elimination of ICMT 
has profound affects on cell proliferation. Conditional deletion of ICMT completely 
blocks the transformation of cells by oncogenic K-Ras [65]. 
 Few inhibitors of RCE1 and ICMT have been developed, due to the fact that 
these enzymes are relatively new targets for anti-proliferation drugs. Inhibitors targeting 
the RCE1 enzyme have been limited primarily to substrate analogs. RPI (Figure 1-7, 7) 
is one such analog that potently inhibits RCE1 activity in vitro. Oncogenic Ras supports 
the growth of cells in soft agar and disruption of Ras cellular signaling cascades inhibits 
anchorage independent cell growth. A series of choromethylketone Ca1a2X substrate 
analogs (Figure 1-9, 8-9) [125-128] also inactivate RCE1 and appear to reduce 
anchorage-independent growth of K-Ras transformed cells.  
Inhibitors of the ICMT enzyme fall into two classes which are mimics of either 
substrates or products of the enzyme [60, 129]. The first class of inhibitor is the reaction 
product adenosyl homocysteine (AdoHCy) and methods to increase cellular 
concentrations of this molecule [130-134]. AdoHCy is the product of many 
methyltransferase reactions including ICMT; therefore, it is not specific for the post-
prenylation processing enzyme. The second class of ICMT inhibitors is based on the 
minimal substrate, farnesylcysteine [135, 136]. N-acetyl farnesylcysteine (Figure 1-7, 
AFC 10) is a substrate for ICMT and can be viewed as a competitive inhibitor of the 
enzyme[59, 137, 138]. The AFC molecule is effective at inhibiting Ras post-translational 
processing, but has also been reported to affect numerous other unrelated cellular 
processes. Recently Gibbs group has focused on altering the structure of the AFC 
molecule (Figure 1-7, 11) to create new more potent inhibitors of the ICMT enzyme with 
limited success [139, 140]. Recently, through small molecule library screening, Winter-
Vann et al. discovered a potent and specific ICMT inhibitor, cysmethynil (Figure 1-7, 12) 
[123]. Cysmethynil blocks anchorage independent cell growth and treatment of cancer 
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cells with this molecule results in Ras mislocalization and impaired epidermal growth 
factor signaling. Cysmethynil is one of the first inhibitors discovered for one of the 
downstream processing enzymes that is not a substrate or product analog. 
Prenyl Function Inhibition 
Another important alternative to the inhibition of prenylated protein function by 
farnesyl transferase inhibition is alternative prenylation of the protein with non-functional 
analogs of the farnesyl lipid moiety. The farnesyl lipid group is required for recognition 
by both of the downstream processing enzymes. In addition the prenyl group may 
participate in direct protein:protein interactions with chaperone and effector proteins. 
Numerous analogs of FPP have been designed and synthesized that are inhibitors as 
well as substrates for the FTase enzyme (Figures 1-8 13-30). Changing the structure of 
the farnesyl moiety has been shown to disrupt the function of cellular Ras proteins. The 
analog 3vFPP 13a (Figure 1-8) is a substrate for FTase in vitro and in cell culture [141]. 
Treatment of cells with 3vFPP 13a blocks anchorage-independent growth of ras-
transformed cells.  Presumably, this effect is due to FTase catalyzed modification of 
proteins with the 3-Vinyl-farnesyl group. These observations suggest that alternative 
prenylation with farnesyl analogs may be an effective way to inhibit prenylated protein 
function. 
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Figure 1-8 FPP Analogs 
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The affect of the farnesyl group structure on the activity of an oncogenic H-Ras 
proteins was directly studied in a Xenopus laevis oocyte model system [142-147]. The 
Xenopus laevis oocyte is a convenient in vitro system for studying farnesylation 
dependent cellular signal transduction. Oocytes are naturally arrested at the G2-M 
boundary of the first meiotic cell division. Microinjection of bacterially expressed, 
oncogenic H-Ras (H-Ras Q61L) promotes meiotic maturation in a process accompanied 
by activation of MAPK. Since, bacteria lack the enzymes required for protein 
isoprenylation and subsequent processing, the ability of bacterially expressed 
recombinant H-Ras to induce meiotic maturation is completely dependent on 
intracellular farnesylation of the protein or in vitro farnesylation of the protein prior to 
injection [142, 143]. FPP analogs stripped of most isoprenoid features such as methyl 
groups and unsaturation to more resemble simple fatty acids (16-18) can be transferred 
to Ras by FTase and support Ras function in the Xenopus signal transduction system. 
However, analogs that were shorter and lower in hydrophobicity than the natural FTase 
substrate were transferred to Ras, but unable to support Ras function. These results 
suggested an isoprenoid structure dependent activity of the H-Ras protein in this 
system. 
Analogs of Farnesyl Diphosphate 
Numerous analogs of FPP have been developed to probe the structural 
relationship of FPP with the activity of FTase and target proteins (Figure 1-8) [141, 148-
163]. These analogs include molecules with altered diphosphate groups (Figure 1-8, 
15a-b) and a plethora of changes in the structure of the α, β and ω isoprene units of 
FPP (Figure 1-8, 13a-f, 14a-e, 19-30). Small changes in the structure of FPP apparently 
have significant affects on FTase reactivity [154, 161]. Substitutions in the diphosphate 
leaving group have been used to study the interaction of the highly polar diphosphate 
leaving group with the enzyme active site. One of the most important of this class of 
analogs was the non-hydrolyzable analog 4 which allowed crystallographers and 
kineticists to study the interaction of the isoprenoid and Ca1a2X substrate [76]. Other 
diphosphate analogs have been utilized to show that the diphosphate linkage is simply 
a leaving group and energy release from phosphoanhydride hydrolysis is not required 
for the FTase reaction to occur (Figure 1-8, 15a-b) [164]. 
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Alterations in the structure of the α, β and ω isoprene units of FPP have shed 
light on the importance of the lipid isoprene structure on FTase reactivity. FTase is 
incapable of efficiently binding GGPP as a substrate, but GGTaseI can bind both FPP 
and GGPP as a substrate. This gave rise to the “molecular ruler” hypothesis which 
ascribes FTase isoprenoid substrate binding discrimination to the length of the 
isoprenoid diphosphate [149]. Micali et al. synthesized a series of benzyloxy FPP 
analogs in which the ω-terminal isoprene of FPP was replaced with a benzyloxy group 
and the β-isoprene was replaced with variable length methylene chains (Figure 1-8, 19-
24) [160]. Modeling and kinetic studies indicated that even the longer chain analogs 
could bind to the FTase enzyme although the reactivity and binding of the analogs was 
best where there were only 4 or 5 methylene units between the α and ω isoprenes. 
Modeling of the longer chain isoprenoid analogs into the FTase active site indicated that 
these analogs bound to the enzyme with a bent conformation in which part of the lipid 
chain protruded into the binding site of the target Ca1a2X sequence. This protrusion of 
the molecule may lead to Ca1a2X peptide exclusion from the enzyme active site 
suggesting that larger isoprenoids reacted poorly due to a second substrate exclusion 
rather than inability to bind. Additional support for the second substrate exclusion 
hypothesis was later generated in crystallographic studies of GGPP or a benzophenone 
analog (Figure 1-8, 25a-b) bound to the FTase enzyme [149]. In the GGPP•FTase 
crystal structures the longer prenyl chain did fit into the FTase active site, but the 
structure of the molecule was “kinked” where part of it protruded into the region typically 
occupied by the target Ca1a2X sequence.  
Gibb’s group attempted to exploit the interaction of the isoprenoid and target 
peptide with the α-isoprene substituted FPP analog 3-BFPP (Figure 1-8, 13c) [154]. The 
hypothesis was that changing the structure of FPP may lead to alterations in the activity 
of particular Ca1a2X targets due to the direct interaction of the substrates in the enzyme 
active site. 3BFPP 13c was a substrate for FTase when the target Ca1a2X sequence 
mimicked the proteins H-Ras and K-Ras4B, but was poorly utilized by FTase when the 
target Ca1a2X structure mimicked the RhoB Ca1a2X motif. However, FPP was an 
efficient substrate with all three Ca1a2X sequences.  The analog apparently changed the 
ability of FTase to react with a particular Ca1a2X peptide without significantly affecting 
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the reactivity of other Ca1a2X peptide sequences. Interestingly, the reactivity of the 
analog did not appear to be due to the interaction of the isoprenoid with the Ca1a2X 
target prior to the chemistry step of the reaction. These results suggested that the 
pathway after the chemistry step of the reaction may also be important for FTase 
Ca1a2X sequence selectivity.  
Chehade et al previously developed a series of analogs where the ω-terminal 
isoprene of FPP was replaced with an aniline moiety or substituted aniline moieties 
[159, 161]. 8-anilinogeranyl diphosphate (AGPP, Figure 1-8 26a) was a substrate for 
FTase and the analog dependent steady-state transfer kinetics to H-Ras and an H-Ras 
based Ca1a2X peptide were nearly identical to the natural substrate of the enzyme. 
Modeling studies indicated that the aniline moiety behaved as an isostere for the ω-
isoprene of FPP, and AGPP likely binds to FTase in a conformation similar to FPP. 
However, addition of a p-NO2 group (26b) to the aniline moiety or substitution of the 
aniline H atoms with fluorine (26c) decreased FTase catalytic efficiency. Understanding 
the structural relationships between FTase reactivity and lipid structure will be crucial for 
the development of new FTase transferable, Ca1a2X selective analogs of FPP. 
In addition to studying the prenyl transferase reaction and inhibiting the function 
of FTase protein targets, analogs of FPP may also be useful as unique cellular tags to 
study protein prenylation in cells. The anthranillate analog of AGPP 26d (Figure 1-
8)[165] and the nitro-benzo-oxadiazol analog 27 (Figure 1.8, NBD-GPP)[166] are 
fluorescent AGPP based analogs. The ortho- substituted anthranillate analog 26d is an 
FTase inhibitor while the NBD-GPP 27 isoprenoid analog is a substrate for FTase. The 
NBD-GPP 27 analog has proved very useful in studying cellular prenylation of FTase 
substrates allowing researchers to follow cellular protein prenylation in real time.  
The analogs ETAZ-AGPP (Figure 1-8, 28)[161], the benzophenone analogs 
(Figure 1-8, 25a-b)[150], and DATFP (Figure 1-8, 29)[167] are photoactivatible cross-
linking compounds. In these compounds the ω-terminus of FPP is replaced with 
photoactivatible units that can be covalently attached to regions of the FTase enzyme or 
protein binding partners that interact directly with the lipid. The benzophenone analogs 
25a-b are FTase inhibitors, yet the ETAZ-AGPP 28 and DATFP 29 analogs are 
substrates for FTase. Another azido function containing molecule, farnesyl azide 30, 
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has been used by Kho et al for a tagging-via-substrate methodology to specifically label 
cellular proteins and isolate those proteins for mass spectral identification [168]. A better 
understanding of the structural parameters that distinguish substrate analogs from 
inhibitors will be essential for the design of new probes of the prenylation pathway and 
the prenyltransferase enzymes. 
Objectives 
Solid Phase Parallel Chemistry, Structural Diversity, and Prenyl Function 
Inhibition 
The lipid structure of FPP appears to affect both transferability of target peptides 
and protein target function. The FPP binding site is made up primarily of aromatic amino 
acid residues, and the molecule interacts directly with a target protein throughout FTase 
catalysis [80]. AGPP is a transferable analog of FPP with kinetics nearly identical to the 
natural substrate, yet it has drastically different chemical and physical properties [159, 
161]. We hypothesized that with the right combination of interactions between FTase, 
the protein target, and alternative lipid structures, some analogs could be efficiently 
transferred to proteins by FTase, yet unable to support the protein function normally 
supported by a farnesyl lipid. 
In order to study the affect of changing the FPP structure on protein target 
activity we needed an array of compounds with varying chemical structures and 
properties. The AGPP skeleton allows simple structure diversification. AGPP was 
therefore an excellent lead compound for the development of structurally diverse 
transferable FTase analogs that could be used to probe the relationship of the 
isoprenoid structure and isoprenoid function. The typical solution phase route to 
producing AGPP and AGPP analogs was slow and not amenable to a library synthesis 
[159, 161]. In order to develop large numbers of ω-terminally substituted FPP analogs 
we utilized a solid-phase parallel chemistry method. Solid-phase chemistry allows the 
production of small molecules rapidly without tedious purification steps between every 
chemical manipulation by doing all reaction on solid-phase. Parallel chemistry is the 
synthesis of multiple compounds simultaneously and is especially amenable to solid-
phase methodologies.  
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We designed and synthesized a library of AGPP analogs with various functional 
groups in the ortho-, meta-, and para- positions of the AGPP aniline ring. We found that 
a number of analogs appeared to be FTase transferable. As expected, based on the 
interaction of the isoprenoid and peptide target in the FTase active site the analog ability 
to transfer was dependent on the identity of the Ca1a2X sequence. However, the ability 
of the analog to transfer did not appear to be dependent on the hydrophobicity of the 
analogs. Instead, the analog reactivity was much more dependent on the size and 
position of the aniline ring substitution. Since many of the transferable analogs were 
much more hydrophilic than the natural substrate of the reaction, we tested the ability of 
theses analogs to support oncogenic H-Ras function in the Xenopus signal transduction 
model system. We found that several analogs that were efficiently transferred to FTase 
target substrates were unable to support normal farnesyl group function in this system. 
These results indicated that FPP analogs could be designed with low hydrophobicity 
that could be transferred to FTase protein targets, yet were unable to support normal 
prenyl group function in target proteins. These analogs will be key lead compounds for 
the development of a new class of prenyl group function inhibitors.  
FTase Mechanism of Product Release 
The FTase reaction mechanism involves multiple interactions between FTase the 
isoprenoid donor and Ca1a2X sequence [80]. It has been supposed that the mechanism 
of the FTase reaction occurs through FPP binding to the E•product complex to stimulate 
the release of product from the enzyme [74]. The consequence of this is direct 
regeneration of the E•FPP complex which is highly committed toward catalysis, and 
association of FPP to the free enzyme is tight. FPP dissociation from the free enzyme is 
in fact slower than the overall rate of catalysis. However, it appears that the Ca1a2X 
peptide can inhibit the FTase reaction [55, 71]. In the generally accepted kinetic 
mechanism Ca1a2X peptide inhibition occurs through binding of the Ca1a2X sequence to 
the free enzyme apparently blocking access of the isoprenoid diphosphate to the 
enzyme active site. However, if FPP is so tightly bound to the enzyme and the E•FPP 
complex is so highly committed to catalysis it is unreasonable for the Ca1a2X peptide to 
inhibit the FTase reaction especially at concentrations well below isoprenoid 
concentrations. 
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We hypothesized that the generally accepted FTase mechanism was incomplete 
and required inclusion of peptide stimulated product release to account for Ca1a2X 
substrate inhibition. We tested this, using peptide competition reactions and found that 
the Ca1a2X selectivity of the FTase enzyme was highly dependent upon peptide 
stimulated product release rather than isoprenoid stimulated product release. These 
results suggested that peptide selectivity for the FTase enzyme was highly dependent 
on the kinetic flux between the FPP stimulated and peptide stimulated product release 
pathways. These results also suggested that although FPP stimulated product release 
may be faster than peptide stimulated, the peptide stimulated release pathway may be 
more efficient. 
Chemical Manipulation of FTase Ca1a2X peptide Selectivity 
Chemical genetics is a research method that uses small molecules to change the 
way proteins work. The FTase reaction is an excellent target for chemical genetic 
research because the isoprenoid lipid forms a significant portion of the binding pocket 
for a target Ca1a2X sequence motif. We hypothesized that by changing the ω-terminal 
isoprene unit of FPP the interactions with a target Ca1a2X motif would be altered leading 
to chemical genetic changes in the activity of the FTase enzyme and different protein 
targets. Such alterations would be analogous to amino acid mutations in the enzyme 
active site, potentially leading to enhanced reactivity of particular Ca1a2X sequences as 
well as decreases in the reactivity of other Ca1a2X peptides. The reactivity of the FPP 
analogs with different Ca1a2X peptide structures varied a great deal, and did not 
correlate with the differences in reactivity with FPP as the isoprenoid donor. Most 
importantly we have found that by changing the structure of FPP the target selectivity of 
FTase ca be altered. 
FPP analogs as unique cellular protein tags 
FPP analogs are not only useful as inhibitors and FTase reactivity probes they 
have also been used to tag endogenous proteins with unique properties that could be 
used to track cellular FTase targets. Tritiated farnesyl diphosphate analogs and farnesyl 
diphosphate precursors have been used for years to track the endogenous modification 
of proteins by FTase [169, 170]. Treatment of cells with tritiated farnesol led to the 
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discovery that a cell contains endogenous kinases that phosphorylate the allylic alcohol 
producing intracellular farnesyl diphosphate that can be utilized by FTase. We 
hypothesized that the isoprenoid alcohol precursors of AGPP would be taken up into a 
cell, endogenously diphosphorylated and incorporated into cellular proteins by FTase. 
To test this we developed antibodies to the anilinogeranyl modification and discovered 
that the anilinogeranyl moiety of AGPP is incorporated into cellular proteins, and the 
analogue is competitive with endogenous pools of FPP. In the event that a particular 
allylic alcohol analog structure would not be converted to diphosphate endogenously, 
we also developed a diphosphate anion masking scheme to build cell permeant analogs 
of FPP. 
GGPP analogs and GGTaseI 
We found important effects with the FPP analogs on FTase activity. We 
hypothesized that the technology developed for studying FTase would also be 
applicable to the related GGTaseI enzyme. We developed two analogs of AGPP with an 
extended isoprenoid chain and measured the affect of changing the terminal isoprene of 
GGPP on the kinetics of GGTaseI. Like FTase with AGPP, the longer chain analog was 
a substrate for GGTaseI with kinetics similar to GGPP. The ability of GGTaseI to utilize 
target peptides was also altered by the GGTaseI substrate analogs, which indicated 
similar interactions between the isoprenoid diphosphate and target peptides in the 
GGTaseI reaction as in the FTase reaction. In addition, we found that the antibody 
reagents developed for the AGPP analogs were also useful for the longer chain 
anilinofarnesyl analogs. 
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CHAPTER 2 PRENYL FUNCTION INHIBITION 
 
Introduction 
A wide variety of proteins, including Ras, require post-translational prenylation for 
their proper membrane localization and activity [171-175]. Protein farnesyltransferase 
(FTase) catalyzes the transfer of a farnesyl group from farnesyl diphosphate (FPP, 1 
Figure 2-1) to proteins with a cysteine residue located in a C-terminal Ca1a2X sequence 
motif where C is the modified cysteine, a1 and a2 are often an aliphatic amino acid, and 
X is typically Ser, Met, or Gln [50, 84, 176, 177]. Farnesylation is the first and obligatory 
step in an ordered series of post-translational modifications that direct membrane 
localization and potentially protein:protein interactions for a variety of proteins involved 
in cellular regulatory events [19, 42, 178, 179]. Subsequent to farnesylation, the a1a2X 
peptide is cleaved by the endoprotease RCE1 [65, 180] followed by methylation of the 
now terminal farnesylated cysteine residue by the carboxymethyl transferase ICMT.  
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Figure 2-1 Analog structures 
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The Xenopus laevis oocyte is a convenient in vitro system for studying 
farnesylation dependent cellular signal transduction [143, 181]. Microinjection of 
bacterially expressed, oncogenic H-Ras (H-Ras Q61L) promotes meiotic maturation in a 
process accompanied by activation of mitogen-activated protein kinase (MAPK) [143, 
181, 182]. Maturation of the oocytes can be easily scored by the appearance of a white 
spot on the dark hemisphere of the oocytes which signifies germinal vesicle breakdown 
(GVBD) in the oocytes. Since, bacteria lack the enzymes required for protein 
isoprenylation and subsequent processing, the ability of recombinant H-Ras to induce 
meiotic maturation is completely dependent on intracellular farnesylation of the protein 
[183]. Depletion of the endogenous isoprenoid pools by treatment of the oocytes with 
inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase) such as 
lovastatin, blocks the ability of bacterially expressed H-Ras to induce maturation. 
Microinjection of H-Ras modified in vitro by FTase with FPP analogs into Xenopus 
laevis oocytes allows the biological signal transduction functions of the lipidated protein 
to be studied [142, 181]. 
Proteins modified with the 20 carbon geranylgeranyl group from geranylgeranyl 
diphosphate (GGPP 2, Figure 2-1) are more hydrophobic than the 15 carbon farnesyl 
group and both classes of prenylated proteins are processed by the same RCE1 
endoprotease and ICMT methyltransferase. Replacement of the farnesyl group with 
FTase transferable lipid analogs of similar or greater hydrophobicity than FPP are 
effective in allowing all of the subsequent downstream processing events to take place 
[181]. Substitution of the smaller, less hydrophobic 10 carbon geranyl group from 
geranyl diphosphate (GPP, 3 Figure 2-1) for the farnesyl group significantly delays the 
membrane association of H-Ras [181]. Importantly, it was concluded that the reduced 
hydrophobicity of the geranyl group impaired processing downstream of prenylation by 
slowing either the endoproteolysis or carboxyl methylation steps [181]. Once C-terminal 
processing of the geranylated H-Ras was complete, normal palmitoylation followed by 
membrane association was observed. These observations suggest that the precise 
structure of the farnesyl group is not critical for the function of the protein as long as it is 
sufficiently hydrophobic to allow downstream processing and membrane localization. 
However, it was not possible to distinguish whether the significantly smaller size of the 
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geranyl group impeded the processing of H-Ras by the RCE1 endoprotease, the ICMT 
methyltransferase and/or other unknown farnesyl lipid interactions.  
The above observations suggest that FTase catalyzed transfer of FPP analogs 
with hydrophobicity lower than GPP 3 or with significantly different structures may 
completely block the membrane localization of Ras by preventing the downstream 
processing or membrane interactions of the alternatively prenylated C-terminus. Altering 
the downstream biological function of a prenylated protein with unnatural analogs of 
FPP is an attractive antineoplastic strategy. Synthetic modifications to the farnesyl 
moiety of FPP have generated both FTIs and alternative substrates transferable for 
FTase [153, 157, 159-161, 184, 185]. Definition of the structural features responsible for 
efficient transfer of unnatural analogs to Ras requires the synthesis of additional, 
structurally diverse FPP analogs that are transferable by FTase, and a rapid method for 
determining the ability of the analogs to act as FTase substrates. 
Parallel synthesis of directed libraries is an effective strategy for rapidly 
introducing focused diversity into a target template [186-189]. Directed libraries are 
particularly useful for generating groups of closely related molecules to explore 
structure-activity relationships [190]. We have previously prepared a limited set of 
alternative substrates for FTase by replacing the terminal isoprene of FPP with 
substituted anilines in an effort to define some of the structural features responsible for 
efficient transfer of unnatural analogs to Ras [159, 161]. These 8-anilinogeranyl 
diphosphates AGPP 4a (Figure 2-1) were prepared by solution phase synthesis where 
the key step was reductive amination of an α, β unsaturated aldehyde to form the 
anilinogeranyl skeleton. This approach was appealing because it was carried out under 
mild conditions. However, all intermediates and products required purification by 
chromatography.  
In this chapter, I will describe the synthesis of a series of FPP analogs with a 
wide range of molecular surface areas, shapes and lipophilicities by both solid and 
solution phase methods. An assay for the rapid determination of FTase transferability 
was developed to test the ability of these analogs to react with a variety of Ca1a2X 
sequences that represented the C-terminal sequence motifs of H-Ras, K-Ras4B, RDJ-2 
and a canonical GGTaseI Ca1a2X sequence. A number of the analogs were alternative 
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substrates for mammalian FTase, and the reactivity was dependent on the Ca1a2X 
sequence target. Utilizing the Xenopus laevis oocyte system, we found that H-Ras 
modified with hydrophobic anilinogeranyl diphosphate derivatives support H-Ras 
dependent oocyte maturation. However, hydrophilic anilinogeranyl diphosphate 
derivatives prevent H-Ras dependent oocyte maturation. These hydrophilic FPP 
analogs are Ras function inhibitors (RFIs) and serve as lead compounds for a unique 
class of potential anti-cancer therapeutics.  
Results 
Analog Synthesis 
We have adapted our solution methods to provide a solid phase organic 
synthesis (SPOS) route to anilinogeranyl FPP analogs (Figure 2-2). The advantage of 
an SPOS approach is that it allows for the rapid preparation of additional analogs and 
reduces the number of tedious purification steps needed. The THP resin 5 was 
prepared from the Merrifield-Cl resin as previously described [191]. Attachment of 
synthetic intermediates to the resin through the THP group provides a traceless linker 
for the alcohols 10a-am and the final diphosphate compounds 4a-am (Table 2-1). 
Preparation of resin 5 was achieved by combining a 5-fold excess of 8-oxo-geraniaol 6 
with support 5 in the presence of 0.2 equiv of PPTS at 60 C. Under these conditions, 
excess alcohol 6 can be recovered for reuse. The optimized reaction conditions gave a 
resin loading of 72% for the solid support-linked α,β-unsaturated aldehyde 7. Aldehyde 
loading was determined by cleavage and recovery of alcohol 6 by treatment of resin 7 
with PPTS/MeOH/DCE at 60 C. With resin 7 in hand, we employed a solid-phase 
parallel synthetic strategy to prepare a directed library of the anilinogeranyl analogs 
10a-am. Diversity was introduced into the library by selecting the commercially available 
substituted anilines 8a-am listed in Table 2-1. Optimum yields of the desired resin-
bound anilinogeraniols 9a-am were obtained by performing the reductive amination with 
10 equiv of the anilines and 12 equiv of acetic acid in 1:1 THF/DCE and subsequent 
reduction with 10 equiv of NaBH(OAc)3. Cleavage of the anilinogeraniols 10a-am from 
the resin-bound amines 9a-am was achieved by treatment of the solid support with 
DCE/MeOH/PPTS at 60 C.  
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In solution, FPP analogs are typically prepared by sequential conversion of the 
allylic alcohols into corresponding chlorides followed by diphosphorylation to provide 
diphosphates [159, 192, 193]. Utilizing this approach reduces some of the advantages 
of SPOS, as it requires two solution-phase manipulations after release of the 
anilinogeraniols 10a-am from the resin. In previous solution-phase work, we employed 
an excess of Ph3PCl2 to convert alcohol 10a to its corresponding chloride, which was 
immediately transformed to the diphosphate 4a. Direct cleavage of the resin-linked THP 
ethers to the corresponding allylic chlorides or bromides would reduce the number of 
solution steps to one, diphosphorylation. We observed that addition of Ph3PCl2 to the 
resin-bound ethers and subsequent diphosphorylation resulted in poor yield of 
diphosphates. Alternatively, stirring the THP resin 9a-am with 3 equiv of Ph3PBr2 in 
DCM for 4 h followed by addition of 10 equiv of tris(tetra-n-
butylammonium)hydrogendiphosphate in MeCN gave the desired diphosphates 4a-am 
in moderate yield. Employing Ph3PBr2 not only reduced the reaction time but also 
increased the yield of the desired diphosphates. The release of bromides 11a-am from 
the THP resin by Ph3PBr2 provides a traceless linker path to the FPP analogs 4a-am. In 
practice, bromides 11a-am were not isolated but were converted directly to the 
anilinogeranyl diphosphates 4a-am by addition of tris(tetra-n-
butylammonium)hydrogendiphosphate in dry MeCN in the same reaction vessel.  
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Figure 2-2 Synthesis of AGPP library of analogs 
Reagents and yields: (a) PPTS, DCE, 60˚C; (78%); (b) aniline 8a-am, HOAc, 
NaBH(OAc)3, THF/DCE(1:1), rt; (c) PPTS, MeOH/DCE(1:1), 60˚C; (70-41%); (d) 
PPh3Br2, MeCN, rt; (e) PPh3Br2, MeCN, rt; (f) ((nBu)4N)3HP2O7, MeCN 
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Table 2-1 Analog FTase Reaction Rates and Structural Properties  
Reaction rates measured using 3 µM peptide and 12 µM analog in Tris-HCl buffer 
(pH=7.4) containing DTT reducing agent and DM as the detergent. Rates are reported 
as µM per sec per µM enzyme. Rates below detection limits are reported as < values. 
Each rate was measured in the 96 well plate assay as described in the experimental 
section. Sizes of the terminal isoprene or aniline are reported in cubic angstroms and 
were estimated using the PreADME online molecular descriptor software. The partition 
coefficient LogP was estimated for the alcohol precursors based on RP-HPLC capacity 
factors. Note the large difference in rates depending on the peptide target. 
NH2
R2
8
H
N
R2
R1
10: R1=OH, 4: R2=P2O7
3-
 
R # logP size Å3
Rate 
CVLS 
(s-1•10-2) 
Rate 
CVIM 
(s-1•10-2) 
Rate 
CAHQ 
(s-1•10-2) 
Rate 
CVIL 
(s-1•10-2) 
FPP 1 6.1 102 6 ± 0.9 4.2 ± 0.4 14 ± 2 1.0 ± 0.1 
AGPP 4a 3.6 114 3.6 ± 0.1 <0.6 7.2 ± 0.7 0.6 ± 0.1 
NAGPP 4b 3.1 134 28 ± 1 ND* ND* ND* 
pbnz 4c 5.6 202 <0.9 <0.6 <1 <0.4 
mbnz 4d 5.4 202 <0.9 <0.6 <1 <0.4 
obnz 4e 5.9 202 <0.9 <0.6 <1 <0.4 
pPhO 4f 5.1 198 <0.9 <0.6 <1 <0.4 
mPhO 4g 5 198 <0.9 <0.6 <1 <0.4 
oPhO 4h 5.7 198 <0.9 <0.6 <1 <0.4 
pPh 4i 5.2 187 <0.9 <0.6 <1 <0.4 
oPh 4j 5.8 187 <0.9 <0.6 <1 <0.4 
piPr 4k 5.2 159 <0.9 7.8 ± 0.9 <1 <0.4 
oiPr 4l 5.2 159 <0.9 <0.6 <1 <0.4 
pEtO 4m 4.7 155 <0.9 3.7 ± 0.3 <1 <0.4 
mEtO 4n 3.9 155 <0.9 <0.6 <1 <0.4 
oEtO 4o 4.7 155 <0.9 <0.6 <1 <0.4 
pSMe 4p 4.1 149 <0.9 6.6 ± 0.9 <1 <0.4 
oSMe 4q 5.1 149 <0.9 3.6 ± 0.3 <1 <0.4 
pCF3O 4r 4.9 149 7 ± 1 13.2 ± 0.6 2.9 ± 0.1 <0.4 
mCF3O 4s 4.9 149 11 ± 2 5.2 ± 0.5 1.6 ± 0.3 0.7 ± 0.3 
oCF3O 4t 5.1 149 <0.9 5.2 ± 0.1 <1 <0.4 
pEt 4u 4.7 144 1.2 ± 0.5 6 ± 1 <1 <0.4 
mEt 4v 4.6 144 2.2 ± 0.8 7.8 ± 0.4 <1 <0.4 
oEt 4w 4.8 144 <0.9 <0.6 <1 <0.4 
pI 4x 4.9 146 6.4 ± 0.6 8 ± 1 1.6 ± 0.2 <0.4 
mI 4y 4.8 146 17 ± 3 16 ± 3 1.6 ± 0.3 0.4 ± 0.1 
oI 4z 5.3 146 2.7 ± 0.6 6.0 ± 0.7 1.7 ± 0.4 <0.4 
pBr 4aa 4.6 142 13 ± 1 12 ± 2 4.0 ± 0.6 2.8 ± 0.7 
mBr 4ab 4.5 142 1.5 ± 0.4 <0.6 3.1 ± 0.4 0.9 ± 0.4 
oBr 4ac 5 142 7.7 ± 0.4 0.8 ± 0.1 5 ± 1 <0.4 
mMeO 4ad 3.3 140 8 ± 2 4.6 ± 0.6 <1 <0.4 
oMeO 4ae 4.1 140 9 ± 1 4 ± 1 1.4 ± 0.1 <0.4 
mCF3 4af 4.6 139 5.8 ± 0.4 1.8 ± 0.3 5 ± 1 5.1 ± 0.5 
pCN 4ag 2.9 135 7.1 ± 0.7 13.6 ± 0. ± 7 1.6 ± 0.3 <0.4 
mCN 4ah 3.1 135 3.2 ± 0.2 1.2 ± 0.1 1.7 ± 0.1 3.0 ± 0.1 
pMe 4ai 3.6 129 12 ± 1 3.1 ± 0.2 3.4 ± 0.4 0.6 ± 0.2 
mMe 4aj 3.3 129 4.9 ± 0.3 0.6 ± 0.1 4.3 ± 0.6 0.6 ± 0.3 
pF 4ak 3.5 118 7.7 ± 0.4 0.7 ± 0.1 4.8 ± 0.4 0.7 ± 0.1 
mF 4al 3.7 118 1.6 ± 0.7 0.6 ± 0.2 10.5 ± 0.6 1.6 ± 0.1 
oF 4am 4.1 118 3.3 ± 0.3 <0.6 3.7 ± 0.5 <0.4 
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 The resulting diphosphates 4a-am were first converted to the NH4+ form by ion 
exchange chromatography and then purified by reverse-phase HPLC (RP-HPLC). 
Complete removal of the tetra-n-butylammonium counterions from the sample prior to 
reverse-phase HPLC was required for effective purification. However, efficient recovery 
of the NH4+ form of the diphosphates 4a-am from the ion exchange chromatography 
was highly dependent on the buffer conditions employed. This observation is 
unsurprising, as the various diphosphates 4a-am are expected to have a wide range of 
solubility in aqueous buffer related to the structure of the parent anilines 8a-am. 
Optimization of the ion exchange conditions by altering the concentration of NH4HCO3 
and including compound-dependent proportions of MeCN cosolvent had a profound 
influence on the yield of individual diphosphates 4a-am recovered.   
FTase Analog Transfer 
 
Fluorescence assay for FTase transfer 
In order to examine the reactivity of large numbers of FPP analogs, we desired a 
method that could rapidly sort the molecules into groups of FTase substrates and non-
substrates. Poulter et al. developed a continuous fluorescence assay with N-dansyl-
GCaaX pentapeptides (Figure 2-3) that is often used to analyze FTase activity [194]. In 
this assay a fluorescence enhancement results upon farnesylation of an N-dansyl-
GCaaX peptide due to the increase in local hydrophobicity near the dansyl reporter 
group. However, this assay was not immediately amenable for our purposes; because, 
the assay utilized only a single cuvette and was therefore limited in throughput. We 
adapted the single cuvette method to a microtiter plate assay which would allow the 
analysis of many analogs at once. In individual wells of a 96-well plate, FPP and a 
Ca1a2X peptide (N-dansyl-GCVLS) were mixed, and the initial fluorescence was read in 
a microplate fluorescence reader. The reaction was then initiated by the addition of 
FTase and allowed to continue until fluorescence enhancement had ceased. The final 
fluorescence value was expected to represent complete consumption of the input 
peptide substrate. (Figure 2-4) To confirm total consumption of the peptide reactant the 
reaction mixture was separated by RP-HPLC with fluorescence and absorbance 
detection of the dansyl moiety. We found with excess FPP all peptides were completely 
consumed in the reaction. Fluorescence enhancement from the FTase reaction was 
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similar to that previously found in the single cuvette assay, and the increase in RP-
HPLC retention time of the dansyl peak corresponded to the increase in hydrophobicity 
due to peptide farnesylation. The micro-titer plate assay allowed simple and rapid 
analysis of the transferability of FPP to the dansyl-GCVLS pentapeptide (Table 2-1). 
FTase reaction rate is enhanced by AGPP analogs 
In order to measure the reactivity of the analogs with the CVLS peptide we 
measured the fluorescence increase of FTase reactions containing excess analog and 
the CVLS peptide. The fluorescence enhancement differed depending on the 
hydrophobicity of the isoprenoid. Reactions that did not go to completion within several 
hours were stopped using a solution of acetic acid and isopropanol and the extent of 
modification was determined by RP-HPLC analysis of the dansyl absorbance peaks. A 
time-dependent increase in fluorescence was observed for over half of the analogs in 
the AGPP analog library suggesting that a wide variety of functional groups in various 
positions in the aniline ring were acceptable to the FTase enzyme (Table 2-1, Figure 2-
5a).  
 The analog reactivity ranged from non-transferable to analogs that transferred as 
fast as, or faster than FPP. Interestingly, the mI-AGPP 4y and pBr-AGPP 4aa analogs 
reacted faster than FPP with the CVLS peptide. However, the mBr-AGPP 4ab and oI-
AGPP 4z analogs were poorly transferred to the CVLS peptide. In addition, none of the 
analogs with functional groups larger than an EtO group were efficiently transferred by 
FTase. These results indicated that the transfer rate of the analogs was highly 
dependent upon the size of the aniline substituent as well as the position of the 
substituent in the aniline ring of AGPP. 
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 Figure 2-3 Dansyl peptide structures 
Structures of dansylated peptides representing the Ca1a2X motifs of H-Ras, RDJ2, K-
Ras4B, and a canonical GGTaseI substrate.  
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Figure 2-4 Fluorescence enhancement of N-dansyl-GCVLS modified with FPP 
FPP and the N-dansyl-GCVLS peptide were mixed in individual wells of a 96 well plate 
in Tris-HCl buffer pH=7.4, DTT and DM. The (+) FTase reaction was treated with FTase 
enzyme and the (-) FTase reaction was treated with buffer only and the fluorescence 
increase over time was measured in a microplate reader at 2 second intervals. Fmax-
Fmin is the difference between the (+) FTase and (-) FTase reactions, and the slope is 
the rate of fluorescence change over time.  Note that the initial velocity of the 
fluorescence increase over time and the Fmax-Fmin can be used to calculate the rate of 
the FTase reaction. 
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Figure 2-5 Reaction rates of analogs with N-dansyl-GCaaX motif peptides 
FTase catalyzed analog reaction rates with each peptide relative to the reaction rate 
with FPP. Rates are given in table 2-1. Cross-hatched bar is to show the location of 
FPP. a) analog reactions with N-dansyl-GCVLS b) analog reactions with N-dansyl-
GCAHQ c) analog reactions with N-dansyl-GCVIM d) analog reactions with N-dansyl-
GCVIL. Note that FPP is not always the fastest analog transferred and peptide identity 
as well as analog identity affects transfer rates relative to FPP. 
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c. CVIM 
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Reaction rate changes depending on the structure of the Ca1a2X sequence and 
the analog structure 
The crystal structure of a non-hydrolyzable FPP analog bound to FTase and a 
Ca1a2X target solved by Reid et al. indicated that the ω-terminal isoprene of FPP and 
the a2 position of the target protein Ca1a2X motif are in van der Waals contact with one 
another [49]. In addition, the position of the a2 residue affects the placement of the C-
terminal X residue in the FTase specificity pocket. We hypothesized that by changing 
the ω-isoprene of FPP the ability of FTase to catalyze the modification of different 
Ca1a2X sequences will be affected by the structure of the isoprenoid lipid. To determine 
the effects of different Ca1a2X structures on the reactivity of different Ca1a2X sequences 
we measured the rate of modification of three additional Ca1a2X sequences. The 
Ca1a2X sequences corresponded to the C-terminal sequence of two canonical FTase 
protein substrates RDJ-2 (CAHQ) and K-Ras4B (CVIM) (Figure 2-3 structures, Table 2-
1 and Figure 2-5 reactivity). We also tested the ability of the analogs to react with a 
canonical GGTaseI Ca1a2X substrate CVIL. GGTaseI peptide substrates can often 
readily bind to the FTase enzyme. However, the canonical GGTaseI Ca1a2X sequences 
are thought to bind to the E•FPP complex in a different conformation than the canonical 
FTase substrates. In this alternate conformation the GGTaseI Ca1a2X substrates have 
an even more pronounced interaction with the isoprenoid substrate, where the ω-
isoprene of the isoprenoid forms part of the binding site for both the a2 and X residues 
of the canonical GGTaseI peptide substrates. The increased interaction between the 
peptide and isoprenoid may therefore be even more sensitive to the structure of the ω-
isoprene. 
We hypothesized that the hydrophobicity of the peptide would affect the FTase 
reaction rate since the rate limiting step is product release and the overall product 
volume is dominated by the peptide portion of the product. We found that the rate of the 
peptide reactions with FPP correlated with the retention time of the product in the FPP 
reaction (Figure 2-6). The most hydrophilic peptide, CAHQ, reacted the fastest, followed 
by the CVLS, CVIM and CVIL peptides. The FTase active site is relatively hydrophobic 
and these results are consistent with the idea that product release is rate-limiting due to 
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interactions with the enzyme active site. The interactions of the more polar farnesylated 
peptide products appear to be more easily disrupted than the less polar. 
Since the peptide reactivity appeared to correlate with the hydrophobicity of the 
peptide substrate with FPP, we tested whether the reactivity of the AGPP analogs also 
correlated with peptide target hydrophobicity (Table 2-1, Figure 2-5 a-d). We found that 
with the analogs the peptide reaction rate did not correlate with the HPLC retention time 
of the peptide substrates, and differed substantially depending on both the structure of 
the analog and the peptide. The CVIM peptide reacted readily with a much larger 
number of analogs than any of the other peptides, where several analogs that were not 
reactive with the CVIL, CAHQ and CVLS peptides reacted rapidly with the CVIM 
peptide. In addition, the analogs that transferred with a rate faster than FPP with the 
other peptides were not necessarily the same analogs that were good substrates with 
the CVLS peptide. The mI-AGPP 4y and pBr-AGPP 4aa analogs were still rapid 
substrates reacting three times faster than FPP with the CVIM peptide. However, the 
pMe-AGPP 4ai and mCF3-AGPP 4af analogs which were among the fastest transferred 
to CVLS were considerably slower than FPP when the Ca1a2X substrate was the CVIM 
peptide rather than CVLS. These results indicated that there were major differences 
between the reactivity of the analogs with different peptides and that the change in 
reactivity did not correlate with the change in reactivity with FPP as the isoprenoid 
donor. 
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Figure 2-6 Correlation of peptide HPLC retention and reaction rate with FPP 
C18 retention capacity of each FTase target peptide correlated with the rate of the 
FTase reaction with FPP from table 2-1. The HPLC retention time of each of the 
peptides was measured and the capacity factors calculated as described for the LogP 
measurements in the experimental section. Reaction rates are reported as reciprocal 
seconds • 10-2. Note that there is an excellent linear correlation between peptide 
hydrophobicity and reaction rate with FPP as the isoprenoid donor for the reaction, yet 
this was not the case with the various analogs. 
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 Analog reactivity does not correlate with analog hydrophobicity 
Since the reactivity of the analogs did not appear to correlate with the 
hydrophobicity of the peptide substrate we tested whether the reactivity of the AGPP 
analogs correlated with the analog hydrophobicity. In order to determine the 
hydrophobicity of the AGPP series of analogs we used an RP-HPLC assay to estimate 
the apparent LogP (LogPapp). LogP is a measure used for the hydrophobicity of a 
molecule and represents the partition coefficient of a compound in water saturated 
octanol verses octanol saturated water [195]. The RP-HPLC method uses the HPLC 
capacity factor for a range of compounds with known LogP values as standards to 
determine the apparent LogP of unknown compounds. We found that the LogPapp of the 
analogs ranged from 2.9 for pCN-AGPP 4ag and 5.3 for oI-AGPP 4z. Surprisingly, the 
hydrophobicity of the analogs did not correlate with the rate of the FTase reaction. In 
order to have a molecule with similar size to FPP but greatly reduced hydrophobicity we 
synthesized an additional analog containing an isoxazole moiety in the position of the 
ω-isoprene. The isoxazole-GPP analog 12 was transferable by FTase and had an 
extremely low LogPapp of 0.7. Taken together these results suggest that very hydrophilic 
analogs of FPP can be made that are substrates for the FTase enzyme depending on 
both the analog structure and the target peptide structure(Table 2-1).  
Additional Isoprene Substitutions  
To further explore the ability of the ω-terminal isoprene substituted analogs to be 
utilized as substrates for FTase, Thangaiah Subramanian synthesized four analogs in 
which the aniline nitrogen atom was replaced with an O (13), CH2 (14) S (15), or CH2O 
(16). All four substitutions were acceptable for the FTase catalyzed modification of 
CVLS (Figure 2-7). However, there were major differences in the transfer rate of the 
analogs. When the nitrogen atom was replaced with a methylene or CH2O group, the 
rate of the reaction with CVLS was comparable to that with FPP and AGPP. With both 
sulfur and oxygen substituting the aniline nitrogen, the reaction rate was considerably 
slower. These results indicated that the aniline nitrogen could be replaced, but the 
reactivity of the analogs will change relative to the rate with AGPP. 
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Figure 2-7 Transfer of non-aniline analogs to a CVLS peptide 
FTase reactions were prepared as described in table 2-1 and the experimental section 
with each of the exploratory analogs and the CVLS peptide. In these analogs the AGPP 
nitrogen atom is replaced with an O, CH2, S or OCH2 . Note that the sulfur and oxygen 
substituted compounds are transferred much slower than the other analogs. 
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Analogs with aromatic rings replacing the ω-isoprene of FPP were acceptable 
substrates for the FTase enzyme. We were interested in whether this was also true 
when the β-isoprene of FPP was replaced with an aromatic ring. In order to determine 
whether the β-isoprene could also be replaced Subramanian Thangiah synthesized six 
additional phenoxy substituted isoprene analogs 17-20. We tested the ability of these 
analogs to transfer to the CVLS peptide, and found that several of the β-substituted 
phenoxy analogs were FTase transferable substrates.  The analogs 18, 19 and 20 were 
all acceptable substrates for FTase. Surprisingly, the fluorine substituted diaromatic 
compound 17b was a substrate, while 17a and 17c were not substrates. Interestingly, 
although 17a was not a substrate for the enzyme, switching the position of the ω-PhO 
residue from the meta- to the para- position (18) resulted in a transferable analog.   
These results indicated that the β, ω substituted analogs could be acceptable 
substrates for the FTase enzyme. In addition, the results from compounds 17b, 17a and 
18 indicated that the transferability of these molecules will be highly dependent on the 
structural features. Additional AGPP analogs were also synthesized with increasing 
functionalization in the aniline ring of AGPP. The methylene dioxy-AGPP analog 21 was 
an acceptable substrate for the FTase enzyme. Two other analogs were synthesized as 
potential fluorescent transferable FTase substrates where coumarin units (22a-b) were 
placed in the position of the ω-isoprene unit. However, it is currently not clear whether 
these analogs are substrates.  
H-Ras Function Inhibition 
H-Ras biological function depends on prenyl analog hydrophobicity and 
hydrophilic analogs are Ras Function Inhibitors.  
The delay in post-prenylation maturation for geranylated H-Ras relative to 
farnesylated H-Ras in Xenopus has been attributed to the difference in hydrophobicity 
of the two lipids [181]. The significantly less hydrophobic geranyl group appears to 
interfere with maturation of the lipidated H-Ras by delaying one or more downstream 
processing events. However, it is also possible that the downstream processing 
enzymes or membrane localization may require a lipid with a minimum size for high 
activity. The reduction in lipid hydrophobicity by shortening the 15 carbon farnesyl to the 
10 carbon geranyl group cannot address this point. With the suite of FPP analogs in 
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table 2-2, we were able to separate the effect of lipid size from hydrophobicity in the H-
Ras stimulated maturation of oocytes.  
Incorporation of aromatic rings and heteroatoms into the analogs decreases their 
hydrophobicity relative to hydrocarbons of the same size. As a result, the size and 
hydrophobicity of the analogs are no longer directly related. FPP 1 and AGPP 4a are 
almost identical in size but differ substantially in hydrophobicity. On the other hand, both 
the 10 carbon geranyl group 3 and the anilinogeranyl group 4a have a logP of 3.6 near 
the middle of the range, but differ in surface area by 135 Å2. In order to evaluate the 
effect of the lipid physical properties on Ras function, we prepared H-Ras modified in 
vitro with FPP 1, GPP 3 and the analogs in table 2-2 (AGPP 4a, pNO2-AGPP 4b, 
pCF3O-AGPP 4r, mCF3O-AGPP 4s, mEt-AGPP 4v, mI-AGPP 4y, pBr-AGPP 4aa, pCN-
AGPP 4ag, and isoxazole-GPP 12) for microinjection into oocytes. The extent of H-Ras 
modification for each analog is shown in table 2-2. Lipidated H-Ras is somewhat 
unstable in solution, forming aggregates and precipitates upon standing for very short 
periods. The rate and extent of aggregation was dependent on the lipid analog 
structure. In particular, in vitro modification of H-Ras with pBr-AGPP 4aa results in 
complete denaturation of the H-Ras within five minutes of initiating the FTase reaction. 
The aggregated H-Ras was clearly visible in the microinjection needle under the 
microscope. Except for pBr-AGPP 4aa, aggregation could be controlled by allowing no 
more than 20 minutes to elapse from initiation of H-Ras lipidation and completion of 
oocyte microinjection. Previous studies employed detergent to keep lipidated H-Ras in 
solution. In our hands, the use of sufficient detergent to prevent aggregation of the 
anilinogeranyl-analog modified H-Ras resulted in inconsistent oocyte maturation results. 
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Table 2-2 In vitro modification of H-Ras with isoprenoids 
Ras was modified in an in vitro reaction with each of the given prenyl analogs and the 
extent of modification is given as a percentage of total Ras protein in the reaction 
mixture. Note that even though all of the analogs transfer they do not appear to transfer 
to Ras with equal efficiency. 
 
Isoprenoid 
% H-Ras 
modified in 
vitro for 
microinjection*
1 FPP >90 
3 GPP 70 
4a AGPP >90 
4b pNO2-AGPP >90 
4r pCF3O- >90 
4s mCF3O- >90 
4t oCF3O- 0 
4v mEt-AGPP 70 
4y mI-AGPP >90 
4aa pBr-AGPP >90 
4ag pCN- >90 
12 isoxazole- 50 
*The extent of H-Ras lipidation was estimated from images of SDS-PAGE separations 
of in vitro FTase reactions.  
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Lovastatin treated oocytes were microinjected with 5 pmols of in vitro analog 
modified H-Ras and scored for germinal vesicle breakdown (GVBD) over the 
subsequent 24 to 48 hour period. Microinjection of H-Ras pre-modified with the lipid 
analogs was employed to ensure that the intracellular behavior was not dependent on 
the ability of endogenous FTase to effectively transfer the analogs. The effective dose 
of analog modified H-Ras microinjected into each oocyte was greater than 4.5 pmols 
each for FPP 1, AGPP 4a, pNO2-AGPP 4b, pCF3O-AGPP 4r, mCF3O-AGPP 4s, mI-
AGPP 4y, pBr-AGPP 4aa, and pCN-AGPP 4ag, but only 2.5 pmols for isoxazole-GPP 
12 and 3.5 pmols for m-Et-AGPP 4v and GPP 3 due to incomplete lipidation (Table 2-
2). The time required for 50% maturation of the oocytes was calculated from sigmoidal 
curves fitted to the GVBD time dependence for each of the analogs (Table 2-3). FPP 1, 
GPP 3, AGPP 4a, mCF3O-AGPP 4s, pCF3O-AGPP 4r, mI-AGPP 4y, and mEt-AGPP 
4v, stimulated GVBD, while pCN-AGPP 4ag, pNO2-AGPP 4b and isoxazole-GPP 12 did 
not. Relative to FPP 1, GVBD was delayed for all the analogs other than AGPP 4a. 
Farnesylated H-Ras is the natural substrate for the downstream maturation steps and is 
expected to undergo efficient processing and appropriate membrane localization in the 
oocyte. However, the time required for maturation of 50% of oocytes injected with 
farnesylated H-Ras was highly dependent on the frog from which they were harvested. 
Maturation times varied from 4-10 hours for different batches of oocytes stimulated by 
farnesylated H-Ras. Accordingly, individual experiments were conducted with oocytes 
simultaneously harvested from a single frog. We found that the order in which the 
analog modified H-Ras stimulated 50% maturation relative to farnesylated H-Ras was 
essentially identical from experiment to experiment. This observation gave us 
confidence to combine and analyze data obtained from experiments using oocytes from 
multiple frogs after appropriate normalization. We expressed the maturation half-time for 
analog modified H-Ras as the ratio of the time required for 50% maturation of analog 
modified H-Ras to that of farnesylated H-Ras (Table 2-3).  
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Table 2-3 Maturation kinetics of microinjected oocytes 
Stage V or VI oocytes were incubated with lovastatin for 16 hr and then microinjected as 
described below. Microinjected oocytes were monitored for GVBD at the indicated times 
and the results expressed as a percentage of the number of viable injected oocytes (14-
20/group). The small number of oocytes that did not survive 3 hr post injection were 
removed from the experiment. A. Induction of GVBD following microinjection of pre-
modified activated H-Ras into lovastatin treated oocytes. The t1/2 was 8.8 hr for 
farnesylated H-Ras and 13 hr for anilinogeranylated H-Ras. The ratio of t1/2(AGPP) to 
t1/2(FPP) is 1.5. B. Induction of GVBD following co-microinjection of activated H-Ras and 
isoprenoid diphosphate into lovastatin treated oocytes. The t1/2 was 5 hr for FPP and 6.9 
hr for AGPP coinjected with H-Ras. The ratio of t1/2(AGPP) to t1/2
 
Isoprenoid 
Fold increase in maturation time relative to 50% GVBD for 
FPP 1* 
 In vitro modified H-Ras Coinjected H-Ras and 
1 FPP 1 1 
3 GPP 1.4 ± 0.3 1.7 ± 0.2 
4a AGPP 1.6 ± 0.5 1.5 ± 0.3 
4r pCF3O-AGPP 1.3 ± 0.2 1.7 ± 0.3 
4s mCF3O- 1.6 ± 0.3 2.0 ± 0.8 
4t oCF3O-AGPP nd** nd** 
4v mEt-AGPP 1.2 ± 0.1 3.3 ± 1.0 
4y mI-AGPP 1.6 ± 0.3 1.0 ± 0.1 
4aa pBr-AGPP No assay 1.4 ± 0.2 
4b pNO2-AGPP ndb ndb
4ag pCN-AGPP ndb ndb
12 isoxazole- ndb ndb
*The time required for 50% GVBD for FPP ranged from 4-10 hours (see text for details). 
Average and standard deviation for fold increase are calculated from at least three 
independent experiments.  
**Not detected. 
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The 5 pmols/oocyte dose of modified H-Ras is in excess of that required to 
induce maximal rates of oocyte maturation. Previous studies of prenyl function showed 
that 2 pmols/cell of farnesylated H-Ras induced maximal rates of maturation [181]. 
Under suboptimal conditions of 0.5 pmols/cell of modified H-Ras, the oocyte system is 
very sensitive to structural alterations of the lipid, which affects its biological activity. For 
example, under suboptimal conditions, microinjection of 0.5 pmols of geranyl modified 
H-Ras results in maturation half-times that are 2.5 to 3.3 times longer than farnesyl 
modified H-Ras [181]. The increase in maturation time is closely associated with delays 
in the downstream endoproteolysis, carboxyl methylation and subsequent palmitoylation 
[181]. In contrast, the maturation of oocytes microinjected with 5 pmols/cell of 70% 
lipidated geranyl H-Ras (3.5 pmols of modified protein) is only delayed by 40% relative 
to farnesylated H-Ras. Conditions of high H-Ras dose reveal any signal transduction 
activity, expressed as GVBD, which is supported by the analogs. These observations 
suggest that lipid analogs that do not support GVBD in oocytes microinjected with these 
high doses of modified H-Ras are extremely compromised in their ability to support 
oncogenic Ras function.  
In each experiment, unmodified H-Ras was injected into both lovastatin treated 
and untreated oocytes to test for the completeness of the isoprenoid depletion and as 
an additional check on the quality of the oocytes. As previously reported, untreated 
oocytes injected with activated H-Ras underwent GVBD, whereas those pre-incubated 
with lovastatin failed to mature. Progesterone stimulates GVBD via a Ras-independent 
pathway, and is therefore unaffected by lovastatin treatment [196]. In each experiment, 
a small number of the oocytes injected with the individual analog modified H-Ras were 
withheld and treated with progesterone to test the overall oocyte quality and to ensure 
that the manipulations did not interfere with maturation. In all cases, the progesterone 
treated oocytes matured.  
Table 2-3 shows that the ability of the analogs to support oocyte maturation fell 
into three categories. The first category is represented by oCF3O-AGPP 4t which does 
not support oocyte maturation because it is not transferred to H-Ras by FTase. 
Microinjection of the H-Ras/oCF3O-AGPP 4t reaction mixture was no different from 
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injection of unlipidated H-Ras into the lovastatin treated oocytes. In the second category 
are GPP 3, AGPP 4a, mCF3O-AGPP 4s, pCF3O-AGPP 4r, mI-AGPP 4y, and mEt-
AGPP 4v which are transferred by FTase to H-Ras in vitro and support GVBD. 
Interestingly, the half-time for maturation stimulated by these analogs was delayed from 
20-60% relative to farnesylated H-Ras. The third category consists of analogs pCN-
AGPP 4ag, pNO2-AGPP 4b, and isoxazole-GPP 12 which are transferred by FTase to 
H-Ras in vitro but do not support GVBD. These analogs are Ras function inhibitors 
(RFIs). The lipid chains of FPP 1 and the transferable analogs are similar in length, size 
and excluded volume, but have different hydrophobicities. The delay in oocyte 
maturation kinetics does not show any correlation with the length or surface area of the 
lipid moiety. Rather, it appears that H-Ras is capable of initiating GVBD if the lipid 
alcohol has a logP of at least 3.6, yet they were unable to support oncogenic H-Ras 
function when the LogP of the parent alcohol was less than 3.2.  
In situ lipidation of H-Ras by hydrophobic FPP analogs rescues Ras biological 
function in X. laevis oocytes.  
The loss of H-Ras function in the experiments described above is independent of 
differences in their rates of transfer by FTase. However, partial loss of the in vitro 
lipidated H-Ras to aggregation was inevitable and prevented evaluation of the pBr-
AGPP 4aa analog. The possibility existed that different substitution patterns on the 
analog might affect the ability of the lipid to support oocyte maturation. Analogs mEt-
AGPP 4v and pBr-AGPP 4aa share the same logP and have similar surface areas and 
excluded volumes. However, they differ in structure. Previous studies showed that the 
X. laevis FTase was competent to transfer alternative lipids with similar or greater 
hydrophobicity than FPP to H-Ras in situ [181]. The rate of transfer was sufficiently high 
that the maturation half-time for co-injected H-Ras and in vitro modified H-Ras was 
indistinguishable. These results suggest that the substrate specificity of X. laevis FTase 
is sufficiently similar to mammalian FTase to allow efficient modification of the H-Ras by 
other, structurally unrelated analogs.  
We co-injected 5 pmols each of the lipid diphosphates and H-Ras into lovastatin 
treated oocytes and scored for GVBD. The half-times for oocyte maturation are shown 
in Table 2-3. Consistent with the in vitro modification results, coinjection of H-Ras and 
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FPP or the analogs GPP 3, mCF3O-AGPP 4s, pCF3O-AGPP 4r, mI-AGPP 4y,  mEt-
AGPP 4v, pBr-AGPP 4aa or AGPP 4a results in maturation of the oocytes, while 
coinjection of H-Ras and analogs oCF3O-AGPP 4t, pNO2-AGPP 4b, pCN-AGPP 4ag, 
and isoxazole-GPP 12 failed to promote maturation. Interestingly, the p-Br-AGPP 
analog 4aa, promotes oocyte maturation about as effectively as GPP 3. The mEt-AGPP 
4v was the only FPP analog which showed a significant increase in the half-time to 
maturation upon co-injection with H-Ras. On the other hand, co-injection of the H-Ras 
with mI-AGPP 4y results in a slight enhancement in the rate of oocyte maturation 
compared to pre-modified protein. The half-time to maturation for co-injected H-Ras with 
both FPP and mI-AGPP 4y are identical. None of the analogs accelerated the 
maturation of the oocytes relative to farnesylated H-Ras. Thus, it is likely that the X. 
laevis FTase is able to transfer the FPP analogs to H-Ras in situ. However, these 
results suggest that mEt-AGPP 4v is a poor substrate for X. laevis FTase catalyzed 
transfer to H-Ras. With the exception of mEt-AGPP 4v it appears that the rate of in situ 
FTase catalyzed modification of H-Ras by the analogs was not rate limiting for oocyte 
maturation. From these data, it is not possible to determine if the X. laevis FTase was 
able to transfer the analogs unable to support maturation to coinjected recombinant H-
Ras.  
Discussion 
 
Implications 
These results have important implications for the development of RFIs as 
potential alternatives to FTIs. It is now well established that isoprenylation is required for 
Ras function, and that oncogenic Ras activity may be inhibited by pharmacologic 
inhibitors of FTase (FTIs). However, while the farnesylation of Ras, and a variety of 
additional proteins, is blocked by FTI treatment, the Ras protein that is most often 
mutated in human cancer (K-Ras) undergoes alternative prenylation. Since, 
geranylgeranyl-modified Ras is effectively targeted to cellular membranes and retains 
its transforming ability, K-Ras function is not disrupted by FTI treatment. Our work 
suggests that the hydrophilic RFI lipid structures may act by interfering with membrane 
localization rendering the modified protein non-functional. The results seen with H-Ras, 
lead us to predict that modification of oncogenic K-Ras4B with RFI prenyl analogs 
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would both prevent its transforming ability and block GGTaseI-mediated alternative 
prenylation.  
Hydrophobicity and FTase Transfer 
Another important implication from this chapter is that the structural parameters 
that control transferability do not appear to affect the ability of the analogs to support H-
Ras biological function. This provides an orthogonal relationship between transferability 
and prenyl group function that could be exploited for the design of new potent 
transferable analogs that transfer very well to proteins, yet poorly support prenylated 
protein membrane localization. The assay used in this chapter to screen the majority of 
the FTase analogs was limited in its ability to characterize the efficiency of transfer of 
the analogs relative to FPP. The next important step for the characterization of these 
analogs would be to determine if they can compete with FPP and can they be 
incorporated into cellular proteins. The Xenopus model system avoids issues related to 
cell penetrance due to the fact that the compounds are directly injected into the 
cytoplasm of the cell.  
Analog Reactivity Dependent on Both Substrate Structures 
The lipid binding pocket of the FTase enzyme is considerably hydrophobic and 
evolutionarily designed to bind hydrophobic isoprenoid chains. However, the enzyme 
binds a wide variety of Ca1a2X sequences with very different chemical properties. In 
particular the a2 binding site of the enzyme accepts a variety of amino acids that do not 
conform to the classical Ca1a2X aliphatic amino acid paradigm. Not only can this region 
of the enzyme bind a variety of different amino acids, the a2 binding site also can form 
aromatic interactions with a number of potent FTase inhibitors. The aniline moiety of 
AGPP replaces the ω-isoprene of FPP which also forms part of the a2 binding site. 
AGPP may be less polar and therefore less able to interact with the hydrophobic 
farnesyl binding site of FTase, but it is possible that the loss of binding energy to the 
hydrophobic groove may be made up for with aromatic stacking interactions. 
FTase Accepts a Diverse Array of Substrate Structures  
We also found that both the structure of the isoprenoid and the structures of the 
target peptide affect the transferability of the FTase analogs. A number of the analogs 
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could be rapidly transferred to particular Ca1a2X sequences, while they were unable to 
react with other Ca1a2X peptides. These studies imply that it may be possible to 
selectively modify particular Ca1a2X sequences of proteins with certain analogs even in 
the presence of multiple other Ca1a2X sequences. However, the assay used to 
determine peptide reactivity was limited and does not directly address the efficiency of 
the reactions with the different peptides. Enzyme catalytic efficiency is highly dependent 
on both the rate of an enzyme reaction and the enzyme affinity for particular substrates. 
Issues relating to target selectivity will be addressed in later chapters of this 
dissertation. 
Experimental 
General 
Reaction temperatures refer to the external bath. All solvents were purchased from 
VWR (EM Science-Omnisolv high purity) and used as received. All other reagents were 
purchased from Aldrich, Alfa Aesar or GIBCO.  Merrifield-Cl resin was purchased from 
Argonaut technologies.  1H and 13C NMR Spectra were obtained in CDCl3 with a Varian 
Inova spectrometer operating at 400 and 100.6 MHz respectively. Chemical shifts are 
reported in ppm from CDCl3 internal peak at 7.27 ppm for 1H and 77.4 ppm for 13C. ESI-
MS were performed at the University of Kentucky Mass Spectra Facility. HPLC analysis 
was performed with an Agilent 1100 series purification system equipped with a diode 
array detector and autoinjection system. All the reactions except for resin preparation 
were performed in PTFE tubes using a Quest 210 apparatus manufactured by Argonaut 
Technologies.  
Credits: Zhongwen Wang and I were responsible for the development and 
implementation of the solid phase synthetic route. Thangiah Subramanian was 
responsible for re-synthesis and optimization. All molecules for the Xenopus study were 
synthesized by me and all Xenopus assays were performed by Mike Roberts.  
Synthesis 
Preparation of aldehyde resin 5  
THP resin 3 (0.50 g, 0.82 mmols), geranyl aldehyde 4 (1.35 g, 8.2 mmols), PPTS 
(41.2 mg, 0.164 mmols), and 2.5 ml of anhydrous DCE were combined and stirred at 60 
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ºC for 48 hours.  The resin was recovered by filtration and washed sequentially with 
DCM (3x), DMF/H2O (1:1) (4x), DMF (3x) and DCM (3x), followed by vacuum drying at 
rt. to afford 636 mg of light yellowish resin 5 (74% based on recovery of aldehyde 4 after 
treatment of resin 5 with PPTS/MeOH).  Unreacted geranyl aldehyde 4 can be 
recovered from the filtrate and reused.  . 
Reductive amination and cleavage (8a-8al, 2a-2al) 
Reductive amination and cleavage (Compounds 8a-8al) 
Aldehyde resin 5 (100 mg, 0.10 mmols), the appropriate aniline 6a-ad (0.50 
mmols), acetic acid (36 mg, 0.60 mmols), 2 ml anhydrous THF and 1 ml anhydrous 
DCE were combined in individual reactor tubes and agitated at rt. under N2 for 12 hours.  
NaBH(OAc)3 (42 mg, 0.20 mmols) was added and the slurry agitated at rt. under N2 for 
an additional 60 hours.  The resin was filtered and washed sequentially with THF (4x), 
aq. NaHCO3 (3x), H2O (3x), THF (4x) and anhydrous methanol (1x).  PPTS (50 mg, 
0.20 mmols) in 1 ml of anhydrous methanol and 1 ml of anhydrous DCE was added and 
the slurry and agitated at 60 ºC under N2 for 20 hours.  After cooling to rt., the resin was 
filtered and washed with 2 ml of methanol.  The filtrate and washing were combined and 
evaporated to dryness under reduced pressure. Each residue was dissolved in 5 ml 
chloroform and washed with water (1x) and the organics evaporated to dryness under 
reduced pressure.  The crude products were purified by RP-HPLC (Ranin Microsorb 89-
203-C5, 5µm, 300 Å, C-18 (10mm x 250 mm) column with an isocratic mobile phase: 
65%Acetonitrile-35%H2O; Monitored at 254 nm and 298 nm).   
Reductive amination and cleavage (compounds 2a-ai) 
Aldehyde resin 5 (100 mg, 0.10 mmols), the appropriate aniline 6a-ad (0.50 
mmols), acetic acid (36 mg, 0.60 mmols), 2 ml anhydrous THF and 1 ml anhydrous 
DCE were combined in individual reactor tubes and agitated at rt. under N2 for 12 hours.  
NaBH(OAc)3 (42 mg, 0.20 mmols) was added and the slurry agitated at rt. under N2 for 
an additional 60 hours.  The resin was filtered and washed sequentially with THF (4x), 
aq. NaHCO3 (3x), H2O (3x), THF (4x) and anhydrous CH3CN (1x).  Ph3PCl2 (66 mg, 
0.20 mmols) in 2 ml of anhydrous CH3CN was added and the slurry and agitated at 
room temperature under N2 for 2 hours.  The resin was filtered and washed with 1 ml of 
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anhydrous CH3CN.  The combined filtrate was directly introduced into glass tubes 
containing tris(tetra(tert-butyl)ammonium)diphosphate ( 451mg, 0.50 mmols). The 
mixtures were stirred at room temperature for 30 mins under N2. Volatiles were removed 
under vacuum after which the residue was suspended in 4 ml of 25 mM NH5CO3.and 
extracted with ether (3x). The aqueous phase was applied to an NH4+ form ion-
exchange column and eluted with two-column volume 25 mM NH4HCO3 buffer.  The 
eluent was applied to a fresh NH4+ form ion-exchange column and eluted with a further 
two-column volume 25 mM NH4HCO3 buffer.   The combined aqueous phase was 
lyophilized, the residue dissolved in a minimum volume of 25 mM NH4HCO3 buffer and 
the diphosphates 2a-ad purified by RP-HPLC (Varian Dynamax, 10 µm, 300 Å, C-4 
(10mm x 250 mm) column with an gradient mobile phase: 100% 25 mM NH4OAc buffer 
for 3 mins, 100% 25 mM NH5AcO buffer to 80% MeCN 20% 25 mM NH5AcO buffer over 
20 mins; Monitored at 254 nm and 298 nm). 
Protein Farnesyl Transferase Transfer Rates  
Reaction rates of the analogs with each N-dansyl-GCaaX peptide were 
determined in triplicate measurements using a continuous spectrofluorometric assay 
adapted for a 96-well plate. The following assay components were assembled in 
individual wells of a 96-well plate and incubated at 30° C for 20 minutes: 180 µL of 
assay buffer (52 mM Tris-HCl, 12 mM MgCl2, 12 µM ZnCl2 pH 7.4), 40 µL of detergent 
(0.125% n-dodecyl- β-D-maltoside in assay buffer), 40 µL of reducing agent (50 mM 
DTT in assay buffer) 20uL of FPP or AGPP (200 µM in 25 mM NH4HCO3) and 20 µL of 
N-dansyl-GCaaX peptide(final concentration 3 µM).  Fluorescence was detected using a 
time based scan at 30° C for 120 minutes. The velocity of each reaction was determined 
by converting the rate of increase in fluorescence intensity units (FLU/s) to µM/s with 
equation 2-1.  
Equation  2-1: vi=(R·P)/(FMAX-FMIN) 
Where vi is the velocity of the reaction in µM/s. R is the rate of the reaction in FLU/s. P 
is equal to the concentration of modified product in µM (see below). FMAX is the 
fluorescence intensity of fully modified product. FMIN is the fluorescence of a reaction 
mixture that contained 20 µL of assay buffer in the place of FTase. Complete 
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modification of peptides was assumed when fluorescence stabilized for more than 10 
minutes and was confirmed by RP-HPLC analysis of the reaction mixture. 
Analog Structure Properties 
LogP determination 
The apparent LogP values for the corresponding alcohols of diphosphates were 
estimated from the capacity factors (k’) using high performance reverse phase liquid 
chromatography (HPLC) (added high performance and abbreviation) [197, 198]. A 
BioBasic-8 RP-C8 column was used as the stationary phase, and the mobile phase 
consisted of a mixture of 20mM phosphate buffer (pH=6.0) and methanol (3:7) as 
described by Niemi et al. [199] Solutions with known LogP values were dissolved in 3:7 
phosphate buffer in methanol [1mM progesterone (logP 3.87), 1mM norgestrel (logP 
3.7), 100 mM anthracene (logP 4.54), 1mM hydrocortisone (logP 1.53), 0.01 mM 
nitrobenzene (logP 3.3), 0.01 mM anisole (logP 1.85), 1 mM perylene (logP 2.11) 0.05 
mM naphthalene (logP 3.3)] 5 up of each standard was injected and monitored at 254 
and 280 nm. A standard curve was generated from the log of the capacity factor k 
calculated with equation 2 where Rt is the retention time and R0 is the time for a 5 µL 
injection of 1mM benzoic acid to pass through the column. 
Equation 2-2: k=(Rt-R0)/R0
   The log of the capacity factor was plotted against the known logP values to generate a 
standard curve R2 0.97. A Pasteur pipette tip was placed into each of the neat alcohols 
and the drawn up solution was taken up in 1000 up of mobile phase and 1 µL was 
injected onto the column. The capacity factor for each of the alcohols was calculated 
from equation 2-2 and the standard curve was used to determine the apparent logP of 
the alcohol.  
Surface area calculation  
Surface area calculations were achieved using the online PreADME molecular 
descriptor calculation software.  
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H-Ras Preparation and Microinjection 
H-Ras protein  
Oncogenic H-RasQ61L was expressed in the Rosetta DE3 strain of E. Coli 
(Novagen, CA, USA) using the pTrc-His A plasmid (Invitrogen corporation, CA, USA). 
Expression was induced by 1 mM isopropyl-beta-D-thiogalactopyranoside (IPTG) when 
the optical density of bacteria reached 0.6, and the bacteria harvested after 4 hrs [200]. 
Bacteria were pelleted by centrifugation, resuspended in 20 mM Tris, pH 8.0 containing 
0.5 M NaCl, 1mM BME, 1mM MgCl2, 10% glycerol and 20 mM imidazole, lysed using a 
French Press, and H-RasQ61L purified on a nickel column by Fast Protein Liquid 
Chromatography using an imidazole gradient. Aliquots from the resulting fractions were 
separated on a 12% SDS-PAGE gel, and proteins stained by incubation with coomassie 
blue (0.625 g in 250 ml 50% MeOH, 10% acetic acid) for 1 hr followed by destaining 
(3:1 MeOH:Acetic acid). Fractions shown to contain pure (>90%) H-RasQ61L by SDS-
PAGE were dialyzed against Tris and protein content measured using the BCA Protein 
Assay Kit (Pierce, IL, USA), and this value was used as the concentration of protein in 
subsequent experiments. 
Pre-Modification of Ras in vitro using FPP Analogs. 
 100 µM RasQ61L was incubated in assay buffer (52 mM Tris-HCl, 12 mM 
MgCl , 12 µM ZnCl , 5.8 mM DTT), with 100 µm FPP or FPP analogs, 1 µM 
recombinant FTase and 0.04% n-dodecyl-β-D-maltoside in a total volume of 15µl for 20 
min at 37°C [159]. The reaction mixture containing the lipidated H-RasQ61L was then 
immediately injected into lovastatin treated oocytes as described below.  
2 2
Oocyte extraction and microinjection 
Oocytes were isolated from Xenopus laevis females (Xenopus Express, Inc., 
Florida, USA) that were primed with gonadotropin before shipment and allowed to 
acclimatize to their new environment for a minimum of 30 days after arrival before 
surgery. Frogs were housed in tanks with water and room temperature kept at 17°C and 
given a 12/12 hr light/dark cycle for optimal egg production. Frogs were anesthetized 
with 0.01% MS-222 (Argent, Washington, USA), the oocytes surgically removed, and 
the frog returned to the communal tank for recovery. Oocytes were defoliculated by 
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incubation with 3 mg/ml type 3 collagenase (Worthington Chemical Corp., NJ, USA), in 
30 ml Barth’s medium (88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 0.82 mM MgSO4, 
0.33 mM Ca(NO3)2, 0.41 mM CaCl2, 20 mM HEPES, pH 7.5), for 60-90 min. Following 
defoliculation, oocytes were washed 3X in Barth’s medium (30 ml each time), followed 
by 3 X in one half Leibowitz L15 medium (Invitrogen, NY, USA) (30 ml each time), and 
allowed to recover for at least 4 hr before manipulation. Following recovery, stage V and 
VI oocytes were selected and incubated overnight (16 hr) in one half L15 medium +/- 50 
µm lovastatin (LKT laboratories, MN, USA). Following incubation in lovastatin, any 
oocytes that were not of uniform pigmentation and otherwise healthy were discarded, 
and the remaining oocytes microinjected with H-RasQ61L pre-modified as described 
above, or H-RasQ61L was co-injected with the FPP analogs synthesized in our 
laboratory [161, 163]. 50 nL total volume was injected per oocyte. All microinjections 
were done using a Nanoject II microinjector (Drummond Scientific Company, PA, USA) 
mounted on a micromanipulator (Narishige, NY, USA). Oocytes were scored hourly for 
germinal vesicle breakdown (GVBD), as evidenced by the appearance of a white spot in 
the otherwise dark colored animal hemisphere. Progesterone was used as a positive 
control to induce GVBD in lovastatin treated and untreated oocytes and was also used 
to determine whether any oocytes that did not undergo GVBD following microinjection of 
the FPP analogs were still responsive to maturation signals.  
 
Gel Shift Assay 
Following modification of Ras for exactly 20 min as described above, a 1 µl 
sample was taken and immediately mixed with 4 µl 2 X Laemmli SDS sample buffer. 
Samples were boiled for 5 min, then loaded onto 12% SDS-PAGE gels and modified 
Ras separated from unmodified Ras by running at 200V for 80 min. Proteins were 
stained by incubation with Coomassie blue (0.625 g in 250 ml 50% MeOH, 10% acetic 
acid) for 1 hr followed by destaining (3:1 MeOH:Acetic acid). Ras modified with a prenyl 
group shows higher electrophoretic mobility than unmodified Ras. The extent of protein 
modification by each analog was estimated from images of the gel analyzed using NIH 
Image 1.63.  
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The solid phase work has been reported in the following citation: 
1. Subramanian T, Wang Z, Troutman JM, Andres DA, Spielmann HP. “Directed library 
of anilinogeranyl analogues of farnesyl diphosphate via mixed solid- and solution-phase 
synthesis.” Org Lett. 2005 May 26;7(11):2109-12 
Credits: 
1. Post-doctoral researcher, Michael J. Roberts was responsible for all Xenopus assays 
and Ras modifications 
2. Post-doctoral researcher Thangiah Subramanian was responsible for yield 
optimization of the solid phase reaction scheme, resynthesis of many of the 
compounds, the use of Ph3PBr2 as a cleavage reagent replacing Ph3PCl2, and as cited 
in the text the synthesis of the exploratory FPP analogs. 
3. Post-doctoral researcher Zhongwen Wang in collaboration with me was responsible 
for the development of the solid-phase synthetic scheme, most notably using the α,β-
unsaturated aldehyde as the first isoprenoid linked resin reagent. 
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CHAPTER 3 FARNESYL TRANSFERASE TARGET SELECTIVITY IS DEPENDENT 
ON PEPTIDE CATALYZED PRODUCT RELEASE 
Introduction 
The mechanism of the protein prenyltransferases is unexpectedly complex 
(Figure 3-1) [49, 82]. Substrate association is assumed to proceed through a 
functionally ordered mechanism where FPP (1) (Figure 3-2) binds FTase first, giving the 
enzyme-FPP complex (E•FPP) followed by Ca1a2X substrate association forming the 
enzyme-FPP-Ca1a2X peptide complex (E•FPP•CaaX) [72, 201]. After thioether 
formation, the modified peptide remains associated with FTase in an enzyme-product 
complex (E•product) [72, 74]. Product release is the rate determining step (kcat) for the 
FTase reaction mechanism [72, 80]. An unusual feature of the FTase mechanism is that 
product dissociation is greatly enhanced by binding of either a new FPP or Ca1a2X 
peptide substrate [74]. Apparently, two competing pathways can lead to the release of 
farnesylated peptide, depending on whether FPP or Ca1a2X peptide binds to the 
E•product complex. However, for the farnesylation of CVIM, FPP stimulates release 
slightly faster than does peptide [74]. It is generally accepted in the literature that FPP is 
the substrate primarily responsible for stimulating product release [74, 154]. The steady-
state kinetic constant kcat/Km is often used to describe the selectivity of an enzyme for 
its substrates (Equation 3-1) [202]. The kcat/Kmpeptide is also the catalytic efficiency of 
FTase, and measures the ability of the enzyme to catalyze a reaction at low substrate 
concentrations. Unlike the selectivity constant, catalytic efficiency does not depend on 
the competitive interaction of an alternative substrate target. In the case of FTase, the 
kcat/Kmpeptide should describe FTase selectivity for different Ca1a2X peptide substrates 
[154, 203]. For example, kcat/Kmpeptide for the H-Ras CVLS peptide is twice that 
measured for the K-Ras CVIM peptide. If kcat is dominated by FPP stimulated product 
release, kcat/Kmpeptide should describe FTase selectivity. Therefore, the expected ratio of 
products from the farnesylation of two competing Ca1a2X substrates is given by 
equation 3-1. Interestingly, the ratio of products from the FTase catalyzed farnesylation 
of competing Ca1a2X peptides has not been reported. However, there are a number of 
reports suggesting that FPP binding may not be the sole, or even dominant mechanism 
for product release [49, 74, 80, 203]. A crystal structure of FTase bound to both the 
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farnesylated peptide and FPP (E•FPP•product) revealed that the product prenyl chain is 
displaced from the active site into an external hydrophobic groove (“exit groove”) and 
the new FPP is bound in the active site [49]. Surprisingly, the farnesylated peptide was 
not dissociated from the crystal by the presence of excess FPP. However, the 
farnesylated product was dissociated by additional peptide. Complicating matters 
further, Hartman et al [203]. found that some FTase reaction products do not dissociate 
from the enzyme even in the presence of excess FPP or peptide. However, the addition 
of a different un-farnesylated Ca1a2X peptide stimulated product release. These 
observations are inconsistent with FPP stimulated product release as the sole 
mechanism for dissociation, and indicate that Ca1a2X substrate stimulated product 
release may also be important.  
 
Equation 3-1 kcat/Km as a selectivity factor 
Va and Vb are the rates of modification of the individual reaction components A and B, 
A and B are the concentrations of the reactants in the mixture, the Km is the Michaelis-
Menten constant for each substrate, et is the total enzyme concentration.  
Va
Vb
Vmaxa A. et.
Kma 1
B
Kmb
. A
Vmaxb B. et.
Kmb 1
A
Kma
. B
kcata
Kma
A.
kcatb
Kmb
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Figure 3-1 Minimum reported FTase reaction mechanism 
FTase kinetic pathway where E is the FTase enzyme, E-FPP is the FTase•FPP 
complex, E•FPP•CaaX is the FTase•FPP•CaaX peptide complex, E-Product is the 
FTase bound product complex, E-Product-FPP is the FTase bound to both FPP and the 
reaction product, and E-CaaX is the peptide bound FTase inhibitory complex. Note that 
E•FPP is formed after product release and is not likely to dissociate to the free enzyme. 
 
E-FPP E-ProductE-FPP-CaaX
E-Product-FPP
[CaaX]
[FProduct]
E
E-CaaX
[FPP]
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Figure 3-2 Analog Structures 
Structure of farnesyl diphosphate (1, FPP) 8-anilinogeranyl diphosphate (2, AGPP) 
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A wide range of Ca1a2X sequences have been identified as potential FTase 
substrates [56]. However, farnesylation has only been confirmed for some of them. 
Understanding FTase substrate specificity may be critical for understanding which 
Ca1a2X motifs are farnesylated. Hartman et al. reported that the kcat/Kmpeptide varies over 
400 fold for 14 Ca1a2X peptides with different X-groups [203]. However, it is unclear 
whether the product distribution for the competition of peptides for farnesylation by 
FTase will be adequately predicted by the kcat/Kmpeptide since product release can be 
stimulated by either of the two peptides or FPP [74].  
The FTase reaction is unique because the FPP lipid moiety forms a substantial 
part of the binding surface for the target Ca1a2X peptide [80, 204]. Crystallographic 
studies of FTase with a bound Ca1a2X substrate and a non-hydrolyzable FPP analog 
indicate that the ω-terminal isoprene unit of the lipid is in direct contact with the a2 
residue of the Ca1a2X motif [80, 205]. Unnatural FPP analogs with structures that differ 
from FPP may be useful in determining the molecular features of both the lipid and 
Ca1a2X peptide that contribute to the FTase mechanism [149, 154, 163, 192]. 8-
anilinogeranyl diphosphate (AGPP (2)) contains an aniline moiety which replaces the ω-
terminal isoprene of FPP (1). AGPP (2) is a good substrate for FTase with steady-state 
transfer constants Kmanalog and kcat/Kmanalog nearly identical to those of FPP (1) [159, 
161].  Recent studies with other FPP analogs have shown that the lipid structure can 
significantly affect the Ca1a2X target selectivity of the FTase enzyme [154].  
In this chapter, I describe studies to measure the ability of FTase to selectively 
modify peptides corresponding to six different Ca1a2X motifs with the isoprenoid donors 
FPP and AGPP. The reactivity and the selectivity of FTase for the peptides were similar 
for both isoprenoid donors. Surprisingly, we found that the Ca1a2X substrate selectivity 
of the enzyme is not predicted by the selectivity factor kcat/Kmpeptide. The ratio of 
products from competition reactions between two Ca1a2X peptides correlated with the 
ratio of Kmpeptide instead of the kcat/Kmpeptide ratios. We further analyzed the steady-state 
peptide dependent kinetics of the FTase reaction and found that there were at least 
three Ca1a2X substrate concentration dependent binding states in the FTase reaction 
mechanism. We propose that the binding states are due to peptide binding to the E•FPP 
complex, the E•product complex and a substrate inhibition complex. These results 
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demonstrate the importance of peptide stimulated product release in the mechanism of 
FTase and the involvement of this pathway in the selectivity of the FTase enzyme for 
different Ca1a2X targets.  
Results 
Individual Ca1a2X peptide reactivity is similar with both FPP and AGPP 
In order to determine if kcat/Kmpeptide is the selectivity factor for FTase, we 
measured the apparent kcat/Kmpeptide and Kmpeptide for six dansylated-GCa1a2X peptides 
with saturating concentrations of the isoprenoids FPP and AGPP utilizing a continuous 
fluorescence assay (Table 3-1). The steady state kinetics of the K-Ras4B (CVIM) and 
H-Ras (CVLS) full length proteins and the corresponding Ca1a2X peptides with FPP 
have been extensively characterized [50, 76, 90, 154, 206]. We confirmed that 
kcat/Kmpeptide for the dansylated-GCVIM (Dns-GCVIM) and dansylated-GCVLS (Dns-
GCVLS) substrates were identical to those previously reported in the literature [154]. 
The other four substrates correspond to Ca1a2X motifs from physiologically important 
proteins, three of which are canonical FTase substrates:  CenpF-F (CKVQ) [207], the 
DNAJ homologue, RDJ2 (CAHQ) [200], and the hepatitis delta virus (HDV) large 
antigen protein (CRPQ) [113], and the fourth, a canonical GGTaseI-I substrate Ca1a2X 
motif (CVIL) [56, 208].  
The catalytic efficiency (kcat/Kmpeptide ) of the Ca1a2X substrates varied over a 11- 
and 20-fold range with FPP and AGPP, respectively (Table 3-1). The difference in 
reactivity of the peptides with each isoprenoid was similar, where CVLS was the most 
reactive peptide with both isoprenoids. FTase showed slightly enhanced catalytic 
efficiency with AGPP relative to FPP for the CRPQ peptide. Interestingly, the catalytic 
efficiency with the canonical GGTaseI substrate CVIL was decreased over three-fold 
with AGPP relative to FPP. 
Peptide selectivity is not predicted by kcat/Kmpeptide rather, it is correlated with 
Kmpeptide  
We performed competition reactions between pairs of Ca1a2X peptides in order 
to determine whether kcat/Kmpeptide is the selectivity factor for FTase. The products from 
competition reactions for pairs of Ca1a2X peptides with either FPP or AGPP were 
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separated by RP-HPLC and quantified by integration of the dansyl absorbance (Table 
3-2). The competition reactions were stopped prior to 50% consumption of either 
Ca1a2X substrate in order to ensure that the peptide concentration did not fall below its 
Kmpeptide. We found that the ratio of kcat/Kmpeptide for any of the pairs of Ca1a2X peptides 
examined did not predict the actual ratio of products formed (Table 3-2). For example, a 
1:1 product ratio of farnesyl-CVIM (fCVIM) to farnesyl-CVLS (fCVLS) was expected if 
kcat/Kmpeptide is the selectivity factor for FTase (Table 3-2). Instead, we found a product 
ratio of 3:1 fCVIM:fCVLS (Table 3-2). The CVIM peptide was three-fold more 
competitive over the CVLS peptide than predicted by the ratio of kcat/Kmpeptide. We also 
found that the ratio of products was invariant for reactions where from 10% to 50% of 
the CVIM peptide was consumed. Results from competition reactions with AGPP as the 
isoprenoid donor mirrored those of FPP. However, the product ratios of competition 
reactions for pairs of Ca1a2X peptides with either 12 µM FPP or AGPP did correlate with 
the ratio of the apparent Kmpeptide with a slope of 0.8 for FPP and 2.1 for AGPP (Figure 
3-3). In order for equation 3-1 to accommodate these observations, the ratio of kcat for 
the competing substrates must be equal to an isoprenoid dependent constant. However, 
inspection of the experimentally determined values for kcat (Table 3-1) indicates that this 
is not the case. 
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Table 3-1 peptide steady-state kinetic  parameters 
 
Kinetic parameters Kmpeptide, kcat and kcat/Kmpeptide for N-dansyl-GCa1a2X peptides with 
FPP or AGPP as the isoprenoid donor at 6.7 µM and peptide at varying concentrations 
in Tris-HCl buffer (pH=7.4) plus reducing agent and detergent. Note that FPP and 
AGPP are nearly identical based on the steady state rate constants, except with the 
CVIL and CRPQ peptides.  
 
donor peptide Km
peptide 
(µM) 
kcat
(s-1)•10-2
kcat/Kmpeptide 
(µM-1•s-1)•10-2
FPP CVLS 0.8 ± 0.1 14 ± 2 18 ± 3 
FPP CVIM 0.30 ± 0.06 4.3 ± 0.5 14 ± 3 
FPP CAHQ 2.0 ± 0.3 20 ± 2 10 ± 2 
FPP CKVQ 1.5 ± 0.3 8 ± 1 5 ± 1 
FPP CVIL 6.6 ± 0.6 23 ± 2 3.5 ± 0.4 
FPP CRPQ 5 ± 1 8 ± 1 1.6 ± 0.4 
AGPP CVLS 0.5 ± 0.1 12 ± 2 24 ± 6 
AGPP CVIM 0.18 ± 0.06 1.6 ± 0.3 9 ± 3 
AGPP CAHQ 2.4 ± 0.5 21 ± 3 9 ± 2 
AGPP CKVQ 1.7 ± 0.2 11 ± 1 7 ± 1 
AGPP CVIL 16 ± 2 17 ± 1 1.1 ± 0.1 
AGPP CRPQ 10 ± 1 21 ± 2 2.1 ± 0.3 
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Table 3-2 Ratios of products 
Ratios of products from reaction mixtures containing FPP or AGPP at 6.7 µM each with 
two N-dansyl-GCa1a2X peptides at 3 µM each. Product ratios were determined from 
HPLC analysis of competition reactions containing two peptides and FPP. Product was 
quantified by integration of 340 nm trace chromatogram. Note that the ratio of the 
Kmpeptide change with the product ratio but not the ratio of the kcat or kcat/ Kmpeptide
 
Reactants FPP AGPP 
peptide 
A 
peptide 
B 
product 
ratio 
fA:fB 
kcat/Kmpeptide 
ratio 
fA:fB 
Kmpeptide 
ratio 
fB:fA 
kcat 
ratio 
fA:fB 
product 
ratio 
agA:agB 
kcat/Kmpeptide 
ratio 
agA:agB 
Kmpeptide 
ratio 
agB:agA 
kcat 
ratio 
agA:agB 
 
CVIM CVLS 3 ± 1 0.8 ± 0.2 2.7 ± 0.31 ± 2.1 ± 0.1 0.4 ± 0.2 3 ± 1 0.13 ± 
CVLS CKVQ 1.4 ± 0.2 3.6 ± 0.9 1.9 ± 1.8 ± 0.3 2.8 ± 0.8 3 ± 1 3.4 ± 0.8 1.1 ± 0.2 
CVLS CAHQ 1.8 ± 0.1 1.8 ± 0.5 2.5 ± 0.7 ± 0.1 2.4 ± 0.1 2.7 ± 0.9 5 ± 1 0.6 ± 0.1 
CKVQ CAHQ 0.7 ± 0.1 0.5 ± 0.1 1.3 ± 0.4 ± 0.9 ± 0.1 0.8 ± 0.2 1.4 ± 0.3 0.52 ± 
CAHQ CVIL 1.5 ± 0.2 2.9 ±`0.7 3.3 ± 0.9 ± 0.1 ND* NA** NA** NA** 
CAHQ CRPQ 2.4 ± 0.2 6 ± 2 2.5 ± 2.5 ± 0.4 2.6 ± 0.1 4 ± 1 4 ± 1 1.0 ± 0.2 
CVIM CRPQ 13.4 ± 9 ± 3 17 ± 5 0.54 ± 23 ± 2 4 ± 2 60 ± 20 0.08 ± 
CVLS CRPQ 3.5 ± 0.2 11 ± 3 6 ± 1 1.8  0.3 14.9 ± 11 ± 3 20 ± 4 0.6 ± 0.1 
CVIL CRPQ 1.5 ± 0.3 0.5 ± 0.1 1.3 ± 0.35 ± 0.5 ± 0.1 0.52 ± 0.09 0.6 ± 0.1 0.81 ± 
*ND: not determined 
**NA= not applicable 
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Figure 3-3 Comparison of the Ratio of products with the Kmpeptide
 
Product ratio verses the ratio of the Kmpeptide for each competition reaction in Table 3-2 
a) FPP or b) AGPP. Note that the slope of the two graphs differ where the Kmpeptide ratio 
correlates directly with the product ratio with FPP but is two times the product ratio with 
AGPP. R value for both lines is greater than 0.95 
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Product ratio is dependent on the isoprenoid donor concentration 
Since the observed product ratios were not predicted by the ratio of kcat/Kmpeptide 
but did correlate with an isoprenoid dependent ratio of the apparent Kmpeptide we 
examined the dependence of the product ratios on the concentration of isoprenoid 
diphosphate. There are two isoprenoid diphosphate bound states in Figure 3-1 and the 
experimental Km for both FPP and AGPP is 46 nM with the CVLS peptide. We did not 
expect any change in the product ratios, as the isoprenoid concentrations used in the 
competition reactions were well above saturation for the isoprenoid donor. We 
measured the ratio of product from the CVIM and CVLS peptides over a range of FPP 
and AGPP concentrations. (Figure 3-4) The product ratio decreased with increasing 
concentrations of the isoprenoid donor, trending towards the ratio expected from 
equation 3-1. These unanticipated results suggest that the mechanism shown in Figure 
3-1 is incomplete.  
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Figure 3-4 Product ratio dependence on isoprenoid concentration 
CVIM/CVLS peptide pair product ratios were measured from reaction mixtures 
containing 3µM of the CVIM and CVLS peptide with a) FPP or b) AGPP at increasing 
concentrations. Note that the effect of increasing concentration of FPP on the product 
ratio is much greater than the effect with increasing AGPP concentrations  
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Overall rate of competition reactions is governed by the rate of the peptide with 
the lowest Kmpeptide 
In order to characterize the unusual dependence of the product ratios on 
Kmpeptide, we examined the overall velocity of the competition reactions relative to the 
velocity of reactions for the individual peptides. For competition reactions between 
CVIM and CVLS peptides the overall reaction rate was the same as for the CVIM 
peptide alone. CVIM has both a lower Kmpeptide and rate of transfer than does CVLS. We 
examined the dependence of the overall competition velocity on the component Ca1a2X 
peptide Kmpeptide and rates of transfer. Competition reactions between the CKVQ/CAHQ 
and CRPQ/CVIL peptide pairs with AGPP as the isoprenoid donor were run in parallel 
with the corresponding single peptide reactions at the same individual substrate 
concentrations (Figure 3-5). The total peptide concentration in the competition reactions 
was twice that of the single peptide reactions. The overall rate of the CKVQ/CAHQ 
competition reaction was the same as for the reaction of the CKVQ peptide alone. Of 
the pair, the CKVQ peptide has the lower Kmpeptide and the slower reaction rate. 
Similarly, the overall rate of the CRPQ/CVIL reaction was the same as for the lower 
Kmpeptide CRPQ substrate alone. However, under these conditions, the reaction rate of 
the CRPQ peptide is higher than that of the CVIL. We conclude that the overall rate of 
the competition reactions is governed by the rate of the peptide with the lowest Kmpeptide 
.  
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Figure 3-5 Rate of the competition and individual peptide reactions 
Reactions were prepared that contained the peptide pair indicated in parallel with each 
individual peptide reactions at the same enzyme and peptide concentration. Error bars 
represent values from triplicate reactions 4-5a: Competition of CAHQ and CKVQ 
peptides for AGPP modification. 4-5b: Competition of CAHQ and CKVQ peptides for 
AGPP modification. Note that the rates of the competition reactions are the same as the 
rates of the single peptide reaction where the peptide is the one with the lowest Kmpeptide
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There are a minimum of three peptide binding states in the FTase steady-state 
reaction  
In the generally accepted FTase mechanism, FPP association with the E•product 
complex is solely responsible for stimulating product release (Figure 3-1). As noted 
above, Ca1a2X peptides can stimulate product release, suggesting that peptide also 
interacts with the E•product complex. In addition, substrate inhibition of the FTase 
reaction by both Ca1a2X peptides and full length proteins, including CVLS and H-Ras, 
have previously been reported [55, 71]. In order to characterize Ca1a2X peptide 
stimulated product release, we investigated the FTase reaction using peptide 
concentrations higher than required to reach maximum velocity. Much to our surprise, 
we found increasing concentrations of the CKVQ substrate in reactions with both FPP 
and AGPP had more complex effects than simple inhibition (Figure 3-6). As previously 
reported, the reaction rate increased to a maximum, before falling as the concentration 
of peptide was increased. Surprisingly, at even higher concentrations of peptide, the 
rate again increased slightly to a smaller second maximum before finally approaching 
zero. To our knowledge, the second peptide concentration dependent rate increase has 
not been previously described. To confirm these observations, we examined the FTase 
reaction for the Ca1a2X concentration dependence of the CVLS and CAHQ peptides 
with FPP. The appearance of two peptide substrate concentration dependent maxima in 
the CVLS and CAHQ reaction profiles was similar to what we observed for CKVQ. The 
second rate maximum for the CVLS peptide was less pronounced than for CKVQ. 
Interestingly, with increasing concentrations of CAHQ we found that the rate dipped 
slightly after the first maxima, then rose gradually to a second, higher maximum before 
decreasing.  
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Figure 3-6 Steady state reaction of FPP with peptides 
Response of reaction rate with increasing concentrations of peptide well above 
concentration required to reach the first Vmax. Note the second increase in the reaction 
rate after the first Vmax point has been reached. 
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The presence of two peptide substrate concentration dependent maxima and 
substrate inhibition in the steady-state reaction profile requires a minimum of three 
peptide binding states. The generally accepted mechanism (Figure 3-1) has only two 
peptide bound states. The second peptide bound state, E•CaaX is thought to result from 
dissociation of FPP from the E•FPP complex, followed by peptide binding to FTase. 
Previous reports have shown that E•CaaX is non-productive, and is unable to bind FPP 
to form the reactive E•FPP•CaaX complex [72]. Rather, the productive E•FPP complex 
is generated by peptide dissociation from E•CaaX followed by FPP binding. In this 
model, formation of the inhibitory E•CaaX requires peptide to out-compete FPP for 
association with the free enzyme. However, FPP has a much higher affinity for FTase 
than do the Ca1a2X peptides, and CVLS peptide affinity for E•FPP is 70 fold higher than 
for the free enzyme [90]. Also, the E•FPP complex is highly committed towards catalysis 
since FPP dissociates at a rate 2.5 times slower than kcat [55].  
Here we propose a more complex model for the FTase reaction mechanism that 
takes these observations into account (Figure 3-7). In common with the generally 
accepted mechanism, the first peptide bound state is the E•FPP•CaaX complex. The 
second state is the E•product•CaaX complex which is responsible for peptide stimulated 
product release. This state is formed in competition with E•product•FPP. Release of 
product from the E•product•CaaX complex would leave the third state, E•CaaX. In this 
scheme, product dissociation from E•product•CaaX (Figure 3-7) would form the 
inhibitory E•CaaX complex as a natural consequence of catalysis. Additionally, higher 
concentrations of Ca1a2X peptide will drive formation of the inhibitory E•CaaX complex 
at the expense of E•FPP by favoring formation of E•product•CaaX relative to 
E•product•FPP without requiring dissociation of FPP from E•FPP.  
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Figure 3-7  FTase reaction mechanism 
Extended mechanism incorporating peptide stimulated product release. The mechanism 
is split into two pathways path A representing FPP stimulated product release and path 
B representing peptide stimulated product release.  E is the FTase enzyme, E-FPP is 
the FTase•FPP complex, E•FPP•CaaX is the FTase•FPP•CaaX peptide complex, E-
Product is the FTase bound product complex, E-Product-FPP is the FTase bound to 
both FPP and the reaction product, and E-CaaX is the peptide bound FTase inhibitory 
complex, E-Product-CaaX is the new peptide bound enzyme product complex 
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Competition by two Ca1a2X peptides for the E•product complex suggests a 
mechanistic explanation for the observations that the peptide with the lowest Km 
controls the overall FTase reaction rate. In this scheme, the overall rate will depend on 
the relative affinity of the peptides and isoprenoid diphosphate for the E•product 
complex, as well as the rate of product release from the E•product•CaaX and 
E•product•FPP complexes. If one of the competing peptides binds the E•product 
complexes more efficiently and/or stimulates faster product release from 
E•product•CaaX, then its rate will determine the overall rate. Consequently, the kcat for 
both peptides in equation 3-1 will be the same. Secondly, increasing isoprenoid will 
compete with the peptides for E•product and increase flux through path A of Figure 3-7. 
Consequently, the ratio of products formed under high concentrations of isoprenoid 
donor in a competition reaction between two peptides will be less dependent on peptide 
stimulated release. These conclusions are consistent with the experimental findings that 
the peptide with the lowest measured Kmpeptide determines the overall rate and that the 
ratio of kcat for each of the competing substrates will be equal to an isoprenoid 
dependent constant.  
Discussion 
 
Peptide verses FPP stimulated release efficiency 
The efficiency of the FPP and peptide stimulated release pathway could be 
dependent on the binding affinity of the peptide or FPP to the E•product complex as well 
as the rate of release due to binding of either substrate. Under competition conditions 
this scheme becomes even more complex due to a third route to product release with 
the alternative peptide substrate. It is possible that peptide binding affinity to the 
E•product complex is attenuated depending on the identity of the isoprenylated Ca1a2X 
sequence in the active site of the enzyme. The Ca1a2X binding affinity to the E•product 
complex may be completely unrelated to the binding affinity to the free enzyme or the 
enhanced affinity with the E•FPP complex. For example, a TKCVIC peptide can 
stimulate the release of a farnesylated TKCVIL peptide product from the FTase active 
site, yet the affinity of TKCVIC for the E•FPP complex is 7-fold lower than the affinity of 
TKCVIL [203]. In addition, FPP binding affinity for the E•product complex will not 
necessarily correlate with the binding affinity to the free enzyme. The relative efficiency 
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of peptide stimulated release verses FPP stimulated release is not known. However, 
large quantities of isoprenoid were required for the competition reaction product 
distribution to approach the ratios predicted from the kcat/Kmpeptide suggesting that 
peptide stimulated release may be more efficient that isoprenoid stimulated. In addition, 
AGPP stimulated product release appears to be even less efficient than FPP stimulated. 
AGPP is less hydrophobic than FPP and may not associate with E•product complex as 
readily as the natural substrate.  
Altering FTase selectivity 
The isoprenoid and target peptide interact directly with one another throughout 
the FTase reaction, and changes in the structure of the isoprenoid may alter the 
interactions between them. Changing the interactions of the isoprenoid with the target 
Ca1a2X motif could lead to the selective modification of particular Ca1a2X substrates 
with unnatural probes specific for certain Ca1a2X sequences. The reactivity of the 
canonical FTase Ca1a2X substrates was nearly identical with both FPP and AGPP as 
the isoprenoid donors.  However, with AGPP as the isoprenoid donor the selectivity was 
markedly decreased for the canonical GGTaseI substrate over the CRPQ Ca1a2X 
sequence. AGPP is more readily utilized to modify the HDV large antigen based Ca1a2X 
peptide over the GGTaseI target peptide in contrast to FPP which is more readily 
utilized to modify the GGTaseI Ca1a2X substrate. To our knowledge this is the first 
example of an analog switching the Ca1a2X selectivity of the FTase enzyme. Further 
alterations of the isoprenoid diphosphate may therefore lead to analogs that further alter 
FTase target selectivity for different Ca1a2X sequences.  
FTase clearance mechanism 
Peptide stimulated product release may be essential to allow slowly turned over 
FTase substrates to be cleared from the enzyme active site. A wide variety of peptides 
including GGTaseI substrate peptides have a high affinity for the FTase•FPP complex 
and thioether formation occurs. However, some of these Ca1a2X sequences such as the 
GGTaseI substrate TKCVIL are not readily released from the active site with excess 
FPP or substrate peptide [203]. In order for FTase to be functional after formation of a 
slowly dissociating or single turnover product a cell may require product release to be 
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stimulated by an alternative Ca1a2X substrate. The GGTaseI reaction mechanism is 
similar to that of FTase and it is likely that the peptide stimulated release mechanism 
also exists for the GGTaseI enzyme.  
Experimental 
General 
AGPP and FPP were synthesized as described previously. All RP-HPLC was 
performed on an Agilent 1100 HPLC system equipped with a microplate autosampler, 
diode array and fluorescence detector. The HPLC analysis was performed with a 
microsorb C18 column with 0.01% TFA in water (A) and 0.01% TFA MeCN (B) as the 
mobile phase. Peptides were purchased from peptidogenics and each contained a 
dansyl group N linked to a glycine linker followed by a C residue then a variable aaX 
sequence (VLS, VIM, AHQ, RPQ, VIL or KVQ). Spectrofluorometric analyses were 
performed in a 96-well flat bottom, non-binding surface, black polystyrene plate 
(Excitation wavelength, 340 nm; emission wavelength 505 nm with a 10 nm cutoff). The 
plate reader was a SpectraMax GEMINI XPS fluorescence well-plate reader. 
Absorbance readings were determined using a Cary UV/Vis spectrophotometer. 
Steady-state peptide kinetics  
The kinetic constants Kmpeptide and kcat with FPP, and AGPP for each dansyl-
GCaaX peptide were determined in triplicate measurements using a continuous 
spectrofluorometric assay adapted for a 96-well plate. The following assay components 
were assembled in individual wells of a 96-well plate and incubated at 30° C for 20 
minutes: 180 µL of assay buffer (52 mM Tris-HCl, 12 mM MgCl2, 12 µM ZnCl2 pH 7.4), 
40 µL of detergent (0.125% n-dodecyl- β-D-maltoside in assay buffer), 40 µL of 
reducing agent (50 mM DTT in assay buffer) 20uL of FPP or AGPP (200 µM in 25 mM 
NH4HCO3) and 20 µL of N-dansyl-GCaaX peptide (variable concentration).  
Fluorescence was detected using a time based scan at 30° C for 120 minutes. The 
velocity of each reaction was determined by converting the rate of increase in 
fluorescence intensity units (FLU/s) to µM/s with equation 3-2.  
Equation  3-2: vi=(R·P)/(FMAX-FMIN) 
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Where vi is the velocity of the reaction in µM/s. R is the rate of the reaction in FLU/s. P 
is equal to the concentration of modified product in µM (see below). FMAX is the 
fluorescence intensity of fully modified product. FMIN is the fluorescence of a reaction 
mixture that contained 20 µL of assay buffer in the place of FTase. Complete 
modification of peptides was assumed when fluorescence stabilized for more than 10 
minutes and was confirmed by RP-HPLC analysis of the reaction mixture. 
Final analysis peptide concentrations were chosen based on preliminary 
determination of the Kmpeptide with 0.5, 1, 5 and 10 µM dansyl-GCaaX concentrations 
(see below). The final analysis used 8 peptide concentrations which were: 1/6, 1/5, 1/4, 
1/2, 3/4, 1, 2, and 3 times the estimated Kmpeptide value except with the CVIM peptide 
where we used concentrations at 0.3, 0.45, 0.675, 0.9, 1.8, 2.7, 3.6, and 4.5 times the 
estimated Kmpeptide. The reaction was then initiated by the addition of 20 µL of FTase 
(final concentration 5 nM with the CLVS, CAHQ, CVIL and CRPQ peptide, 10nM with 
the CVIM peptide). Fluorescence enhancement determined as described above. 
Complete modification of peptides was assumed when fluorescence stabilized for 
more than 10 minutes and was confirmed by RP-HPLC analysis of the reaction mixture. 
If the reactions that contained higher concentrations of peptides did not go to 
completion the Fmax-Fmin value was extrapolated using a linear plot of the Fmax-Fmin 
for each of the lower concentration reactions that did go to completion. Alternatively the 
extent of input peptide modified was determined by RP-HPLC analysis of the dansyl 
moiety peak absorbance corresponding to the unmodified and modified peptides. The 
percent of modified peptide relative to the total input peptide was used to calculate the 
concentration of product in the mixture. 
 The velocities of the reactions were plotted against the concentration of peptide 
and were fit to the Michaelis-Menten equation (Equation 3-3) to give the apparent kcat 
(appkcat) and Kmpeptide (appKmpeptide) values. Where et was the total enzyme 
concentration and [Pep] was the total input peptide. The kcat/Kmpeptide value was derived 
from a Lineweaver-Burke plot of the same data points.  
Equation 3-2: vi/et=(appkcat*[Pep])/(appKmpeptide+[Pep]) 
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Substrate inhibition analysis 
The steady-state reaction profiles with high concentrations of peptide were 
analyzed as described above with peptide concentrations 4, 5, 6, 7, 8, 9, and 10 fold 
higher than the appKmpeptide. 
Peptide competition 
Competition reactions were prepared with the same components given for the 
kcat/Kmpeptide analysis except two peptides were added to the mixture at a single 
concentration. Peptides A and B were diluted to 45 µM in Tris-HCl buffer (pH=7.4) and 
the concentration checked by reading the Abs of the solution at 340 nm (εdansyl=4250 
Abs·M-1·cm-1). 20 µL of peptide A and 20 µL of peptide B were then added to reaction 
mixtures as described above except only 160 µL of assay buffer was added.  Separate 
reactions were prepared as a standard with FPP or AGPP and only one peptide as 
described above.  The reactions were then initiated with the addition of FTase and 
analyzed spectrofluorometrically (Reactions containing CVIM peptide used 20 nM final 
FTase concentration all other used 10 nM). The reactions were stopped prior to 
consumption of more than 50% of either peptide by adding 20 µL of a stop solution 
(isopropyl alcohol and acetic acid 8:2). HPLC analysis was then performed with 100 µL 
of the reaction mixture loaded onto C18 column and eluted with a linear gradient of 0-30 
min 10% B to 100% B at a flow rate of 1 mL/min. Peaks on the 340 nm trace 
chromatogram that corresponded to both the standard reactions and fluorescent peaks 
were then integrated. The ratios of products were calculated according to equation 3-4. 
Equation  4-4: (IAmod/ IAtot)/(IBmod /IBtot) 
Where IAmod is the integral of the modified peptide A, IAtot is the integral of the 
modified peptide A plus the unmodified peptide A, IBmod is the integral of the modified 
peptide B and IBtot was the integral of the modified peptide B plus the unmodified peptide 
B. Alternatively, the ratios were calculated using the integrals of the standard peptides 
fluorescence relative to competition product fluorescence giving less than a 5% 
difference in the calculated ratio.  
 
Overall rate of competition reactions 
The overall rate of the competition reaction was determined using equation 2 and 
the amount of total peptide modified based on RP-HPLC analysis. Alternatively peptide 
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competition reactions were scaled up to a 1000 µL solution and sampled for RP-HPLC 
analysis every 45 minutes for 6 hours.  
Increasing FPP and AGPP concentrations effect on product ratio 
To determine the effect of increasing isoprenoid concentration the FPP and 
AGPP concentrations in the competition mixtures were increased from 0.5-66 µM with 
FPP and 0.5-400 µM AGPP.  
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CHAPTER 4 FARNESYL DIPHOSPHATE ANALOG COMPETITION FOR FARENSYL 
TRANSFERASE 
Introduction  
An interesting feature of the FTase reaction mechanism (Figure 4-1) is the 
association between the isoprenoid lipid and the target Ca1a2X sequence in both the 
E•product•FPP and E•FPP•CaaX complexes [80]. In each of these complexes, FPP 
binds at the same hydrophobic surface and interacts directly with the terminal residues 
of the target Ca1a2X sequence. Pre-steady state kinetic studies have shown that FPP 
association with the free enzyme enhances Ca1a2X peptide affinity up to 70 fold [90]. 
The interaction between the target Ca1a2X motif and the isoprenoid suggests that 
changes in the structure of FPP may be analogous to amino acid mutations in the active 
site of the enzyme, where the reactivity of the Ca1a2X motif can be modulated by 
changes in the structure of FPP [154]. The ω-isoprene of FPP associates directly with 
the a2 residue of the target Ca1a2X peptide, but it is not clear how altering the ω-
isoprene structure affects Ca1a2X peptide reactivity.  
Isoprenoid analogs of FPP have been used to study the physical interactions 
between the isoprenoid, FTase and the Ca1a2X peptide. The analog, 8-anilinogeranyl 
diphosphate (AGPP, 2a, Figure 4-2) contains an aniline moiety in the place of the ω-
terminal isoprene of FPP. AGPP is transferable to Ca1a2X substrates with steady-state 
kinetics nearly identical to FPP, and the aniline moiety appears to act as an isostere for 
the terminal isoprene of FPP [159, 161]. AGPP has been used to probe the endogenous 
modification of proteins by FTase and is competitive with FPP both in vitro and in cell 
culture [159, 209]. However, when the aniline moiety of AGPP is replaced with a p-NO2 
aniline 2b or a pentafluoro-aniline the analog dependent steady-state transfer efficiency 
is severely reduced [161].  
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Figure 4-1  FTase reaction mechanism 
Extended mechanism incorporating peptide stimulated product release. The mechanism 
is split into two pathways path A representing FPP stimulated product release and path 
B representing peptide stimulated product release.  E is the FTase enzyme, E-FPP is 
the FTase•FPP complex, E•FPP•CaaX is the FTase•FPP•CaaX peptide complex, E-
Product is the FTase bound product complex, E-Product-FPP is the FTase bound to 
both FPP and the reaction product, and E-CaaX is the peptide bound FTase inhibitory 
complex, E-Product-CaaX is the peptide bound enzyme product complex 
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Figure 4-2 Analog Structures 
Structure of farnesyl diphosphate (1, FPP) 8-anilinogeranyl diphosphate (2a, AGPP) 
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Understanding the ability of substrate analogs to compete with the natural 
substrate will improve the ability to develop new analogs to probe the FTase reaction 
mechanism as well as the development of potential inhibitors of prenylated protein 
function. In chapter 2, I described the synthesis of a library of AGPP analogs with a 
variety of functional groups in the ortho-, meta- and para- positions of the AGPP aniline 
ring. In this section, I utilize this library of molecules to probe the relationships of the 
AGPP structure on Ca1a2X peptide reactivity and competitiveness with FPP. We have 
found that the position and size of the aniline ring substitution has a major affect on the 
reactivity of the AGPP analogs. With simple conservative substitutions in the AGPP 
aniline ring, the reactivity of the analogs range from molecules that transfer more 
efficiently than FPP to analogs that are inhibitors of the FTase catalyzed farnesylation of 
Ca1a2X substrates. We also found that the structure of the analogs affected the 
competitiveness with FPP and that the molecular features that improved peptide 
reactivity improved FPP competitiveness for the CVLS peptide. These results 
demonstrate that with only subtle alterations in the structure of an FPP analog, FTase 
activity can be effectively modulated depending on the structure of the analog. These 
results also suggest that the natural substrate of FTase can be improved upon, to 
develop molecules that can efficiently and competitively be transferred to FTase target 
Ca1a2X sequences. 
Results  
Peptide target reactivity is dependent on size and position of substitutions in the 
aniline moiety of AGPP 
In order to determine how changing the structure of AGPP affects the reactivity of 
an FTase target peptide we measured the steady-state transfer kinetics of a dansylated-
GCVLS (CVLS) pentapeptide with a library of structurally diverse AGPP analogs. (Table 
4-1) The CVLS peptide corresponds to the Ca1a2X sequence of H-Ras, and the steady-
state transfer kinetics of both H-Ras and the CVLS peptide have been extensively 
characterized. Utilizing a continuous fluorescence assay we found kcat, Kmpeptide and 
kcat/Kmpeptide values with CVLS and FPP that were identical to those previously reported 
for both CVLS and a full length H-Ras protein.  
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Over half of the 50 molecule AGPP library 2a-aq was transferred to the CVLS 
peptide by FTase. The ability of the peptide to react with the various analogs was highly 
dependent on the size and position of the functional group substitution in the AGPP 
aniline ring. Analogs with functional groups larger than an ethoxy group 2ac-2aq were 
poorly transferred to the CVLS peptide independent of the aniline ring position that was 
substituted. However, when the aniline ring was substituted with a fluorine atom at 
either the meta- 2d or ortho- 2c positions the CVLS peptide reacted with a catalytic 
efficiency (kcat/Kmpeptide) nearly identical to that with FPP and AGPP. Surprisingly, with 
the pF-AGPP 2e analog the catalytic efficiency of the enzyme with the CVLS peptide 
was increased.  
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Table 4-1 Michaelis-Menten Peptide Kinetics 
Steady state kinetic parameters were measured with varying concentrations of N-
dansyl-GCVLS peptide FPP and each of the AGPP analogs with FTase in Tris-HCl 
buffer (pH=7.4) plus detergent and reducing agent. Note that some analogs increase 
efficiency and/or decrease the Kmpeptide
R # kcat (s-1)•10-2
KmCVLS 
(µM) 
kcat/KmCVLS 
(µM-1•s-1)•10-2
FPP 1 14 ± 2 0.8 ± 0.1 18 ± 3 
H 2a 12 ± 2 0.5 ± 0.1 24 ± 6 
pNO2 2b 160 ± 20 15 ± 2 10.7 ± 0.2 
oF 2c 15 ± 3 0.9 ± 0.2 16 ± 1 
mF 2d 10 ± 1 0.34 ± 0.08 26 ± 3 
pF 2e 9.5 ± 0.4 0.26 ± 0.04 35 ± 4 
oMe 2f 16.6 ± 0.9 4.0 ± 0.4 4.2 ± 0.5 
mMe 2g 6.9 ± 0.5 0.17 ± 0.06 38 ± 8 
pMe 2h 60 ± 20 4 ± 1 16 ± 1 
mCN 2i 13 ± 1 1.0 ± 0.1 11.5 ± 0.3 
pCN 2j 70 ± 3 10.2 ± 0.6 6.8 ± 0.1 
oMeO 2k 8.8 ±  0.9 0.9 ± 0.2 9.3 ± 0.6 
mMeO 2l 53 ± 5 4.3 ± 0.6 12 ± 2 
pMeO 2m 140 ± 40 30 ± 10 5 ± 2 
oI 2n Slow** >10 ND*** 
mI 2o 24 ± 2 0.9 ± 0.1 26 ± 3 
pI 2p 17 ± 3 1.4 ± 0.4 12 ± 4 
oCF3O 2q Slow** >10 ND*** 
mCF3O 2r 40 ± 10 2.3 ± 0.6 19 ±1 
pCF3O 2s 27 ± 6 3.1 ± 0.9 8.7 ± 0.3 
oCl 2t 10 ± 1 0.8 ± 0.2 10.3 ± 0.3 
mCl 2u 13 ± 2 1.0 ±0.2 13 ± 3 
pCl 2v 30 ± 10 1.9 ± 0.8 18 ± 1 
oBr 2w 13 ± 1 1.0 ± 0.2 13 ± 3 
pBr 2x 27 ± 8 1.7 ± 0.5 16 ± 2 
oCF3 2y 30 ± 10 >10 0.9 ± 0.1 
oEt 2z 17 ± 2 7 ± 1 2.4 ± 0.6 
mEt 2aa 8 ± 2 3.8 ± 0.8 2.1 ± 0.1 
pEt 2ab NR* NR* NR* 
oEtO 2ac NR* NR* NR* 
mEtO 2ad NR* NR* NR* 
pEtO 2ae NR* NR* NR* 
oSMe 2af NR* NR* NR* 
pSMe 2ag NR* NR* NR* 
oiPr 2ah NR* NR* NR* 
piPr 2ai NR* NR* NR* 
oPh 2aj NR* NR* NR* 
pPh 2ak NR* NR* NR* 
oPhO 2al NR* NR* NR* 
mPhO 2am NR* NR* NR* 
pPhO 2an NR* NR* NR* 
oPhCH2 2ao NR* NR* NR* 
mPhCH2 2ap NR* NR* NR* 
pPhCH2 2aq NR* NR* NR* 
 
* NR=No Reaction 
** slow indicates that some reaction did occur, but not enough to characterize 
*** ND=not determined due to the inability to measure kcat 
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When the functional group in the aniline ring was smaller than an ethoxy group 
2b-2ab the reactivity of the molecules was highly dependent on the position of the 
aniline ring that was functionalized. Aside from the fluorine substituted analogs the 
reactions with the meta- substituted analogs were in general the most efficient. In 
particular, the position of an Iodine and Methyl functional group in the aniline ring 
drastically altered the catalytic efficiency of FTase with the CVLS peptide. The efficiency 
of the CVLS reaction with both the mI-AGPP 2o and mMe-AGPP 2g analogs was much 
higher than the efficiency with the natural substrate. However, when the functional 
group of the Iodo and methyl AGPP analogs was shifted to the para- and ortho- 
positions the efficiency of the reactions was drastically reduced. In particular, reactions 
containing the oI-AGPP 2n analog and the CVLS peptide resulted in little to no product 
formation even in the presence of enzyme concentrations well above what was required 
for complete modification of the CVLS peptide with the other iodine substituted analogs. 
The individual kcat and Kmpeptide were significantly affected by the functionalized position 
of the aniline ring, even-though the effects may not have been observed in the 
kcat/Kmpeptide. We found that AGPP analogs with para-functional group substitutions, in 
general, increased both the kcat and Kmpeptide of the CVLS substrate relative to the ortho- 
and meta- isomers.  On the other hand, we found that the ortho- substituted analogs 
tended to reduce the kcat of the CVLS peptide reactions.  These results indicated that 
the reactivity of the Ca1a2X peptide was highly dependent on the position and size of the 
aniline ring substitution in AGPP. 
Non-substrate ortho- substituted analogs are potent FTase inhibitors 
A number of the AGPP analogs were not substrates for the FTase catalyzed 
modification of the CVLS peptide, but analogs that were not substrates may still bind to 
the enzyme and act as an inhibitor. To determine if the non-substrate analogs were 
FTase inhibitors we mixed FPP and each analog 1:1 in excess of the CVLS peptide, 
and determined the reaction rate relative to the rate with FPP alone (Figure 4-3). We 
found that the rate of farnesylation was decreased over 50% with the ortho- but not the 
meta- and para- substituted AGPP non-substrate analogs. In order to more closely 
examine the ability of these analogs to inhibit the FTase reaction we measured the 
analog concentration dependence on the FTase inhibition. The Ki of the ortho- 
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substituted non-substrate analogs were well below the previously reported Km of FPP 
(KmFPP = 46 nM). (Table 4-2) These results indicated that these analogs could readily 
bind to the enzyme, but the reaction with the CVLS peptide was compromised.  
Analogs are competitive with FPP for target modification  
In order for an analog to be utilized in cells they must be competitive with FPP. 
Previous studies to determine the kinetic factors that predict FTase selectivity for 
peptide targets suggested that simple steady-state catalytic efficiency measurements do 
not predict the selectivity of the enzyme for Ca1a2X peptides in competition with one 
another. AGPP is competitive with FPP both in vitro and in cell culture [159], but it is not 
clear how well steady-state kinetic measurements predict the ability of AGPP to 
compete. Instead of relying on steady-state kinetic measurements we directly measured 
the ability of AGPP and the analogs to compete with FPP. We mixed AGPP and FPP 
1:1 in excess of the CVLS peptide and analyzed the resulting CVLS modified product by 
HPLC and integration of the dansyl peak absorbance. We found that the resulting 
product ratio was 2:1 farnesyl to anilinogeranyl modified CVLS peptide. This was 
significantly less anilinogeranylated peptide than would have been predicted based 
solely on previous steady-state kcat/KmAGPP measurements (kcat/KmAGPP=1.8 µM-1•s-1 
KmAGPP =46 nM kcat/KmFPP =2.2 µM-1•s-1 KmFPP =46 nM)[159, 161].  
We found that a number of the analogs were utilized by FTase even in the 
presence of FPP. The competitiveness of the analogs with functional groups larger than 
fluorine was highly dependent on the position of the aniline ring that was functionalized. 
The meta- substituted analogs were the most competitive followed by the ortho- and 
para- substituted analogs. Several of the functionalized AGPP analogs were even more 
competitive than AGPP including all three of the fluorine substituted analogs. The 
structure dependence of analog competition with FPP appeared to correlate with the 
structure dependence on peptide reactivity. 
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Figure 4-3 Farnesylation Inhibition 
N-dansyl-GCVLS was mixed with FPP and an equimolar amount of the analog. FTase 
was added and the percent inhibition was calculated by comparing the rate of reactions 
containing the analog and FPP to the reaction rate with FPP alone. Note that only the 
ortho- substituted analogs inhibit greater than 50%. 
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Table 4-2 Analog Ki 
Analog Ki values were calculated from reaction rates of FPP/analog competition 
reactions for an N-dansyl-GCVLS peptide, where the analog concentration was varied 
and the FPP concentration was held at 6.7 µM. Note that the Ki of the ortho- substituted 
AGPP analogs is lower than the KmFPP which is 40 nM. 
 
R # Ki
XPP 
(nM) 
oCF3O 2q 3.0 ± 0.3
oEtO 2ac 12 ± 1 
oSMe 2af 2.4 ± 0.2
oiPr 2ah 4.4 ± 0.2
oPh 2aj 3.6 ± 0.4
oPhCH2 2ao 18 ± 1 
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 Figure 4-4 Analog/FPP competition for CVLS 
Ratios of products, analog modified CVLS:farnesylated CVLS were found from 
reactions set up with 3µM peptide and 6 µM of the analog and FPP. Reactions were 
allowed to continue until all peptide was consumed and were then analyzed by RP-
HPLC. Fluorescence detection indicated the retention time of each of the products and 
integration of peaks at 340 nm was used to quantify products. Analogs pNO2-AGPP 2b 
and mCN-AGPP 2i increased absorption at 340 nm so product from reactions 
containing these analogs was calculated based on input peptide relative to peptide 
unmodified. * indicates that the ortho- analogue was not available. 
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Discussion 
FPP Analog Reactivity and Peptide Substrate Inhibition 
We found that a number of the AGPP analogs were FTase transferable 
substrates with transfer properties that could not have been predicted by the analysis 
presented in chapter 2. In chapter 2, I described the reactivity of the analogs based on 
reaction rates with high concentrations of peptide and analog. However, the 
concentration of peptide that would be required to be saturating would differ depending 
on the analog and at concentrations that are too high the analog reaction may be 
inhibited by the peptide. When using only the reaction rate to study the analog reactivity 
analogs that induce a low Kmpeptide will also increase the ability of the peptide to inhibit 
the reaction with that analog. In other words analogs that appeared in the earlier 
analysis to be poor substrates, in fact increased the reactivity of the peptide. The effects 
of peptide inhibition therefore make it very difficult to study the FTase reaction without a 
steady-state kinetic evaluation with variable peptide concentrations.  
Cellular protein Incorporation 
A number of the analogs that were rapidly transferred in the FTase reaction were 
not competitive with FPP. In chapter 2 the pCN-AGPP analog was utilized in the 
Xenopus studies and was a Ras function inhibitor. However, the analysis in this chapter 
indicates that the pCN-AGPP analog would be a poor choice to study analog 
incorporation into cells that contained endogenous FPP due to the extremely poor ability 
to compete with FPP. Instead, the equally hydrophilic mCN-AGPP analog may be a 
much more competitive and therefore potent analog to use for cell studies. Several of 
the analogs were more competitive than AGPP which is competitively incorporated into 
cellular proteins. This indicates that numerous analogs could be used for cellular protein 
incorporation. 
Reactivity and Hydrophobicity 
Previous studies have suggested that reactive FPP analogs must be hydrophobic 
to bind the active site of the FTase enzyme. However, we found that the relatively 
hydrophilic analogs containing a nitrile group in both the para- and meta- positions of 
the AGPP aniline ring were highly reactive in the FTase transfer reaction. In particular, 
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the position of a nitrile group in the aniline ring of AGPP had a major affect on the ability 
of the analog to compete with FPP. The hydrophobicity of the mCN-AGPP 2i and pCN-
AGPP 2j analogs based on RP-HPLC retention times of the parent alcohols are much 
lower then farnesol. Surprisingly, the mCN-AGPP 2i analog reaction with CVLS was as 
efficient as the reaction with FPP and the analog competed with FPP giving nearly 1:1 
product ratios. However, the pCN-AGPP 2j analog was unable to effectively compete 
with FPP. These results indicated that the structure of the AGPP analogs was much 
more significant than the hydrophobicity of the analogs on FTase transferability and 
competitiveness. 
Competition with FPP Occurs at Free Enzyme 
The transferable analogs may compete with FPP for either the E•product 
complex or the free enzyme. Since AGPP does not compete with FPP as well as would 
be expected based on the catalytic efficiency of the analog, it is likely that the analog is 
competing primarily for the free enzyme. This suggests that the ability of the analogs to 
compete with FPP may also be dependent on the identity of the target Ca1a2X 
sequence. Different functional groups in the aniline ring of AGPP may more readily 
interact with particular product amino acid residues and therefore enhance 
competitiveness depending on the identity of those residues. Peptide, FPP and the 
analog may stimulate product release and the ability of the analog to compete would be 
highly dependent on the mechanism of product release. Under competition conditions 
the kcat/Kmpeptide would likely predict selectivity assuming only isoprenoid or only peptide 
stimulated product release. However, with both mechanisms of product release it is 
possible that AGPP poorly stimulates release of the isoprenylated target yet can 
effectively compete for free enzyme under peptide stimulated release conditions.  
Relationships of Analog Structure on Transfer and Competition 
As described earlier the rate limiting step of the FTase reaction is product release 
from the enzyme active site. The kcat of the reaction represents the rate of product 
release. An increase in kcat and Kmpeptide suggests that the product from a reaction is 
rapidly released from the enzyme active site, while a decrease in the kcat indicates that 
the reaction product is slowly released from the enzyme active site. The larger ortho- 
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substituted analogs reacted very slowly with the enzyme, but were potent inhibitors 
indicating that they most likely bind, but the product of the reaction is not rapidly 
released. However, the para- substituted analog products were released rapidly as 
indicated by the high kcat and Kmpeptide values for the reactions. The meta- substituted 
analogs were most like the parent molecule AGPP and the natural substrate FPP. In 
several cases the efficiency of the FTase reaction was even increased with by the meta- 
substituted AGPP analogs. These results suggest that by simply moving the functional 
group from one position to another in the AGPP aniline ring there were drastic effects 
on the reactivity of the FTase enzyme. These changes in reactivity are likely a direct 
result of changing the interactions between the isoprenoid, the target peptide and the 
enzyme itself.  
Implications 
In this chapter, I have shown that the FTase enzyme can accept analogs of 
AGPP with a wide variety of functional groups in the ω-terminal isoprene position of 
FPP. The analogs affect the reactivity of a CVLS target peptide depending on both the 
size and position of the functional group in the AGPP aniline moiety. Analogs with ortho- 
substituted anilines were potent inhibitors of the FTase reaction, while analogs with 
para- substituents were rapidly transferred yet unable to effectively compete with FPP. 
The AGPP analogs that contained meta- substitutions often enhanced the catalytic 
efficiency of the FTase reaction with a CVLS peptide and effectively competed with FPP 
for the modification of the CVLS peptide. This chapter demonstrates that subtle 
alterations in the structure of a transferable analog of FPP can drastically alter FTase 
activity towards a peptide substrate. Such analogs will be important for understanding 
and exploiting the activity of the FTase enzyme for the design of selective FTase 
inhibitors or the design of unnatural probes to alter FTase protein target activity. 
 
Experimental 
General 
Analogs and FPP were synthesized as described previously. All RP-HPLC was 
performed on an Agilent 1100 HPLC system equipped with a microplate autosampler, 
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diode array and fluorescence detector. The HPLC analysis was performed with a 
microsorb C18 column with 0.01% TFA in water (A) and 0.01% TFA CH3CN (B) as the 
mobile phase. N-dansyl-GCVLS peptide was purchased from peptidogenics. 
Spectrofluorometric analyses were performed in a 96-well flat bottom, non-binding 
surface, black polystyrene plate (Excitation wavelength, 340 nm; emission wavelength 
505 nm with a 10 nm cutoff). The plate reader was a SpectraMax GEMINI XPS 
fluorescence well-plate reader. Absorbance readings were determined using a Cary 
UV/Vis spectrophotometer. 
Steady-state peptide kinetics  
The kinetic constants Kmpeptide and kcat with FPP, and the analogs with the N-
dansyl-GCVLS peptide were determined in triplicate measurements using a continuous 
spectrofluorometric assay adapted for a 96-well plate. The following assay components 
were assembled in individual wells of a 96-well plate and incubated at 30° C for 20 
minutes: 180 µL of assay buffer (52 mM Tris-HCl, 12 mM MgCl2, 12 µM ZnCl2 pH 7.4), 
40 µL of detergent (0.125% n-dodecyl- β-D-maltoside in assay buffer), 40 µL of 
reducing agent (50 mM DTT in assay buffer) 20uL of FPP or AGPP (200 µM in 25 mM 
NH4HCO3) and 20 µL of N-dansyl-GCaaX peptide (variable concentration).  
Fluorescence was detected using a time based scan at 30° C for 120 minutes. The 
velocity of each reaction was determined by converting the rate of increase in 
fluorescence intensity units (FLU/s) to µM/s with equation 4-1.  
Equation  5-1: vi=(R·P)/(FMAX-FMIN) 
Where vi is the velocity of the reaction in µM/s. R is the rate of the reaction in FLU/s. P 
is equal to the concentration of modified product in µM (see below). FMAX is the 
fluorescence intensity of fully modified product. FMIN is the fluorescence of a reaction 
mixture that contained 20 µL of assay buffer in the place of FTase. Complete 
modification of peptides was assumed when fluorescence stabilized for more than 10 
minutes and was confirmed by RP-HPLC analysis of the reaction mixture. 
Final analysis peptide concentrations were chosen based on preliminary 
determination of the Kmpeptide with 0.5, 1, 5 and 10 µM dansyl-GCaaX concentrations 
(see below). The final analysis used 8 peptide concentrations which were: 1/6, 1/5, 1/4, 
1/2, 3/4 1, 2, and 3 times the estimated Kmpeptide value except with the CVIM peptide. 
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The reaction was then initiated by the addition of 20 µL of FTase (final concentration 5 
nM). Fluorescence enhancement was determined as described above. 
Complete modification of peptides was assumed when fluorescence stabilized for 
more than 10 minutes. If the reactions that contained higher concentrations of peptides 
did not go to completion the Fmax-Fmin value was extrapolated using a linear plot of 
the Fmax-Fmin for each of the lower concentration reactions that did go to completion. 
Alternatively the extent of input peptide modified was determined by RP-HPLC analysis 
of the dansyl moiety peak absorbance corresponding to the unmodified and modified 
peptides. The percent of modified peptide relative to the total input peptide was used to 
calculate the concentration of product in the mixture. 
 The velocities of the reactions were plotted against the concentration of peptide 
and were fit to the Michaelis-Menten equation (Equation 4-2) to give the apparent kcat 
(appkcat) and Kmpeptide (appKmpeptide) values. Where et was the total enzyme 
concentration and [Pep] was the total input peptide. The kcat/Kmpeptide value was derived 
from a Lineweaver-Burke plot of the same data points.  
Equation 4-2: vi/et=(appkcat*[Pep])/(appKmpeptide+[Pep]) 
FPP competition 
Competition reactions were prepared with the same components given for the 
kcat/Kmpeptide analysis except two analogs were added to the mixture and the peptide 
concentration was held constant. FPP and the analog were diluted to 200 µM in 25 mM 
NH4HCO3. 10 µL of FPP and 10 µL of analog were then added to a 280 µL solution of 
peptide, DTT and detergent in 52 mM Tris-HCl buffer pH=7.4 (final concentrations 
DTT=6.7 mM, DM=0.033%, Peptide=3µM, analog= 6.7 µM and  FPP=6.7 µM). The 
concentration of peptide was determined by absorbance of the dansyl group and 
isoprenoid diphosphate concentration was determined by consumption of isoprenoid in 
FTase reactions with the CVLS peptide where the isoprenoid was limiting. The reactions 
were initiated with the addition of FTase and analyzed spectrofluorometrically (20 nM 
final FTase concentration). The reactions were stopped after 2 hours with a mixture of 
acetic acid and iPrOH. HPLC analysis was then performed with 100 µL of the reaction 
mixture loaded onto C18 column and eluted with a linear gradient of 0-30 min 10% B to 
100% B at a flow rate of 1 mL/min. Peaks on the 340 nm trace chromatogram that 
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corresponded to standard reaction fluorescent peaks were then integrated. The ratios of 
products were calculated using Ianalog/IFPP, where Ianalog is the integral of the peptide 
modified with the analog and IFPP is the integral of the peptide modified with FPP.  
Inhibition 
Inhibition Screen 
The analog ability to inhibit FTase transfer of FPP was initially determined by 
measuring the percent inhibition in farnesylation rate in the presence of equimolar 
amounts of FPP and the analog. Reactions were prepared as described for the FPP 
competition analysis and the rate of FPP modification was determined based on the rate 
of fluorescence increase over time with or without the analog present. The % inhibition 
was determined using equation 4-3. 
Equation 4-3: % inhibition=[1-(rateFPP/rateI)]*100 
Where the rateFPP was the rate of the CVLS reaction without the analog present and the 
rateI was the rate of the reaction with the analog present. 
Ki determination 
The Ki of the analogs was determined for analogs which showed no product 
formation with 3 µM peptide. The Ki was determined from reactions containing 3 µM 
peptide 16 µM FPP and varying concentrations of the analogs (0.016-16 µM). The data 
was fit to the 3 parameter hill function in equation 4-4 and the Ki was calculated from 
equation 4-5. 
Equation 4-4: v/vo=(a·Ib)/(IC50b+[I]b) 
Where I is the concentration of the inhibitor, IC50 is the IC50 of the inhibitor, v/vo is the 
rate of the inhibited reaction divided by the rate of the uninhibited reaction and a and b 
are coefficients for Hill function fitting. 
Equation 4-5: Ki=IC50/(1+([FPP]/KmFPP)) 
Where [FPP] is the concentration of FPP and KmFPP is the known Km for FPP. 
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CHAPTER 5 ORTHO SUBSTITUTION AND THE SELECTIVE MODIFICATION OF A 
K-RAS PEPTIDE 
Introduction  
The oncoprotein Ras must be prenylated for both membrane localization and to 
participate in cellular transformation [57]. Constitutive activation of Ras is transforming 
in a wide variety of cell types and mutations that activate Ras have been found in 30% 
of all cancers [26, 108, 210]. A wide variety of other proteins with C-terminal Ca1a2X 
boxes have also been implicated in oncogenesis and tumor progression [18, 211]. 
Consequently, development of inhibitors of both FTase and GGTaseI are subjects of 
major drug discovery programs [212, 213]. Several FTase inhibitors (FTIs) are currently 
in phase I, II and III clinical trials for the treatment of cancer [15, 17, 92, 94]. However, 
K-Ras is the most prevalent mutated Ras isoform found in human cancers, and cells 
transformed by K-Ras are often resistant to FTI treatment. The K-Ras Ca1a2X sequence 
(CVIM) is normally farnesylated, but in the presence of an FTI it can be alternatively 
prenylated by GGTaseI [107]. Alternative prenylation of K-Ras is thought to contribute to 
K-Ras FTI evasion.  
Over 30 proteins are known FTase substrates [49] and as many as 700 proteins 
in the human genome contain a C-terminal Ca1a2X box [56]. The Ca1a2X sequence 
alone is all that is required for FTase recognition and small peptides corresponding to 
the Ca1a2X sequence often mimic the reactivity of full length proteins [204, 214]. The 
Ca1a2X sequence of a protein is often unique to a single protein or to subsets of 
proteins [56]. An alternative mechanism to inhibit the function of prenylated proteins is 
to selectively modify particular Ca1a2X sequences with lipid groups that do not support 
normal prenyl group function [141]. Numerous analogs of FPP such as 8-anilinogeranyl 
diphosphate (AGPP, 2a) are utilized by farnesyl transferase to modify Ca1a2X proteins 
both in vitro and in cell culture [159]. The aniline moiety of AGPP appears to act as an 
isostere for the ω-isoprene unit of FPP and reacts with various Ca1a2X peptides with 
steady-state kinetics nearly identical to FPP [161]. However, subtle changes in the 
structure of AGPP drastically alter FTase activity [161]. 
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Figure 5-1 Analog Structures 
Structure of farnesyl diphosphate (1, FPP) 8-anilinogeranyl diphosphate (2a, AGPP) 
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The reaction mechanism of FTase is unexpectedly complex (Figure 5-2) [49, 82]. 
Substrate association is assumed to proceed through a functionally ordered mechanism 
where FPP (1) binds first, giving the enzyme-FPP complex (E•FPP) followed by Ca1a2X 
substrate association forming the enzyme-FPP-Ca1a2X peptide complex (E•FPP•CaaX) 
[72, 201]. FPP binding to free enzyme enhances association of the Ca1a2X substrate up 
to 70-fold. After thioether formation, a modified peptide remains associated with FTase 
in an enzyme-product complex (E•product) [72, 74]. Product release is the rate 
determining step (kcat) for the FTase reaction mechanism, and must be stimulated by 
the binding of either a new FPP or Ca1a2X peptide substrate to the E•product complex. 
Another interesting feature of the FTase reaction mechanism is the close association 
between the isoprenoid lipid and the target Ca1a2X sequence in the E•product•FPP and 
E•FPP•CaaX complexes. In both complexes, FPP binds at the same hydrophobic 
surface and the ω-isoprene of FPP associates directly with the C-terminal amino acids 
of the Ca1a2X sequence. The interaction between the target Ca1a2X motif and the 
isoprenoid indicates that changes in the structure of FPP may be analogous to amino 
acid mutations in the active site of the enzyme.  
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Figure 5-2  FTase reaction mechanism 
Extended mechanism incorporating peptide stimulated product release. The mechanism 
is split into two pathways path A representing FPP stimulated product release and path 
B representing peptide stimulated product release.  E is the FTase enzyme, E-FPP is 
the FTase•FPP complex, E•FPP•CaaX is the FTase•FPP•CaaX peptide complex, E-
Product is the FTase bound product complex, E-Product-FPP is the FTase bound to 
both FPP and the reaction product, and E-CaaX is the peptide bound FTase inhibitory 
complex, E-Product-CaaX is the new peptide bound enzyme product complex 
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Since the isoprenoid donor of the FTase reaction interacts directly with the target 
Ca1a2X substrate then the activity of an analog may be highly dependent upon the 
sequence of the isoprenylation target [80, 154]. In this chapter, to determine the effects 
from altering the acceptor peptide sequence and the isoprenoid structure we have 
tested the ability of ortho- substituted AGPP analogs to act as substrates with multiple 
Ca1a2X peptides. Several analogs that were potent FTIs with a H-Ras based CVLS 
peptide as the acceptor were excellent substrates when the isoprenylation target was a 
K-Ras4B based CVIM peptide. Several of the analogs enhanced the selectivity of 
FTase for CVIM over several other important Ca1a2X sequences. These results suggest 
that analogs of the transferable FTase substrate AGPP can convert FTase from a 
relatively promiscuous enzyme to an enzyme that selects for specific Ca1a2X 
substrates. Selective modification of FTase target substrates is the first step to 
designing Ca1a2X sequence selective molecules that can be used to inhibit the function 
of specific cellular proteins. 
Results 
AGPP analog reactivity is dependent on Ca1a2X acceptor sequence 
In order to investigate the relationship of the isoprenoid donor and peptide target 
structure on the FTase reaction we measured the steady-state transfer kinetics of a K-
Ras4B based CVIM peptide and 15 ortho- substituted AGPP analogs 2a-p. The reaction 
kinetics were measured utilizing a continuous fluorescence assay with peptides N-linked 
through a glycine linker to a fluorescent dansyl reporter group. We then compared the 
catalytic efficiency of these reaction with those previously published with a H-Ras based 
CVLS peptide. The CVIM (K-Ras4B) and CVLS (H-Ras) Ca1a2X sequences are two of 
the most extensively characterized Ca1a2X substrates in the literature and we found 
kcat/Kmpeptide values with FPP identical to those previously published (Figure 5-3) [154]. 
We found that the kcat/Kmpeptide with the two Ca1a2X peptides differed depending on both 
the Ca1a2X substrate sequence and the isoprenoid analog structure. With FPP and 
AGPP as the isoprenoid donors the catalytic efficiency with CVLS was nearly two-fold 
higher than the catalytic efficiency with CVIM. However, with the oCl-AGPP 2c, oCF3-
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AGPP 2e, oEt-AGPP 2h, oI-AGPP 2i, oCF3O-AGPP 2j, and oSMe-AGPP 2k analogs 
the catalytic efficiency of the reaction with CVIM was much higher than the efficiency 
with CVLS. Surprisingly, CVIM was efficiently utilized with the oCF3O-AGPP 2j analog 
although previously we observed that this analog was not a substrate with CVLS and 
was a potent inhibitor of CVLS farnesylation.(Table 5-1) These results indicated that the 
reactivity of the analogs was highly dependent on the identity of the Ca1a2X target 
sequence. 
In chapter 4, I showed that the ortho- substituted AGPP analogs were unable to 
effectively compete with FPP for CVLS modification. The ability of the analogs to 
compete with FPP may also be dependent on the target Ca1a2X sequence. To test the 
ability of the analogs to compete with FPP for the CVIM modification we mixed each 
analog and FPP 1:1 in excess of the CVIM peptide and analyzed the resulting product 
by HPLC and integration of the dansyl peak absorbance. We found that AGPP 
competed with similar effectiveness when CVLS and CVIM were the isoprenylation 
targets (Figure 5-4). However, the oCF3O-AGPP 2j, oMe-AGPP 2d, and oMeO-AGPP 
2f analog competition with FPP was enhanced when CVIM was the target Ca1a2X motif. 
Interestingly, the ability of the oF-AGPP 2b analog to compete was decreased with 
CVIM. These results suggested major differences in the activity and competitiveness of 
the AGPP analogs depending on the amino acid sequence of the target peptide Ca1a2X 
motif.  
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Figure 5-3 Peptide transfer efficiency 
Steady-state kcat/Kmpeptide values from each of the ortho- substituted AGPP analogs with 
the CVLS and CVIM peptides. Kinetics were measured with varying concentrations of 
peptide and holding the analog concentration constant at 6.7 µM. All reactions were 
performed in Tris-HCl (pH=7.4) buffer containing reducing agent and detergent. Note 
that the efficiency of the reactions with CVIM and CVLS change with the different 
analogs and that several analogs are effective substrates with CVIM but not CVLS. 
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Figure 5-4 Analog Competitiveness with FPP 
Ratios of products analog modified Ca1a2X:farnesylated Ca1a2X were found from 
reactions set up with 3µM peptide and 6 µM of the analog and FPP. Reactions were 
allowed to continue until all peptide was consumed and were then analyzed by HPLC. 
Fluorescence detection indicated the retention time of each of the products and 
integration of peaks at 340 nm were used to quantify products. Note that the ability of 
the analogs to compete is also dependent on the identity of the peptide. 
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AGPP analog substituent size affects Ca1a2X reactivity 
 The peptide target selectivity of the FTase enzyme can be predicted by the ratio 
of the Ca1a2X Kmpeptide.(see chapter 3) The Kmpeptide values of the different Ca1a2X 
sequences suggests that the analogs may increase the selectivity of the enzyme for 
particular Ca1a2X peptides. To investigate the structural properties of the ortho- 
substituted AGPP analogs that affected FTase target selectivity we determined the 
steady-state Kmpeptide of four Ca a X1 2  sequences with all 15 ortho- substituted AGPP 
analogs. (Table 5-1) The peptide targets included the CVLS and CVIM Ca a X1 2  
sequences as well as the Ca a X1 2  motifs of the DNAJ homologue RDJ-2 (CAHQ) and 
the centromere protein, CenpF-f (CKVQ). The analogs that were not substrates were 
further screened for their ability to act as a FTI. (Figure 5-5) 
The ortho- substituted analog reactivity fell into four general categories of 
substrate/inhibition activity that appeared to be dependent on the size of the ortho- 
substituent. The largest analogs (class 4, 2m-p) were not substrates with any of the 
peptides, and three of these analogs (oPh-AGPP 2n, oiPr-AGPP 2m, and oPhCH2-
AGPP 2p) were able to inhibit the farnesylation of the CVLS, CVIM and CAHQ peptides. 
(Figure 5-5)  All of the other AGPP analogs tested (Class 1-3, 2a-l) were substrates, but 
the activity depended on the target Ca1a2X sequence. The Kmpeptide in reactions where 
the analogue functional group substitutions were the smallest were similar to those with 
FPP and AGPP (class 1, 2b-c, 2f-g). The medium sized analogs (class 2, 2d-e, 2h-i 
and class 3, 2j-l) were selective for CVIM, based on the apparent Kmpeptide. The class 2 
analogs showed some reactivity with the CVLS peptide while the class 3 analogs 
reacted very poorly with all of the peptides other than CVIM. The class 3 analogs also 
potently inhibited the farnesylation of CVLS. These results indicated that the selectivity 
of the FTase enzyme for the different Ca1a2X substrates is highly dependent on the size 
of the ω-aniline moiety.  
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Table 5-1 Kmpeptide for ortho substituted analogs 
Kmpeptide kinetics were measured with varying concentrations of peptide and with analog 
concentrations constant at 6.7 µM. All reactions were performed in Tris-HCl (pH=7.4) 
buffer containing reducing agent and detergent. The size of each of the aniline units 
was estimated using the PreADME online molecular descriptor software. The analog 
class is based on the ability of each analog to inhibit and act as a substrate for the 
FTase enzyme as discussed in the text. Note that the analogs fall into four general 
categories of reactivity. 
class R # Size*
KmCVLS * 
(µM) 
KmCAHQ  
(µM) 
KmCKVQ  
(µM) 
KmCVIM 
(µM) 
KiXPP *
CVLS (nM) 
1 FPP 1 102 0.8 ± 0.1 2.0 ± 0.3 1.5 ± 0.3 0.30 ± 0.06 NA 
1 H 2a 114 0.5 ± 0.1 2.4 ± 0.5 1.7 ± 0.2 0.18 ± 0.06 NA 
1 oF 2b 118 0.9 ± 0.2 3.3 ± 0.4 0.19 ± 0.07 0.23 ± 0.05 NA 
1 oCl 2c 129 0.8 ± 0.2 1.9 ± 0.1 1.9 ± 0.2 1.8 ± 0.3 NA 
2 oMe 2d 129 4.0 ± 0.4 >10 >10 0.3 ± 0.1 NA 
2 oCF3 2e 139 >10 >10 >10 1.0 ± 0.2 NA 
1 oMeO 2f 140 0.9 ± 0.2 >10 2.9 ± 0.2 0.7 ± 0.1 NA 
1 oBr 2g 142 1.0 ± 0.2 5.3 ± 0.9 1.7 ± 0.2 0.11 ± 0.01 NA 
2 oEt 2h 144 7 ± 1 >10 >10 3.6 ± 0.9 NA 
2 oI 2i 146 8 ± 3 >10 >10 1.1 ± 0.1 NA 
3 oCF3O 2j 149 >10 >10 >10 2.76 ± 0.08 2.4 ± 0.2 
3 oSMe 2k 149 >10 NR*** >10 4.4 ± 0.6 3.0 ± 0.3 
3 oEtO 2l 155 NR*** NR*** >10 4.0 ± 0.6 12 ± 1 
4 oiPr 2m 159 NR*** NR*** NR*** >10 4.4 ± 0.2 
4 oPh 2n 187 NR*** NR*** NR*** NR*** 3.6 ± 0.4 
4 oPhO 2o 198 NR*** NR*** NR*** NR*** > 40  
4 oPhCH2 2p 202 NR*** NR*** NR*** NR*** 18 ± 1 
 
*   NR indicates no reaction was observed 
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Figure 5-5: Percent inhibition of FTase farnesylation 
N-dansyl-GCaaX a)CVIM or b)CAHQ was mixed with FPP and an equimolar amount of 
the analog. FTase was added and the percent inhibition was calculated by comparing 
the initial rate of reactions containing the analog and FPP to the reaction rate with FPP 
alone. Note that the largest analogs inhibit both CVIM and CVLS and that CAHQ 
farnesylation is more easily inhibited than CVIM. 
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 Analogs with similar structures to oCF3O-AGPP are highly selective for 
CVIM peptide 
The third class of molecules was made up of analogs that only reacted with the 
CVIM peptide and inhibited farnesylation of the other peptides. In order to determine 
whether or not the analogs were selective for only CVIM we measured the competition 
products from reactions containing the class 3 analogs oCF3O-AGPP 2j or oSMe-
AGPP 2k (Figure 5-6) with competing CVIM and CVLS or CVIM and CAHQ peptide 
targets. We found with both analogs only the CVIM peptide was modified at the 
detection limits of the assay. Interestingly, even after the CVIM peptide had been 
completely consumed with the oCF3O-AGPP 2j analog, very little if any modified CVLS 
peptide was detected.  (Figure 5-5a) 
The reaction rate of the CVIM/CVLS competition reaction with oCF3O-AGPP 2j 
appeared to be the same as the reaction rate with only CVIM present. This indicated 
that the presence of CVLS had no affect on the modification of CVIM. To determine if 
higher concentrations of CVLS could effectively inhibit the modification of CVIM, we 
measured the reaction rate with increasing CVLS concentrations. At CVLS 
concentrations as much as five times the concentrations of CVIM no inhibition was 
observed. Taken together these results suggest that the class 3 analogs convert FTase 
from a relatively promiscuous enzyme to one that selects for only the CVIM peptide. 
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Figure 5-6 Competition oCF3O and oSMe plus two peptides 
Reactions containing two peptides mixed at equimolar concentrations with excess 
oCF3O-AGPP or oSMe-AGPP were initiated by the addition of FTase. After several 
hours the reaction was stopped and analyzed by HPLC. Below are the fluorescence 
chromatograms from each reaction. a) oCF3O-AGPP, N-dansyl-GCVIM, N-dansyl-
GCVLS b) oCF3O-AGPP, N-dansyl-GCVIM, N-dansyl-GCAHQ c) oSMe-AGPP, N-
dansyl-GCVIM, N-dansyl-GCVLS d) oSMe-AGPP, N-dansyl-GCVIM, N-dansyl-GCAHQ. 
Note that the CVIM peptide is the only peptide modified even after the majority of it has 
been consumed. 
a) 
 
  
b) 
 
117
  
c) 
 
d) 
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 oCF3O-AGPP inhibits CVLS farnesylation only when CVIM is not present 
Since the oCF3O-AGPP 2j analog was an inhibitor of CVLS farnesylation yet a 
competitive substrate when CVIM was the target Ca1a2X sequence we examined the 
affect of CVIM on the CVLS farnesylation inhibition reaction. To do this we prepared a 
CVIM spike experiment where CVLS, FPP and oCF3O-AGPP 2j were mixed and 
allowed to react for 10 minutes. After the ten minute period CVIM peptide was added to 
the reaction mixture and the rate of the reaction was measured. Upon CVIM addition the 
reaction rate immediately increased to the modification rate of CVIM with the oCF3O-
AGPP 2j analog. These results indicated that the presence of the CVIM peptide relieved 
FTase inhibition. However, it was not clear whether the CVLS peptide farnesylation was 
still inhibited after the addition of the CVIM peptide. We prepared a separate reaction 
containing FPP, oCF3O-AGPP 2j, CVLS and CVIM, and allowed the reaction to 
progress for several hours, then analyzed the products by HPLC. (Figure 5-7) 
Surprisingly, we found that CVLS was farnesylated when CVIM was present, yet without 
CVIM in the mixture CVLS was modified to a much lesser extent. Previously we have 
shown that the ratio of products from a CVIM/CVLS competition reaction with FPP was 
3:1 f-CVIM:f-CVLS. However, in the presence of oCF3O-AGPP 2j the ratio of f-CVIM to 
f-CVLS was changed to nearly 1:1. The prenylated CVIM peptide was split between the 
oCF3O-AGPP 2j analog and FPP, while the CVLS peptide was only modified with a 
farnesyl group. These results indicated that oCF3O-AGPP 2j was an inhibitor of the 
farnesylation of CVLS only when the catalytically competent CVIM peptide was not 
present.  
Selectivity is dependent on Ca1a2X motif X residue 
The ω-terminal isoprene unit of FPP is thought to directly interact with the a2 
residue of a target Ca1a2X box; however, it was not clear whether the peptide selectivity 
of the class 2 and 3 analogs was due to an interaction with the X residue or other 
Ca1a2X sequence residues. To determine what residue affected the selectivity induced 
by the analogs we switched the a2 residues of CVLS and CVIM to give CVIS and CVLS 
and determined the Kmpeptide of each with the analogs.(Table 5-2) The activity of the 
ortho- substituted analogs changed with the X residue not the Ca1a2X sequence a2 
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residue. In the case of the class 2 and 3 molecules there was a productive interaction 
with the CVIM and CVLM peptides, but not with the CVIS and CVLS peptides. These 
results suggested that the selectivity of the analogs is dependent on the identity of the X 
residue of the target Ca1a2X sequence. 
Discussion 
Chemical Genetics of FTase 
Previous work with the FTase enzyme has demonstrated that the enzyme 
catalyzes the modification of a wide variety of Ca1a2X substrates with varying steady-
state kinetics. This chapter has shown that by altering the isoprenoid donor of the 
FTase reaction the ability of FTase to catalyze the modification of these different Ca1a2X 
substrates is changed. Several of the analogs that were effective inhibitors of the 
farnesylation of a CVLS peptide were excellent substrates for the enzyme, and induced 
unnatural selectivity for peptide with a methionine residue in the Ca1a2X motif X 
position. This chapter demonstrates that changing the structure of the isoprenoid alters 
the activity of the enzyme in a manner analogous with amino acid mutations in the 
active site of the enzyme. 
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 Figure 5-7 Peptide and FPP competition with oCF3OAGPP 
Quaternary competition reactions between two peptides an analog and FPP 
Reactions containing two peptides mixed at equimolar concentrations with excess 
oCF3O-AGPP equimolar to FPP were initiated by the addition of FTase. After several 
hours the reaction was stopped and analyzed by HPLC. Below are the chromatograms 
from fluorescence detection of the mixtures. a)FPP, oCF3OAGPP, N-dansyl-GCVIM, N-
dansyl-GCVLS b) FPP, oCF3OAGPP, N-dansyl-GCVIM, N-dansyl-GCAHQ. Note that 
the CVIM peptide is modified by both the analog and FPP while the competing peptide 
is only modified with FPP. 
a) 
 
b) 
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Table 5-2 Kmpeptide values with CVIS and CVLM peptides 
Kinetic parameter Kmpeptide for N-dansyl-GCVIS and N-dansyl-GCVLM for comparison 
with N-dansyl-GCVIM and N-dansyl-GCVLS.  Kmpeptide was measured with varying 
concentrations of peptide and with analog concentrations constant at 6.7 µM. All 
reactions were performed in Tris-HCl (pH=7.4) buffer containing reducing agent and 
detergent. Note that the Kmpeptide follows the X residue not the a2 residue. 
 
R  # KmCVLS KmCVIM KmCVIS KmCVLM
FPP 1 0.8 ± 0.1 0.30 ± 0.06 0.22 ± 0.04 0.09 ± 0.01 
oEt 2x 7 ± 1 3.6 ± 0.9 5 ± 1 1.4 ± 0.3 
oI 2x 8 ± 3 1.1 ± 0.1 >10 1.5 ± 0.3 
oCF3O 2j >10 2.76 ± 0.08 >10 4.4 ± 0.4 
oSMe 2x >10 4.4 ± 0.6 >10 8 ± 2 
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 Active Site Discrimination of Peptides 
There are two possibilities that explain the ability of oCF3O-AGPP 2j to inhibit 
CVLS farnesylation, yet act as a substrate with CVIM. The first of these possibilities is 
that the product from the reaction of oCF3O-AGPP and CVLS cannot be dissociated by 
the CVLS peptide, FPP or oCF3O-AGPP 2j. The second possibility is that the chemical 
step of the reaction is compromised with the oCF3O-AGPP analog and CVLS peptide. 
Both mechanisms of inhibition could be relieved by the addition of a more competent 
peptide to either stimulate product release or react with oCF3O-AGPP 2j. If there was 
no discrimination between CVIM and CVLS prior to the chemical step of the reaction, 
CVIM relief of product inhibition would lead to an increase in oCF3O-AG-CVLS 
formation in the CVIM, CVLS, FPP and oCF3O-AGPP 2j quaternary competition 
experiment. However, the amount of CVLS modified with oCF3O-AGPP 2j in the 
quaternary competition experiment was the same as when CVIM was not present. 
Interestingly, the amount of CVLS modified by FPP relative to CVIM increased in the 
presence of oCF3O-AGPP 2j. The most likely cause of this increase is the selective 
depletion of the CVIM peptide by the E•oCF3O-AGPP complex. The ability of oCF3O-
AGPP 2j to inhibit the modification of the CVLS and CAHQ peptides, yet competitively 
react with the CVIM peptide is most likely due to a pre-chemical step discrimination 
between the CVIM and CVLS peptides by the E•oCF3O-AGPP complex. A selective 
target peptide exclusion from the FTase active site demonstrates that changing the 
structure of the isoprenoid alters the activity of the enzyme in a manner analogous with 
amino acid mutations in the active site of the enzyme.  
The exclusion of peptide by an FPP analog has been described previously. 
Turek-Etienne et al described a benzophenone based FPP (benzophenone-GPP 3) 
analog that inhibits FTase by exclusion of a target peptide from the active site of the 
enzyme [215]. Support for this mechanism of inhibition was achieved from a crystal 
structure of the analog bound to FTase where the benzophenone portion of the 
molecule (3) protruded into the X residue binding site, presumably excluding peptide 
from the active site. In this chapter, I have described a similar mechanism except that 
differences in the structure of the target peptide appear to affect the ability of the analog 
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to exclude particular peptides. Interestingly, we have found that the peptide selectivity of 
the molecules reported were dependent upon the X residue of the target Ca1a2X 
sequence. These observations are consistent with the peptide exclusion model of 
inhibition.  
Other Regions of Protein may Affect Reactivity 
This chapter was designed to analyze the Ca1a2X selective properties of the 
enzyme with respect to interactions in the active site of the enzyme. It is not yet clear if 
the peptide selectivity of these analogs with FTase will translate directly to selectivity for 
full length protein targets. In particular, the K-Ras4B protein contains an upstream poly-
basic region that enhances affinity for the enzyme through interactions outside the 
enzyme active site. However, H-Ras proteins do not contain an upstream poly-basic 
region and the steady-state transfer kinetics are nearly identical to those of the Ca1a2X 
peptide alone. We have shown that several of the analogs enhance FTase selectivity for 
the K-Ras4B Ca1a2X peptide. Increased affinity by the upstream poly-basic region 
would likely only further enhance this selectivity. The ability to target K-Ras4B will be 
useful for Ca1a2X selective protein function inhibition. 
Experimental 
General 
AGPP analogs and FPP were synthesized as described in Chapter 2. All RP-
HPLC was performed on an Agilent 1100 HPLC system equipped with a microplate 
autosampler, diode array and fluorescence detector. The HPLC analysis was performed 
with a microsorb C18 column with 0.01% TFA in water (A) and 0.01% TFA CH3CN (B) 
as the mobile phase. Peptides were purchased from peptidogenics and each contained 
a dansyl group N-linked to a glycine linker followed by a C residue then a variable aaX 
sequence (VLS, VIM, AHQ, or KVQ). Spectrofluorometric analyses were performed in a 
96-well flat bottom, non-binding surface, black polystyrene plate (Excitation wavelength, 
340 nm; emission wavelength 505 nm with a 10 nm cutoff). The plate reader was a 
SpectraMax GEMINI XPS fluorescence well-plate reader. Absorbance readings were 
determined using a Cary UV/Vis spectrophotometer.  
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Steady-state peptide kinetics  
The kinetic constants Kmpeptide and kcat with FPP, and the analogs with the each 
peptide were determined in triplicate measurements using a continuous 
spectrofluorometric assay adapted for a 96-well plate. The following assay components 
were assembled in individual wells of a 96-well plate and incubated at 30° C for 20 
minutes: 180 µL of assay buffer (52 mM Tris-HCl, 12 mM MgCl2, 12 µM ZnCl2 pH 7.4), 
40 µL of detergent (0.125% n-dodecyl- β-D-maltoside in assay buffer), 40 µL of 
reducing agent (50 mM DTT in assay buffer) 20uL of FPP or AGPP (200 µM in 25 mM 
NH4HCO3) and 20 µL of N-dansyl-GCaaX peptide (variable concentration).  
Fluorescence was detected using a time based scan at 30° C for 120 minutes. The 
velocity of each reaction was determined by converting the rate of increase in 
fluorescence intensity units (FLU/s) to µM/s with equation 5-1.  
Equation  6-1: vi=(R·P)/(FMAX-FMIN) 
Where vi is the velocity of the reaction in µM/s. R is the rate of the reaction in FLU/s. P 
is equal to the concentration of modified product in µM (see below). FMAX is the 
fluorescence intensity of fully modified product. FMIN is the fluorescence of a reaction 
mixture that contained 20 µL of assay buffer in the place of FTase. Complete 
modification of peptides was assumed when fluorescence stabilized for more than 10 
minutes and was confirmed by RP-HPLC analysis of the reaction mixture. 
Final analysis peptide concentrations were chosen based on preliminary 
determination of the Kmpeptide with 0.5, 1, 5 and 10 µM dansyl-GCaaX concentrations 
(see below). The final analysis used 8 peptide concentrations which were: 1/6, 1/5,1/4, 
1/2, 3/4, 1, 2, and 3 times the estimated Kmpeptide value except with the CVIM peptide. 
The reaction was then initiated by the addition of 20 µL of FTase (final concentration 10 
nM with the CLVS, CAHQ, CVIL and CRPQ peptide, 20nM with the CVIM peptide). 
Fluorescence enhancement was determined as described above. Complete 
modification of peptides was assumed when fluorescence stabilized for more than 10 
minutes. Samples in which the reactions that contained higher concentrations of 
peptides did not go to completion the Fmax-Fmin value was extrapolated using a linear 
plot of the Fmax-Fmin for each of the lower concentration reactions that did go to 
completion. 
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 The velocities of the reactions were plotted against the concentration of peptide 
and were fit to the Michaelis-Menten equation (Equation 5-2) to give the apparent kcat 
(appkcat) and Kmpeptide (appKmpeptide) values. Where et was the total enzyme 
concentration and [Pep] was the total input peptide. The kcat/Kmpeptide value was derived 
from a Lineweaver-Burke plot of the same data points.  
Equation 5-2: vi/et=(appkcat*[Pep])/(appKmpeptide+[Pep]) 
Peptide Competition 
Competition reactions were prepared with the same components given for the 
kcat/Kmpeptide analysis except two peptides were added to the mixture at a single 
concentration. Peptides A and B were diluted to 45 µM in Tris-HCl buffer (pH=7.4) and 
the concentration checked by reading the Abs of the solution at 340 nm (εdansyl=4250 
Abs·M-1·cm-1). 20 µL of peptide A and 20 µL of peptide B were then added to reaction 
mixtures as described above except only 160 µL of assay buffer was added.  Separate 
reactions were prepared as a standard with FPP or the analog and only one peptide as 
described above.  The reactions were then initiated with the addition of FTase and 
analyzed spectrofluorometrically (Reactions containing CVIM peptide used 20 nM final 
FTase concentration all other used 10 nM). The reactions were stopped prior to 
consumption of more than 50% of either peptide by adding 20 µL of a stop solution 
(isopropyl alcohol and acetic acid 8:2). HPLC analysis was then performed with 100 µL 
of the reaction mixture loaded onto C18 column and eluted with a linear gradient of 0-30 
min 10% B to 100% B at a flow rate of 1 mL/min. Peaks on the 340 nm trace 
chromatogram that corresponded to both the standard reactions and fluorescent peaks 
were then integrated. The ratios of products were calculated according to equation 5-3. 
Equation  6-3: (IAmod/ IAtot)/(IBmod /IBtot) 
Where IAmod is the integral of the modified peptide A, IAtot is the integral of the 
modified peptide A plus the unmodified peptide A, IBmod is the integral of the modified 
peptide B and IBtot was the integral of the modified peptide B plus the unmodified peptide 
B. Alternatively, the ratios were calculated using the integrals of the standard peptides 
fluorescence relative to competition product fluorescence giving less than a 5% 
difference in the calculated ratio.  
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FPP competition 
Competition reactions were prepared with the same components given for the 
kcat/Kmpeptide analysis except two analogs were added to the mixture and the peptide 
concentration was held constant. FPP and the analog were diluted to 200 µM in 25 mM 
NH4HCO3. 10 µL of FPP and 10 µL of analog were then added to a 280 µL solution of 
peptide, DTT and detergent in 52 mM Tris-HCl buffer pH=7.4 (final concentrations 
DTT=6.7 mM, DM=0.033%, Peptide=3µM, analog= 6.7 µM and  FPP=6.7 µM). The 
concentration of peptide was determined by absorbance of the dansyl group and 
isoprenoid diphosphate concentration was determined by consumption of isoprenoid in 
FTase reactions with the CVLS peptide where the isoprenoid was limiting. The reactions 
were initiated with the addition of FTase and analyzed spectrofluorometrically (20 nM 
final FTase concentration). The reactions were stopped after 2 hours with a mixture of 
acetic acid and iPrOH. HPLC analysis was then performed with 100 µL of the reaction 
mixture loaded onto C18 column and eluted with a linear gradient of 0-30 min 10% B to 
100% B at a flow rate of 1 mL/min. Peaks on the 340 nm trace chromatogram that 
corresponded to standard reaction fluorescent peaks were then integrated. The ratios of 
products were calculated using Ianalog/IFPP, where Ianalog is the integral of the peptide 
modified with the analog and IFPP is the integral of the peptide modified with FPP.  
Inhibition Screen 
The analog ability to inhibit FTase transfer of FPP was initially determined by 
measuring the percent inhibition in farnesylation rate in the presence of equimolar 
amounts of FPP and the analog. Reactions were prepared as described for the FPP 
competition analysis and the rate of FPP modification was determined based on the rate 
of fluorescence increase over time with or without the analog present. The % inhibition 
was determined using equation 5-4. 
Equation 5-4: % inhibition=[1-(rateFPP/rateI)]*100 
Where the rateFPP was the rate of the CVLS reaction without the analog present and the 
rateI was the rate of the reaction with the analog present. 
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FPP and peptide competition 
Peptides A and B were diluted to 45 µM in Tris-HCl buffer (pH=7.6) and the 
concentration checked by reading the Abs of the solution at 340 nm (εdansyl=4250 Abs·M-
1·cm-1). FPP and oCF3O-AGPP were diluted to 200 µM in 25 mM NH4HCO3. 20 µL of 
peptide A and 20 µL of peptide B were then added to reaction mixtures along with 10 µL 
of FPP and 10 µL of analog were added to reaction mixtures containing 140 µL of assay 
buffer (52 mM Tris-HCl, 12 mM MgCl2, 12 µM ZnCl2 pH 7.4), 40 µL of detergent 
(0.125% n-dodecyl- β-D-maltoside in assay buffer), 40 µL of reducing agent (50 mM 
DTT in assay buffer) Separate reactions were prepared as a standard with FPP or the 
analog and only one peptide as described above.  The reactions were then initiated with 
the addition of FTase (Final concentration 20 nM) and analyzed spectrofluorometrically. 
The reactions were stopped prior to consumption of more than 50% of either peptide by 
adding 20 µL of a stop solution (isopropyl alcohol and acetic acid 8:2). RP-HPLC 
analysis was then performed with 100 µL of the reaction mixture loaded onto C18 
column and eluted with a linear gradient of 0-30 min 10% B to 100% B at a flow rate of 
1 mL/min. Peaks on the 340 nm trace chromatogram that corresponded to both the 
standard reactions and fluorescent peaks were then integrated.  
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CHAPTER 6 CELLULAR ACTIVITY OF ISOPRENOID DIPHOSPHATES 
 
Introduction 
Monitoring the prenylation state of proteins in cells is a challenging undertaking. 
Initially, prenylation of proteins was discovered by metabolic labeling with 
[3H]mevalonolactone [216]. In these experiments, some of the tritium label was 
incorporated into both farnesylated and geranylgeranylated proteins. Subsequently, a 
salvage pathway was discovered where radiolabeled farnesol 1a (FOH) and 
geranylgeraniol 2a (GGOH), precursors of FPP 1b and GGPP 2b, were selectively 
incorporated into their respective farnesylated or geranylgeranylated proteins [217]. A 
significant drawback of these approaches is the inherently low sensitivity of 
autoraidographic detection of the weak tritium β-emission. In fact, it can take up to four 
weeks to visualize proteins extracted from cells labeled with tritiated mevalonate or 
farnesol by autoradiography [141]. Also, the incorporation of tritiated prenyl groups does 
not provide a convenient method for isolation of these modified proteins.  
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Figure 6-1 FPP Analogs 
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The facile detection, isolation and purification of farnesylated proteins based 
solely on their post-translational modification status is essential to understanding the 
mechanism of cellular growth inhibition by FTIs. Antibodies are useful both in the routine 
detection and immunoprecipitation of proteins with other post-translational 
modifications, such as phosphorylation [218]. However, reports of previous attempts to 
produce antibodies to detect farnesylated proteins have had mixed results. Two of these 
reports described non-specific antibodies that could not differentiate between proteins 
modified by farnesylation, geranylgeranylation or other lipids [113, 219]. The other 
report from Baron et al does describe the production of anti-farnesyl antibodies specific 
for farnesylation, but the analysis for specificity was limited [220]. These antibodies are 
apparently not available commercially and all of the commercially available sources for 
anti-farnesyl antibodies cross-react with geranylgeranylated proteins. 
An attractive alternative to targeting the natural farnesyl moiety is to detect 
proteins modified with unnatural farnesyl analogs. Several unnatural analogs of FPP 
appear to be utilized by cells and incorporated into the proteins by FTase, including the 
unnatural FPP analog 3-vinyl-farenesol 3a, a pro-drug of the FTase transferable 3-vinyl-
farnesyl diphosphate (3vFPP) 3b, and 8-azido-farnesol 4 [141]. A tagging-via-substrate 
(TAS) approach to the detection and isolation of farnesylated proteins involving the 
incorporation of 4 into cellular proteins has been developed by Kho et al. [168]  Modified 
proteins were isolated from cell lysates using a biotinylated phosphine capture reagent 
and subsequently identified by mass spectrometry. However, the sensitivity is relatively 
low and the technique does not lend itself to the routine detection of modified proteins. 
A more convenient method to simplify the detection of such proteins would be to use 
antibodies specific for the unnatural modification. 
A variety of FPP analogs that may be useful in implementing this strategy have 
been prepared by our group and others [149, 157, 193, 221].  Anilinogeranyl 
diphosphate (AGPP) 5b is transferred by FTase to protein substrates with kinetics 
similar to those of FPP and does not resemble any known natural protein modification 
[159, 161]. Antibodies against an anilinogeranyl (AG) epitope may circumvent the 
problems associated with tritium labeling and the preparation of anti-farnesyl antibodies, 
and provide a facile way to detect and isolate prenylated proteins.  
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We report the preparation of anti-anilinogeranyl antibodies (anti-AG and anti-
NAG) raised against haptens 12a and 12b that detect proteins modified with 
anilinogeranyl or pNO2-anilinogernayl moieties derived from AGPP 5b and NAGPP 6b. 
Activated ester haptens 9a-b were synthesized and coupled to immunogenic carrier 
proteins and used to raise antibodies directed to the anilinogeranyl modification. The 
primary antibodies were able to bind proteins with an intact analog modified C-terminal 
Ca1a2X motif. We demonstrate that anilinogeraniol 5a, a prodrug form of AGPP 5b, is 
incorporated into cellular proteins in an FTase dependent manner, and that endogenous 
protein labeling was competitive with endogenous FPP 1b. Combining the unnatural 
FPP analog AGPP with anti-anilinogeranyl antibodies provides a useful reagent system 
to monitor the prenylation status and effects of FTIs in cells.  
Results 
Synthesis of Analog modified Antigen  
The preparation of the prenyl analog carrier protein conjugates 12a-b and 13a-b 
is outlined in Figure 6-2. The haptens were designed to mimic the C-terminal peptide of 
a fully processed prenylated protein that had undergone both endoproteolysis and 
carboxyl group methylation. Thioether 8a-b was obtained in 60-74% yield by addition of 
a solution of l-cysteine methyl ester HCl in NH3/MeOH to the previously described 
chloride 7a-b [161]. The farnesyl thioether 6b was prepared by addition of farnesyl 
bromide 6b to l-cysteine methyl ester HCl in NH3/MeOH. Condensation of amines 8a-c 
with succinic anhydride in THF:DCM afforded succinates 9a-c in 57%-85% yield after 
chromatography [222]. Activated esters 10a-c were prepared from carboxylates 9a-c in 
58%-85% yield by reaction with CDI followed by condensation with N-OH phthalimide 
[223]. The N-hysdroxysuccimidyl (NHS) ester of a similar farnesyl hapten is reported to 
undergo an undesired intramolecular cyclization to an unreactive succinimide [219]. In 
contrast to the NHS ester, phthalimides 10a-b were stable and showed no evidence of 
intramolecular cyclization. The suitability of phthalimides 10a-b to form conjugates with 
carrier protein was modeled under conditions typical for coupling activated esters to 
lysine residues. Condensation of benzylamine with phthalimides 10a-b in 1:5 
Acetonitrile:5% NaHCO3 gave model amides 11a-b in 51%-76% yield.  
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With activated haptens in hand, we proceeded to generate anilinogeranyl , 
pNO2anilinogeranyl and farnesyl immunoconjugates. Phthalimides 10a-c were reacted 
with carrier proteins KLH and BSA to provide hapten conjugated proteins 12a-c (AG-
KLH, NAG-KLH and F-KLH) and 13a-c (AG-BSA, NAG-BSA and F-BSA). BSA has 
approximately 32 reactive lysine residues and the extent of covalent modification of 
immunoconjugates 13a-c was quantified by measuring the remaining free amino groups 
relative to unmodified BSA.  BSA, and each of the BSA conjugates 13a-b were reacted 
with trinitrobenzene sulfonate and the ratio of free amines in unmodified BSA to 
modified BSA were determined by UV absorbance at 335 nm [224]. We found that 50% 
of the lysine residues in immunoconjugates 13a-c were modified by the activated esters 
10a-c. As KLH is a heterogeneous protein, similar assays to quantify the coupling 
efficiency were not performed. By analogy with the BSA results, we assumed a similar 
coupling efficiency for the KLH bioconjugates. 
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Figure 6-2 Synthesis of analog modified haptens 
Reagents: (a)Cysteine methyl ester HCl, NH3/MeOH, 0° C (%). (b) Succinic anhydride, 
THF/DCM(%). (c) N-Hydroxyphthalimide, CDI, MeCN (%). (d) R2, NaHCO3(aq)/MeCN 
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Generation of anti-anilinogeranyl antibodies 
Polyclonal antibodies to the anilinogeranyl modification were prepared by 
immunizing rabbits with AG-KLH (12a) and NAG-KLH (12b). In our hands, F-KLH (12c) 
elicited no immunogenic response. This is in agreement with previous reports in which 
attempts to prepare anti-farnesyl antibodies have resulted in weakly binding reagents 
that recognize both farnesyl and geranylgeranyl isoprenoid lipids [113, 219, 220]. Due to 
the poor immune response to the F-KLH protein, (12c) we abandoned attempts to 
prepare an anti-farnesyl antibody. Polyclonal immune sera collected from the rabbits 
were screened using an enzyme linked immunosorbent assay (ELISA). No ELISA 
response was detected to unmodified BSA, AG-BSA (13a), or NAG-BSA (13b) in pre-
immune sera. Gratifyingly, sera antibodies raised against AG-KLH 12a (anti-AG) and 
NAG-KLH 12b (anti-NAG) were able to bind to AG-BSA (13a) and NAG-BSA (13b) 
respectively (Figure 6-3). Interestingly, there was considerable cross-reactivity using the 
anti-AG antibody with the anilinogeranyl and pNO2anilinogeranyl modified BSA proteins. 
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Figure 6-3  ELISA Assay of Anilinogeranylated BSA Constructs 
a) anti-AG and b) anti-NAG ELISA response to AG-BSA (closed squares), NAG-BSA 
(open circles) and unmodified BSA (triangles) (0.1µg BSA/well).Note that the anti-AG 
antibody cross reacts with NAG-BSA and AG-BSA, yet the anti-NAG antibody only 
detects NAG-BSA 
a) Anti-AG ELISA
0
1
2
3
4
1.0E-05
1.0E-04
1.0E-03
1.0E-02
Ab Dilution
In
te
ns
ity
 
b) Anti-NAG ELISA
0
1
2
3
4
1.0E-05
1.0E-04
1.0E-03
1.0E-02
Ab Dilution
In
te
ns
ity
 
 
136
  
Specificity and Analysis of anti-anilinogeranyl antibodies 
The antibodies generated in this study were directed to proteins modified with 
cysteine methyl ester analogs of FPP. However, the actual antigen that is presented to 
the immune system is unknown as the ester may be hydrolyzed by enzymes in the 
whole animal. Additionally, it is possible that in vivo incorporation of unnatural analogs 
into proteins will alter the normal Ca1a2X endoproteolysis and carboxyl group 
methylation steps. The utility of the polyclonal anilinogeranyl antibodies might well be 
limited if they only recognized the cysteine methyl ester form of modified proteins. 
Therefore, it was essential to test the ability of these antibodies to recognize proteins 
modified by FTase with the anilinogeranyl moiety without subsequent endoproteolysis 
and carboxyl group methylation. Bacterially expressed DNAJ-like RDJ2[200] and Q61L 
oncogenic H-Ras proteins contain the un-farnesylated and unprocessed CAHQ and 
CVLS Ca1a2X motifs respectively. FTase catalyzed in vitro modification of these 
proteins with FPP 1b, AGPP 5b, and NAGPP 6b provided lipid thioether linked proteins 
with intact Ca1a2X motifs 14a-c and 15a-c (Figure 6-4). These reaction mixtures were 
then analyzed by western blot with anti-AG and anti-NAG antibody sera. Figure 6-5 
shows that the anti-AG was able to bind to AG-BSA 13a and NAG-BSA 13b derivatized 
by the methyl ester haptens as well as the AG-RDJ2 14c and NAG-RDJ2 14d, but, 
showed no reactivity to the unmodified RDJ2 14a protein. Identical results were found 
when AG-Ras 14c was examined. Additionally, the antibodies were also unreactive 
towards farnesylated F-RDJ2 (13b) and F-Ras (14b). Similar results were found with 
the anti-NAG antibody except the anti-NAG antibody was significantly more specific for 
the pNO2-anilinogeranylated proteins over the anilinogeranylated. 
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Figure 6-4 Ca1a2X modification 
C-terminal structures of in vitro modified RDJ2 and H-Ras proteins 
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 Figure 6-5 Western Analysis of Anilinogeranylated RDJ2 
Western Blot analysis of unmodified (RDJ2-ve control), anilinogeranyl modified and 
Nitroanilinogeranyl modified RDJ2 (AG-RDJ2, NAGRDJ2) and BSA  (AG-BSA, NAG-
BSA) proteins. Probed with anti-AG (AG-Ab) and anti-NAG (NAG-Ab) antibodies. Note 
that as in the ELISA assay the anti-AG antibody detects both AG and NAG modified 
protein. 
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Since there was cross reactivity with the anti-AG antibody we tested the ability of 
the anti-AG and anti-NAG antibodies to recognize other aniline analogs incorporated 
into proteins by FTase. We reacted H-Ras with the analogs pCN-AGPP 16, mCN-AGPP 
17, oCF3O-AGPP 18, mCF3O-AGPP 19, pCF3O-AGPP 20, oF-AGPP 21, mF-AGPP 22, 
pF-AGPP 23, oI-AGPP 24, mI-AGPP 25, pI-AGPP 26, oBr-AGPP 27, mBr-AGPP 28, 
pBr-AGPP 29, oMeO-AGPP 30, mMeO-AGPP 31, mCF3-AGPP 32, mMe-AGPP 33, and 
pMe-AGPP 34. As expected we found that the anti-AG antibody was less specific for 
the aniline substitution and was able to cross-react with the analogs containing small 
substitutions in the aniline ring of AGPP (Figure 6-6). This included the mCN-AGPP 17, 
oF-AGPP 21, mF-AGPP 22, pF-AGPP 23, mBr-AGPP 28, pBr-AGPP 29, mMe-AGPP 
33, and pMe-AGPP 34 modified H-Ras proteins. The anti-NAG antibodies recognized 
the mCN-AGPP 16, pCN-AGPP 17, and pBr-AGPP 29 modified H-Ras proteins. These 
results suggested that the antibodies could be useful for many different anilinogeranyl 
diphosphate analogs not just the ones they were designed to recognize.  
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Figure 6-6 Cross Reactivity 
Western blot analysis of Ras proteins modified with various AGPP analogs as indicated, 
and probed with anti-AG and anti-NAG polyclonal antibodies. Each well contains equal 
amounts of protein. However, extent of modification was not analyzed. Note that both 
antibodies recognize more aniline structure than they were designed to detect, yet they 
are specific for the aniline modified proteins and do not detect unmodified. 
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FTase dependent Anilinogeraniol incorporation into cellular proteins 
Farnesol 1a, geranylgeraniol 2a and a number of farnesol analogs become 
incorporated into cellular proteins when added to the culture media of growing cells 
[141, 170, 217, 225]. These compounds are thought to traverse the plasma membrane 
and act as substrates for sequential kinase reactions to give FPP 1b, GGPP 2b or the 
diphosphate analog which can then be utilized by FTase or GGTaseI to appropriately 
modify cellular proteins [170, 226]. The kinases involved in the phosphorylation 
reactions have been characterized in plants, but not in mammalian cells. In vitro, both 
FPP 1b and AGPP 5b are transferable by FTase to a CVLS substrate with similar kcat 
and Km values [159]. Therefore, we speculated that anilinogeraniol might also cross the 
plasma membrane of cells, be converted to the diphosphate 5b and become 
incorporated into proteins by FTase. However, it was also possible that anilinogeraniol 
5a might be toxic to mammalian cells. Accordingly, the acute cytotoxicity of 
anilinogeraniol 5a was examined by incubating human embryonic kidney (HEK-293) 
cells with up to 100 µM anilinogeraniol 5a for three days. Somewhat surprisingly, we 
found that cells treated with anilinogeraniol showed no morphological changes and no 
decrease in cell growth relative to controls at any of the concentrations tested.  
The anti-AG antibodies were used to probe extracts of HEK-293 cells incubated 
in the presence of AGOH 5a to determine if the anilinogeranyl group was incorporated 
into cellular proteins. These cells were initially blocked with lovastatin an upstream 
inhibitor of endogenous FPP and GGPP formation and treated with GGOH for the 
geranylgeranylation of proteins critical to cell survival [227].  Figure 6-7 shows that there 
are numerous anilinogeranyl modified proteins in cells treated with AGOH 5a, while no 
proteins were detected in the absence of the unnatural FPP analog. In order to 
determine whether the protein modification was FTase dependent, cells were incubated 
in the presence of AGOH 5a and either the farnesyl transferase inhibitor FTI-277 [93] or 
the geranylgeranyl transferase I inhibitor GGTI-2147 [228].  Lane 3 of Figure 6-7 shows 
that no anilinogeranyl modified proteins were detected in the presence of the FTI. 
However, in the presence of the geranylgeranyl transferase I inhibitor, the pattern of 
proteins modified with anilinogeranyl moiety was very similar to that without any inhibitor 
present. Interestingly, some additional, lower molecular weight anti-AG reactive bands 
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appear when GGTaseI is inhibited. FTase catalyzed transfer of the anilinogeranyl lipid 
to protein is the most consistent explanation for these observations. These results also 
suggest that FTase may be able to utilize AGPP to modify some normally 
geranylgeranylated proteins when GGTaseI is inhibited. This is not unreasonable, as 
the normally farnesylated K-Ras4B becomes geranylgeranylated in the presence FTIs 
[229, 230]. 
The AGOH analog must undergo diphosphorylation to be incorporated into 
cellular proteins. This diphosphorylation may not be on time-scale that allows 
competitive modification of proteins in the presence of FPP. Cells were incubated 
without a lovastatin blockade on endogenous FPP formation with 30 µM AGOH and 
sampled every few hours. Figure 6-8 shows that anilinogeranyl incorporation into 
proteins begins within two hours of incubation with AGOH and is therefore competitive 
with the endogenous pools of FPP. Importantly, these experiments demonstrate that 
intracellular concentrations of AGPP 5b can be achieved that are high enough to 
compete with the endogenous pool of FPP 1b for FTase dependent transfer to proteins. 
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Figure 6-7 FTase Dependent Incorporation of Anilinogeranyl Label in Cells 
Incorporation and detection of anilinogeranyl modified endogenous proteins. HEK-293 
cells were incubated with 30 µM lovastatin and 10 µM GGOH for one day then media 
was poured off and the cells were incubated with or without 100 µM AGOH 3a (lane 1-
2), in the presence and absence of an FTI or a GGTI (lanes 2-4). The cells were then 
analyzed by western blot with the anti-AG sera. Note the difference in FTI + and – cells, 
and the 31 kDa band in the GGTI treated cells. 
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Figure 6-8 Endogenous Competition 
Cells with no lovastatin blockade were incubated with 30 µM AGOH for the given time 
points then were harvested and lysed. 50 µg of total protein was loaded onto an SDS-
PAGE gel transferred to nitrocellulose and immunodetected using the anti-AG. Note the 
time dependent increase in anilinogeranylated proteins. 
 
 
145
  
Alternative Pro-drug strategy 
The labile phosphoanhydride bond and the multiple negative charges of FPP 
analogs likely prevent easy diffusion across cell membranes although naturally 
occurring isoprenoids such as FPP and geranylgeranyl diphosphate are apparently 
taken up through an active transport system [231].  The isoprenoids farnesol, 
geranylgeraniol and the unnatural analog 3-vinyl-farnesol (3a) are converted in 
mammalian cells to the corresponding pyrophosphates [141, 226, 232].  3-vinyl-farnesyl 
diphosphate is an alternative substrate for FTase and the prodrug 3-vinyl-farnesol is 
able to block anchorage-independent growth of ras-transformed cells.  Presumably, this 
effect is due to FTase catalyzed modification of proteins with the 3-vinyl-farnesyl group. 
These observations suggest that alcohol precursors of other FPP analogs may also be 
useful prodrugs.    
However, it is far from clear that arbitrary farnesol analogs will be efficiently 
converted to the corresponding pyrophosphates in cells.  An alternative strategy for 
creating membrane permeant molecules is to reduce the overall charge and increase 
the lipophilicity of the analog. The bioavailability of membrane impermeant phosphate 
and phosphonate containing drug molecules has been dramatically increased by 
masking the charged groups with acyloxymethyl esters [233-235]. The acyloxymethyl 
ester allows the drugs to diffuse across the cellular membrane into the cytoplasm where 
general esterases cleave the acyloxymethyl groups revealing the active, charged 
species (Figure 6-10) [195, 236].   However, this strategy is unlikely to succeed for 
uncharged pyrophosphate tetra-esters, as the anhydride linkage is rapidly hydrolyzed at 
physiological pH.  Methylenediphosphonate (MDP) is a structural analog of 
pyrophosphate, which does not contain a labile anhydride linkage.  Replacing the labile 
pyrophosphate with MDP and masking the negative charges with acyloxymethyl esters 
may result in membrane permeant FPP analogs. We found no description of mono-
allylic triacyloxymethyl methylenediphosphonate tetraesters in the literature. We report 
the preparation of three such isoprenoids where the pyrophosphate has been replaced 
by MDP and the negative charges are masked by frangible pivaloyloxymethyl (POM) 
esters.    
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Figure 6-9  Proposed Mechanism of In Vivo Prodrug Activation 
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Farnesyl methylene diphosphonate is transferable. 
The strategy outlined above requires that the substitution of MDP for the 
pyrophosphate in FPP and other analogs results in molecules that are substrates for 
FTase.  Farnesyl methylene diphosphonate (FMDP) 2 has previously been prepared 
and was shown by Eummer et al. to be a competitive inhibitor (IC50=160 nM) of FTase 
[185]. However, the assay used in that study was unable to distinguish whether FMDP 
was an alternative substrate for FTase or an FTI.  To resolve this question, FMDP, 36 
was synthesized as previously described, and was shown to be a substrate for FTase in 
an in vitro fluorescence assay varying isoprenoid concentration [194]. The catalytic 
efficiency for transfer of the farnesyl group from FMDP 36 to a dansyl-GCVLS peptide 
substrate by FTase was found to be an order of magnitude lower than that for FPP 1 
(Table 6-1).  The previous study also reported that treatment of NIH3T3 cells with 36 
had no effect on their growth.  Eummer at al. suggested that this might be due to FMDP 
36 acting as an alternative substrate for FTase, leading to normal farnesylation of Ras. 
The results of the in vitro fluorescent assay are consistent with this observation.  
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Table 6-1 Kinetics of FMDP 
Steady-state transfer kinetics of FPP and FMDP with 1 µM peptide concentration and 
varying FPP and analog concentrations. Rates were measured in a single cuvette 
fluorescence assay using N-dansyl-GCVLS as the peptide substrate and FTase as the 
catalyst in Tris-HCl (pH=7.4) with reducing agent and detergent. Note the order of 
magnitude difference in catalytic efficiency. 
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Analog Km(nM) kcat (s-1) kcat/Km (M-1s-1) 
FPP (1) 40 0.09 2 x 106
FMDP (36) 180 0.06 3 x 105
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Synthesis of masked methylene diphosphonates 
The synthesis of tri-POM esters of isoprenoid diphosphonates is summarized in 
Figure 6-11. Tetrapivaloyloxymethyl methylenediphosphonate (38) was prepared from 
tetramethyl methylenediphosphonate (37) and pivaloyloxymethyl chloride (POM-Cl) in 
47% yield as previously described [237].  In analogy to previously reported methods, 
treatment of 38 with DABCO provided the tripivaloyloxymethyl methylenediphosphonate 
salt 39 in 80-95% yield.  The crude DABCO salt 39, was converted to the corresponding 
chloride 41 with oxalyl chloride and catalytic DMF in toluene in 90-95% yield. The purity 
of the air and moisture sensitive chloride 41 was established by examining the 1H and 
31P NMR spectra of the crude filtrate.  The 1H NMR spectrum of 41 showed no trace of 
the quaternary DABCO cation 40.36 Tri-POM-methylenediphosphonate isoprenoids 42a-
c were prepared by combining the corresponding allylic alcohols with chloride 41 in 
either dilute toluene or methylene chloride solution containing a three fold excess of 
DBU and catalytic DMAP.37 The farnesyl, geranylgeranyl and geranyl isoprenoids 42a-c 
were isolated in 40-50% yield after purification by silica gel flash chromatography using 
1% TEA added to a hexane:ethyl acetate mobile phase.  Significantly lower yields of the 
isoprenoids 42a-c were obtained if TEA was omitted from the eluent.  Isoprenoids 42a-c 
were quite labile and no product was recovered from attempts to purify them using 
alumina and fluorosil.  Purification by RP-HPLC was unsuccessful due to progressive 
decomposition of the tetraesters 42a-c in water or buffer (see below). 
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Figure 6-10 Synthesis of POM protected methylene diphosphonates 
Reagents and Yields: (a)POMCl, NaI, acetonitrile, reflux (47%).(b) DABCO, acetonitrile, 
reflux (90%). (c) (COCl)2, DMF(cat.), rt (96%). (d) ROH, DBU, DMAP(cat.) 
Toluene/mehylene chloride (40-50%) 
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Tetraester stability 
Tetraesters 42a-c were water sensitive and can only be stored for a few days at 
–20˚ C without significant decomposition. There is evidence that indicates 
acyloxymethyl group deprotection occurs chemically at the phosphorous atom in H218O 
[238]. If the chemical hydrolysis occurs at the allylic alcohol linkage rather than the 
acyloxymethyl group linkage then these compounds may not be able to traverse a cell 
membrane as the MDP analog, but rather the parent alcohol. Tetraester stability was 
monitored by RP-HPLC for the disappearance of methylene diphosphonates 42a-b and 
the concomitant appearance of the parent alcohols (Figure 6-12). (Due to low aqueous 
solubility of the tetraesters, decomposition was measured in mixed aqueous/organic 
solution. 50 % of tetraester 42a had decomposed after 200 min in water:acetonitrile 
(99:1) and 42b decomposed after 500 min in pH=7.4 buffered cell culture 
media:acetonitrile (99:1). Under these conditions only 10% of the tetraester 42b was 
converted to the parent alcohol 2a after 500 min. 31P NMR spectra of the time 
dependent breakdown of methylenediphosphonate 42a in 9:1 water:acetonitrile is 
consistent with the formation of the mono-allylic diPOM salt (Figure 6-13). Niemi et al. 
prepared and tested the aqueous stability of tetra-, tri- and P,P'-diPOM esters of 
dichloromethylenediphosphonate [198]. They found that the tri-POM ester had a half-life 
of 78 min in serum and that the insoluble tetra-POM was converted to the P,P'-di- POM 
and tri-POM esters in pH 7.4 serum. Together these data suggest that the charged 
mono-allylic diPOM salts are the primary decomposition products of tetraesters 42a-c. 
Niemi et al have also shown that pivaloyloxymethyl esters of prodrug bisphosphonates 
are fully deprotected in the presence of 10% rabbit liver homogenates.  
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Figure 6-11 Prodrug Decomposition HPLC 
 
All RP-HPLC data calculated based on relative peak integrals of initial tetraester verses 
tetraester or alcohol produced at each time point and fit to exponential curve. a)42a 
decomposition in water b) 42b decomposition in cell media. Note that the rate of 
decomposition does not match the rate of alcohol formation. 
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Figure 6-12 Time dependent decomposition of FTriPOM 9a analyzed by 31P NMR 
73 mg (0.1 mmols) of FTriPOM 42a was dissolved in 2 mL of 10% acetonitrile/water. A 
31P NMR spectrum was taken at time 0 then again 24 hrs later. Note that the 
Tripivaloyloxymethyl ester decomposes into what appears to be the dipivaloyloxy ester, 
but from the previous decomposition data in Figure 6-11 it is not from isoprenoid loss 
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Discussion 
Unnatural analogs as cellular FTase substrate probes 
This chapter outlines a general strategy for detecting prenylated proteins using 
antibodies directed towards unnatural analogs of FPP 1b bearing unique epitopes that 
can be transferred to proteins by FTase. We have found that the farnesol 1a analog 
AGOH 5a can be utilized by a cell to modify proteins in an FTase dependent manner 
and is not particularly toxic. The structure of the anilinogeranyl moiety is also dissimilar 
to any other known cellular components or protein modifications making it an excellent 
epitope for selective antibody recognition. In this chapter I have shown that the AGPP 
prodrug anilinogeraniol is incorporated into cellular protein in the presence of the 
endogenous FPP pool. Previous reports of FPP analog incorporation into cellular 
proteins have required lovastatin to block endogenous FPP formation in order to detect 
modified proteins. These reagents may be useful for the analysis of FTase mediated 
protein modification and cellular events further downstream. The lack of acute cellular 
toxicity of AGOH 5a may allow for long-term analysis of proteins modified by FTase by 
immunohistochemical methods. These antibodies could be especially useful for 
screening the activity and protein targeting of farnesyl transferase inhibitors helping to 
identify the targets of these reagents to better understand the role of farnesylated 
proteins in cancer biology. 
Alternative pro-drugs for FPP analogs 
This chapter also described a synthetic methodology to prepare mono-allylic 
tripivaloyloxymethyl tetraesters of methylene diphosphonic acid and has shown that 
farnesyl methylenediphosphonate is a substrate for protein farnesyl transferase. The 
lipophilicity of isoprenoid methylenediphosphonates is significantly increased by 
masking the phosphonic acid groups with acyloxymethyl esters.  As we increase the 
structural diversity of the FTase transferable substrates it is likely that analogs will 
eventually be developed that cannot be endogenously diphosphorylated. In the event 
that this occurs the tripivaloyloxymethyl methylene diphosphonate masking strategy 
may provide a new efficient delivery mechanism for the isoprenoid analogs. 
Interestingly, bisphosphonates have proved to be very useful for the treatment of bone 
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diseases. The methylene diphosphonate moiety readily chelates Ca2+ ions, and is 
directed by the body to bone. It is possible that the isoprenoid methylene 
diphosphonates could be directed to bone with a similar mechanism and effect delivery 
of such molecules in a whole animal system. However, the stability of the protected 
methylene diphosphonates may present a problem for such molecules, and may need 
to be improved using alternative cell labile masking approaches.  
Experimental 
General 
All reactions were conducted under dry argon and stirred magnetically, except as 
noted. Reaction temperatures refer to the external bath temperatures. Analytical TLC 
was performed on pre-coated (0.25 mm) silica gel 60F-245 (Merck) plates and 
developed with given solvent conditions. Visualization was achieved by UV irradiation, 
iodine or by subjecting the plates to a 15% sulfuric acid, 1% ceric ammonium sulfate, 
2% Molybdic anhydride solution followed by heating. Flash chromatography was 
performed on Merck silica gel 60 (230-400 mesh ASTM). All chromatography solvents 
were purchased from VWR (EM Science-Omnisolv high purity) and used as received. 
All reagents were purchased from Aldrich or Alfa Aesar.  NMR Spectra were obtained in 
CDCl3 (unless otherwise noted) at 200 or 400 MHz. Chemical shifts for the following 
deuterated solvents are reported in ppm downfield using the indicated reference peaks: 
CDCl3 (CDCl3 internal peak 7.27 ppm for 1H, 77.4 ppm for 13C). ESI-MS were performed 
at the University of Kentucky Mass Spectra Facility.  
Synthesis 
Cysteine Methyl Ester Synthesis (8a-c) 
Anilinogeranyl Cysteine Methyl Ester  
2-amino-3-(3,7-dimethyl-8-phenylamino-octa-2,6-dienylsulfanyl)-propionic acid methyl 
ester 8a 
Chloride 7a was prepared from the corresponding alcohol (734mg, 3.0 mmols) in 
10 mL of acetonitrile as previously described [159]. A solution of L-cysteine methyl ester 
hydrochloride (1.13g, 6.50 mmols) in 20 mL of 7M NH3/MeOH was added to the cooled 
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solution (-20º C) of chloride 7a. The reaction initially formed a white precipitate which 
quickly disappeared. After 3 hours, the reaction mixture was allowed to warm to room 
temperature over one hour. The reaction mixture was partitioned between ether and 
water and extracted with ether (3X). The combined organic extracts were then dried 
over MgSO4 and solvent was evaporated. Purification by flash chromatography (1:2:8) i-
Pr-OH:EtOAc:Hexane yielded 625 mg (60%) of a yellow oil. Rf=0.32 in 1:2:5 i-Pr-OH: 
EtOAc: Hexane 1H NMR (CDCl3, 200 MHz) 7.10 (t, 2H, J=8.0 Hz), 6.63 (t, 1H, J=7.2 
Hz), 6.55 (d, 2H, J=8.0 Hz) 5.39 (t, 1H, J=8.0 Hz), 5.23 (t, 1H, J=8Hz), 3.75 (s, 3H), 3.59 
(m, 3H), 3.13 (m, 2H), 2.86-2.95 (2d, 1H), 2.65-2.76 (2d, 1H), 2.06-2.19 (m, 4H), 1.63 
(s, 3H), 1.62 (s, 3H) 13C NMR (CDCl3, 50 MHz) 174.58, 148.77, 139.42, 132.96, 129.38, 
125.75, 120.53, 117.39, 113.08, 54.51, 52.49, 51.96, 39.50, 36.61, 30.14, 26.30, 16.33, 
14.98; MS: (ESI, +) (M-H+) 363   
Nitroanilinogeranyl cysteine methyl ester 
2-amino-3-[3,7-dimethyl-8-(4-nitro-phenylamino)-octa-2,6-dienylsulfanyl]-propionic acid 
methyl ester (8b) 
Purification by flash chromatography (3:2:5 i-Pr-OH: EtOAc: Hexane) yielded 276 mg 
(60%) of a yellow/brown oil. Rf=0.28 (3:2:5 i-Pr-OH: EtOAc: Hexane) 1H NMR (CDCl3, 
400 MHz) 8.65 (d, 2H, J=8.0 Hz), 6.52 (d, 2H, J=8.0 Hz), 5.34 (t, 1H, J=12 Hz), 5.20 (t, 
1H, J=16 Hz), 3.75 (s, 3H), 3.71 (s, 2H), 3.65 (m, 1H), 3.17 (d, 2H, J=16 Hz), 2.84-2.93 
(2d, 1H), 2.64-2.75 (2d, 1H) 2.18 (t, 2H), 2.02(t, 2H) 1.22 (s, 3H), 1.19 (s, 3H) 13C NMR 
(CDCl3, 50 MHz) 174.80, 153.92, 139.04, 131.14, 126.60, 120.79, 111.40, 54.48, 
52.52, 50.99, 39.25, 36.79, 30.25, 25.98, 25.61, 16.26, 14.92; MS: (ESI, +) (M-H+) 408 
Farnesyl Cysteine Methyl Ester  
 2-amino-3-(3,7,11-trimethyl-dodeca-2,6,10-trienylsulfanyl)-propionic acid methyl ester 
(8c) 
Into a 100 mL round bottomed flask at 0 °C was added L-Cysteine methyl ester 
(1.38 g, 10.2 mmols) in 60 mL of 7M NH3/MeOH. Neat farnesyl bromide (7c) (1.00 g 
3.52 mmols) was then added and the solution was stirred at 0° C for four hours. The 
reaction mixture was partitioned between ether and water and extracted 3X with ether, 
extracts were combined, dried over MgSO4 filtered and evaporated. Purification by flash 
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chromatography (1% MeOH:CHCl3) yielded 881 mg (74%) of a clear oil. Rf=0.22 in 5% 
MeOH in CHCl3. 1H NMR (CDCl3, 400 MHz): 5.24 (t, 1H, J=8Hz), 5.10 (m, 2H), 3.75 (s, 
3H), 3.64 (q, 1H), 3.10-3.25 (m, 2H), 2.86-2.91 (2d, 1H), 2.65-2.71 (2d, 1H), 2.04-2.10 
(m, 6H), 2.04(m, 6H) 2.0 (t, 2H), 1.69 (s, 3H), 1.68 (s. 3H), 1.60 (s, 6H); 13C NMR 
(CDCl3, 50 MHz) 174.93, 139.91, 135.71, 131.62, 124.69, 124.11, 120.35, 54.64, 52.35, 
39.93, 36.77, 30.15, 26.98, 26.67, 25.86, 17.86, 16.33, 16.21 MS: (ESI, +) (M-H+) 340    
General Conditions for Succinylation (9a-c) 
Cysteine methyl ester 8c (881 mg, 2.6 mmols) was diluted in 20 mL of 1:1 
THF:CH2Cl2 in a 100mL round bottomed flask. Succinic anhydride (280 mg, 2.8 mmols) 
was then added and the mixture stirred for 4 hours, followed by evaporation of solvent. 
The residue was diluted in ether, washed sequentially with water and brine and then 
dried over sodium sulfate and concentrated in vacuo.
Anilinogeranyl cysteine succinate  
N-[2-(3,7-dimethyl-8-phenylamino-octa-2,6-dienylsulfanyl)-1-methoxycarbonyl-ethyl]-
succinamic acid (9a) 
Cysteine methyl ester 8a (302 mg, 0.83 mmols) provided 250 mg (65%) of 
succinate 9a as a white solid. Purification by flash chromatography (1:4:5: 0.1 i-Pr-OH: 
EtOAc:  hexane: acetic acid)  Rf=0.32 (1:4:5 i-Pr-OH: EtOAc: Hexane.) 1H NMR (CDCl3, 
400 MHz) 7.12 (t, 2H, J=8.0 Hz), 6.65 (t, 2H, J=8.0 Hz), 6.58 (t, 2H), 5.34 (t, 1H, J=8.0 
Hz) 5.14 (t, 1H, J=8.0 Hz), 4.75 (m, 1H), 3.72 (s, 3H), 3.60 (s, 2H), 3.11 (m, 2H), 2.79-
2.93 (m, 2H), 2.65 (t, 2H, J=8.0 Hz), 2.52 (t, 2H, J=8 Hz), 2.11 (t, 2H, J=8 Hz) 2.02 (t, 
2H, J=8 Hz), 1.63 (s, 3H), 1.62 (s, 3H); 13C NMR (CDCl3, 50 MHz) 176.95, 171.84, 
171.55, 148.48, 139.80, 132.79, 129.34, 125.86, 120.06, 117.68, 113.36, 52.91, 52.13, 
39.42, 33.55, 30.69, 30.19, 29.53, 28.92, 26.22, 16.25, 14.96  MS: (ESI, +) (M-H+) 463 
Nitroanilinogeranyl cysteine succinate  
 N-[2-[3,7-dimethyl-8(4-nitro-phenylamino)-octa-2,6-dienylsulfanyl]-1-methoxycarbonyl-
ethyl]-succinamic acid (9b) 
Cysteine methyl ester 8b (339 mg, 0.83 mmols) provided 204 mg (57%) of succinate 9b 
as a yellow solid. Purification by flash chromatography (1:4:5:0.1) i-Pr-OH: EtOAc: 
hexane: acetic acid) Rf=0.3 (3:2:5) i-Pr-OH: EtOAc: hexane 1HNMR (CDCl3, 200 MHz): 
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8.03 (d, 2H, J=8.0 Hz), 6.49 (d, 3H), 5.30 (t, 1H, J=8 Hz), 5.11 (t, 1H, J=8 Hz), 4.75 (m, 
1H), 3.77 (s, 3H), 3.74 (s, 2H), 3.10 (m, 2H), 2.81-3.02 (m, 2H), 2.57-2.76 (m, 4H), 2.06-
2.19 (m, 4H), 1.67 (s, 3H), 1.64 (s, 3H); 13C NMR (CDCl3, 50 MHz): 176.20, 172.00, 
171.50, 153.91, 139.60, 131.17, 126.83, 126.61, 120.39, 111.60, 52.92, 52.33, 51.14, 
39.20, 33.65, 30.70, 30.28, 29.42, 26.01, 16.18, 14.80 MS: (ESI, +) (M-H+) 508 
Farnesyl cysteine succinate  
N-[1-methoxycarbonyl-2-(3,7,11-trimethyl-dodeca-2,6,10-trienylsulfanyl)-ethyl]-
succinamic acid (9c) 
Cysteine methyl ester 8c (881 mg, 2.6 mmols) provided 937 mg (82%) of 
succinate 9c as a white solid. Purification by flash chromatography (1:2:7 i-Pr-OH: 
EtOAc:  hexane) 1H NMR (CDCl3, 400 MHz) 10.55 (bs, 1H), 6.72 (d, 1H, J=8 Hz), 5.17 
(t, 1H, J=8 Hz), 5.07 (m, 2H), 4.75-4.80 (q, 1H), 3.73-3.73 (s, 3H), 3.13 (m, 2H), 2.90-
2.94 (m, 1H), 2.80-2.85 (m, 1H), 2.69 (t, 2H), 2.57 (t, 2H), 1.92-2.08 (m, 8H), 1.65 (s, 
3H), 1.64 (s, 3H), 1.57 (s, 6H); 13C NMR (CDCl3, 100 MHz) 177.40, 171.90, 171.64, 
140.17, 135.44, 131.38, 124.44, 124.38, n123.85, 123.78, 119.60, 119.55, 52.80, 52.75, 
52.01, 51.97, 39.79, 39.72, 33.28, 31.67, 30.55, 29.96, 29.39, 26.80, 26.51, 25.79, 
22.74, 17.78, 16.19, 16.10; MS: (ESI, +) (M-H+) 438 
General Conditions for Activated Ester Formation (10a-c) 
Succinamic acid 8c (59.6 mg, 0.126 mmols) was dissolved in 10mL of dry 
acetonitrile in a 100 mL round-bottomed flask. Carbonyldiimidazole (26.4 mg 0.163 
mmols) was then added and the mixture was allowed to stir for 5 minutes. N-
hydroxyphthalimide (26.4 mg, 0.163 mmols) was added and the solution was stirred for 
1.5 hours. The solvent was then evaporated. 
Anilinogeranyl cysteine succinyl phthalimide  
 N-[2-(3,7-dimethyl-8-phenylamino-octa-2,6-diensulfanyl)-1-methoxycarbonyl-
ethyl]-succinamic acid 1,3-dioxo-1,2-;dihydro-isoindol-2-yl ester (10a) 
Succinate 9a (30 mg, 0.07 mmols) provided 25 mg (63%) of phthalimide 10a as a 
yellow/brown oil. Purified by column chromatography (CHCl3). Rf=0.28 (1:1) 
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Hexane:EtOAc 1H NMR (CDCl3, 400 MHz): 7.88 (q, 2H), 7.78 (q, 2H), 7.16 (t, 2H), 6.68 
(t, 1H), 6.60 (d, 2H), 6.37 (d, 1H), 5.37 (t, 1H), 5.17 (t, 1H), 4.83 (m, 1H), 3.76 (s, 3H), 
3.63 (s, 2H), 3.15 (m, 2H), 3.06 (t, 2H), 2.92 (m, 2H), 2.71 (t, 2H), 2.03-2.18 (m, 4H), 
1.67 (s, 3H), 1.65 (s, 3H); 13C NMR (CDCl3, 50 MHz): 171.43, 169.94, 169.12, 161.93, 
148.70, 139.79, 134.06, 132.89, 129.34, 125.72, 124.19, 120.08, 117.38, 113.07, 52.86, 
52.10, 51.97, 39.43, 33.64, 30.63, 30.21, 26.78, 26.25, 16.26, 14.94 MS: (ESI, +) (M-
H+) 608 
Nitroanilinogeranyl cysteine succinyl phthalimide  
 N-[1-[3,7-Dimethyl-8-(4-nitro-phenylamino)-octa-2,6-diensulfanyl]-1-methoxycarbonyl-
ethyl]-succinamic acid 1,3-dioxo-1,3-dihydro-isoindol-2-yl ester (10b) 
Succinate 9b (38 mg, 0.08 mmols) provided 41 mg (85%) of phthalimide 10b as a 
yellow oil. Purified by column chromatography (CHCl3). Rf=0.12 (1:1) Hexane:EtOAc 
1H NMR (CDCl3, 400 MHz) 8.02 (d, 2H), 7.84 (q, 2H), 7.75 (q, 2H), 6.54 (d, 2H), 6.36 
(d, 1H), 5.30 (t, 1H), 5.11 (t, 1H), 4.78 (q, 1H), 3.73 (s, 3H), 3.70 (s, 2H), 3.10 (t, 2H), 
3.02 (t, 2H), 2.80-2.98 (m, 2H), 2.69 (t, 2H), 2.11 (m, 2H), 2.00 (t, 2H), 1.63 (s, 3H), 1.59 
(s, 3H); 13C NMR (CDCl3 100 MHz) 171.36, 169.17, 161.94, 153.85, 146.06, 139.44, 
138.02, 135.02, 131.06, 129.03, 126.60, 126.56, 124.21, 120.32, 111.40, 52.95, 52.24, 
51.02, 39.21, 33.60, 30.62, 30.24, 27.02, 26.75, 26.00, 16.22, 14.87 
Farnesyl cysteine succinyl phthalimide  
 N-[1-methoxycarbonyl-2-(3,7,11-trimethyl-dodeca-2,6,10-trienylsulfanyl)-ethyl]-
succinamic acid 1,3-dioxo-1,2-dihydro-isoindol-2-yl ester (10c) 
Succinate 9c (60 mg, 0.14 mmols) provided 80 mg (58%) of phthalimide 10c as a 
brown oil. Purified by column chromatography (CHCl3). Rf=0.3 (1:1) Hexane:EtOAc
 1H NMR (CDCl3, 400 MHz) 7.88 (q, 2H), 7.79 (q, 2H), 6.38 (d, 1H), 5.20(t, 1H), 
5.09 (t, 2H), 4.82 (m, 1H), 3.76 (s, 3H), 3.74 (s, 2H), 3.11-3.22 (m, 2H), 3.07 (t, 2H), 
2.86-3.00 (m, 2H), 2.74 (t, 2H), 1.95-2.10 (m, 8H), 1.68 (s, 3H), 1.66 (s, 3H), 1.60 (s, 
6H); 13C NMR (CDCl3, 100 MHz) 171.44, 169.90, 169.93, 161.91, 140.29, 135.57, 
134.96, 131.53, 129.06, 124.50, 124.19, 123.90, 119.64, 52.85, 52.00, 39.88, 39.81, 
33.54, 30.62, 30.14, 29.03, 28.23, 26.90, 26.75, 26.59, 25.90, 17.89, 16.31, 16.21. 
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General Conditions for Benzyl amine Coupling (11a-c) 
Phthalimide 10c (47.2 mg, 0.08 mmols) was dissolved in 1 mL of acetonitrile and 
5 mL of 5% NaHCO3 buffer pH=9 in a 25 mL RB flask. Benzylamine (17.3 mg, 0.16 
mmols) was then added and the reaction was allowed to stir for 1.5 hours at room 
temperature. 10 mL of water was added and organics were extracted with ether (3X), 
dried over MgSO4, and organic solvent evaporated. 
Anilinogeranyl benzyl amine  
2-(3-Benzylcarbamoyl-propionylamino)-3-(3,7-dimethyl-8-phenylamino-octa-2,6-
Dienylsulfanyl)-propionic acid methyl ester (11a) 
Phthalimide 10a (133 mg, 0.22 mmols) provided 59 mg (48%) of amide 11a as a 
white solid. Purification by column chromatography (3:7) Hexane: EtOAc. 1H NMR 
(CDCl3, 400 MHz) 7.21-7.31 (m, 5H), 7.12 (t, 2H), 6.55-6.66 (m, 4H), 6.23 (bt, 1H), 5.34 
(t, 1H), 5.14 (t, 1H), 4.71 (q, 1H), 4.38 (d, 2H, J=6 Hz), 3.70 (s, 3H), 3.59 (bs, 2H), 3.10 
(m, 2H), 2.76-2.91 (m, 2H), 2.50-2.61 (m, 4H), 1.99-2.13 (m, 4H), 1.63 (s, 3H), 1.62 (s, 
3H) 13C NMR (CDCl3, 50 MHz): 172.23, 171.94, 171.46, 148.63, 139.77, 138.41, 
132.84, 129.42, 129.34, 129.19, 128.94, 128.87, 128.08, 127.93, 127.73, 125.74, 
120.08, 117.411, 113.10, 52.82, 52.09, 51.963, 43.85, 39.45, 33.50, 31.71, 31.66, 
30.12, 26.25, 16.28, 14.95 MS: (ESI, +) (M-H+) 552 
Nitroanilinogeranyl benzyl amine  
 2-(3-Benzylcarbamoyl-propionylamino)-3-[3,7-dimethyl-8(4-nitro-phenylamino)-octa-
2,6-dienylsulfanyl]-propionic acid methyl ester (11b) 
Phthalimide 10b (13 mg, 0.02mmols) provided 9 mg (76%) of amide 11b as a yellow 
solid. Purification by column chromatography (3:4) Hexane: EtOAc. 1HNMR (CDCl3, 
400 MHz) 8.01 (d, 2H, J=9.2 Hz), 7.20-7.29 (m, 5H), 6.69 (d, 1H, J=7.6 Hz), 6.48 (d, 2H, 
J=9.2 Hz), 6.26 (t, 1H), 5.30 (t, 1H), 5.12 (t, 1H), 4.96 (t, 1H), 4.68-4.72 (m, 1H), 4.38 (d, 
2H, J=5.6 Hz), 3.70 (s, 3H), 3.68 (d, 2H, J=5.6 Hz), 3.10 (m, 2H), 2.77-2.91 (m, 2H), 
2.51-2.62 (m, 4H), 2.10-2.16 (t, 2H), 2.00-2.03 (t, 2H), 1.62 (s, 3H), 1.60 (s, 3H); 13C 
NMR (CDCl3, 50 MHz): 172.22, 171.92, 171.41, 153.89, 139.39, 138.33, 131.04, 
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128.88, 127.91, 127.67, 126.56, 120.33, 111.38, 52.86, 52.21, 50.99, 43.88, 39.22, 
33.59, 31.67, 31.65, 30.22, 26.00, 16.24, 14.87 MS: (ESI, +) (M-H+) 597 
Farnesyl Benzyl amine  
 2-(3-Benzylcarbamoyl-propionylamino)-3-(3,7,11-trimethyl-dodeca-2,6,10-
trienylsulfanyl)propionic acid methyl ester (11c) 
Phthalimide 11c (47 mg, 0.08mmols) provided 42 mg (67%) of amide 11c as a 
white solid. Purification by column chromatography (4:6) Hexane: EtOAc. 1H NMR 
(CDCl3, 400 MHz) 7.25-7.34 (m, 5H), 6.623 (d, 1H), 6.28 (t, 1H), 5.20 (t, 1H), 5.09 (t, 
2H), 4.75 (q, 1H), 4.44 (d, 2H), 3.75 (s, 3H), 3.09-3.22 (m, 2H), 2.81-2.96 (m, 2H), 2.55-
2.67 (m, 4H), 1.96-2.13 (m, 8H), 1.68 (s, 3H), 1.67 (s, 3H), 1.60 (s, 6H); 13C NMR 
(CDCl3, 50 MHz): 172.21, 171.94, 171.47, 140.29, 138.44, 135.60, 131.54, 128.87, 
127.94, 127.64, 124.53, 123.93, 119.72, 52.79, 52.07, 43.89, 39.92, 39.84, 33.47, 
31.77, 31.73, 30.12, 26.95, 26.66, 25.91, 17.90, 16.36, 16.23; MS: (ESI, +) (M-H+) 529 
General Conditions for Protein Coupling (12a-c and 13a-c) 
Phthalimido esters (10a-c) were dissolved in 6 mL of 1:5 acetonitrile and 5% 
NaHCO3 in a 100 mL pear-shaped flask. BSA (13) (0.1 mL of 10 mg/mL solution in 
phosphate buffered saline (PBS) pH 7.2) or KLH protein (12) (3 mL of 10 mg/mL 
solution in PBS pH 7.2) was added and stirred vigorously for 2 hours or until analysis by 
TLC in 1:1 hexane:EtOAc showed no residual activated phthalimide ester spot. The 
solution was dialyzed overnight in 20% DMSO, PBS pH 7.5 then PBS (3 X 1L, 6 hrs 
each).  
Tetra(pivaloyloxymethyl) Methylenediphosphonate (38) 
A mixture of tetramethyl methylenediphosphonate 37 (3.77g, 17.2 mmols) 
sodium iodide (11.1g, 73.7 mmols) and pivaloyloxymethyl chloride (16.1g, 106 mmols) 
were heated at reflux overnight in acetonitrile. Solvents were evaporated under reduced 
pressure and the residue was partitioned between 100 mL of ether and water. The 
organics were washed with water (2X) and 5% NaHCO3 (2X) and dried over Na2SO4. 
The ether was evaporated under reduced pressure and the residue dissolved in a 
minimal volume of hexanes and placed at 0° C overnight. Crystals were collected and 
 
162
  
dried to constant weight yielding 4.68g (46%) of 38. 1HNMR 5.67 (m, 8H), 2.57 (t, 2H, 
J=21.6 Hz), 1.20 (s, 36H) 13CNMR 177.04, 82.18, 38.93, 27.08 (t, J=143 Hz) 31PNMR 
19.13 (ESI-MS)M-Na+ 655 
Tri(pivaloyloxymethyl) Methylenediphosphonate  
1,4-(N-(pivaloyloxymethyl)) diazonium-bicyclo[2.2.2]-octane salt (39)  
TetraPOM 38 (10.0g, 15.8 mmols) and DABCO (1.70g, 15.2 mmols) in 200 mL of 
acetonitrile were heated at reflux overnight after which solvent was evaporated under 
reduced pressure. The residue was diluted with 100 mL of ether and washed 4X with 
water. The collected aqueous extracts were evaporated under reduced pressure and 
the residue taken up in dry toluene and the solvent evaporated under reduced pressure 
(3X) leaving 9.59g of triPOM salt 39 as a white oily solid (84.2% yield relative to 
DABCO). 1H NMR 5.34 (m, 8H), 3.37 (t, 6H, J=7.2 Hz) 3.00 (t, 6H, J=7.2 Hz), 2.17 (t, 
2H, J=19.8 Hz) 1.00 (s, 9H), 0.94 (s, 18H), 0.92 (s, 9H) 13C NMR 177.71, 177.09, 
175.76, 83.34, 82.11, 80.90, 50.67, 45.17, 44.94, 39.27, 38.85, 27.54, 27.22, 22.81 31P 
NMR 26.77 (d, 1P, J=6.23 Hz) 7.92 (d, 1P, J=6.12 Hz) (ESI-MS)M- 517 
Tri(pivaloyloxymethyl) methylenediphosphonyl Chloride (41)  
TriPOM salt 39 (546 mg, 0.73 mmols) was dissolved in 20 mL of dry acetonitrile 
and the solvent evaporated under reduced pressure (3X) followed by the addition of 10 
mL dry toluene, 40 µL anhydrous DMF and 0.3 mL oxalyl chloride (3.3 mmols). A white 
precipitate formed immediately with evolution of heat and the reaction was stirred at rt 
for 45 min. Solids were removed by filtration through a pad of Na2SO4 which was 
washed with 5 mL of dry toluene.  The combined organics were immediately evaporated 
under reduced pressure to give a pale yellow oil used without further purification (377 
mg, 96%.) 1H NMR 5.64-5.85 (m, 6H) 3.03 (t, 2H, J=20 Hz) 1.23 (s, 27H) 31P NMR 
28.74 (d, 1P, J=10.95 Hz), 15.74 (d, 1P, J=10.95Hz) 
General synthesis of Tri-POM esters (42a-c) 
Farnesyl tri(pivaloyloxymethyl) methylenediphosphonate (42a)  
Chloride 41 (697 mg, 1.3 mmols) diluted in 5 ml of dry toluene or anhydrous 
methylene chloride was added drop wise to a cooled (-20° C), stirred solution of 
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farnesol 1a (94mg, 0.42 mmols) DBU (198 mg, 1.3 mmols) and DMAP (5 mg, 0.04 
mmols) in 10 mL of dry toluene. Stirring was continued for 2 hours followed by the 
addition of 50 ml of ether. The organic layer was washed 2X each with 10 ml of 0.1N 
HCl, water and freshly prepared 5% NaHCO3, then dried over Na2SO4 and evaporated 
under reduced pressure. Farnesyl ester 42a was obtained in 40% yield (121 mg) after 
silica gel flash chromatography with 7:3 Hexane:EtOAc + 1% triethylamine. 1H NMR 
5.61-5.71 (m, 6H) 5.35 (t, 1H), 5.04 (t, 2H), 4.62 (m, 2H), 2.57 (t, 2H, J=21.6 Hz), 1.90-
2.08 (m, 8H), 1.67 (s, 3H), 1.63 (s, 3H), 1.55 (s, 6H), 1.16 (s, 27H) 13C NMR 177.09, 
177.01, 143.80, 135.80, 131.55, 124.55, 124.36, 123,74, 123.55, 118.57, 82.40, 63.59, 
39.87, 38.91, 27.02 31P NMR 20.02 (d, 1P, J=7.29 Hz), 19.30 (d, 1P, J=6.16 Hz). 
Geranylgeranyl tri(pivaloyloxymethyl) methylenediphosphonate (42b)  
Geranylgeraniol 2a (93 mg, 0.32 mmols) provided 124 mg of 9b (48%). 1H NMR 
5.59-5.69 (m, 6H), 5.33 (t, 1H, J=7.2 Hz), 5.01-5.05 (t, 3H), 4.60 (m, 2H), 2.55 (t, 2H, 
J=21.6 Hz), 1.90-2.03 (m, 12H), 1.65 (s, 3H), 1.61 (s, 3H), 1.53 (s, 9H), 1.17 (s, 27H) 
13C NMR 177.08, 177.01, 143.81, 135.83, 135.18, 131.46, 124.41, 124.24, 123.73, 
123.55, 118.54, 82.46, 82.13, 63.65, 39.90, 38.91, 27.07, 16.17; 31P NMR 20.04 (d, 1P, 
J=7.29 Hz), 19.31 (d, 1P, J=7.45 Hz) 
Geranyl tri(pivaloyloxymethyl) methylenediphosphonate (42c)   
Geraniol (28 mg, 0.18 mmols) provided 62 mg of 42c (55%).  1H NMR 5.61-5.71 
(m, 6H), 5.35 (t, 1H, J=7.2 Hz) 5.03 (t, 1H, J=6.8 Hz), 4.60 (m, 2H), 2.57 (t, 2H, J=22 
Hz), 1.98-2.06 (m, 4H), 1.67 (s, 3H), 1.64 (s, 3H), 1.56 (s, 3H), 1.19 (s, 27H); 13C NMR 
177.06, 176.99, 143.65, 132.14, 124.03, 123.48, 118.65, 82.21, 63.68, 39.70, 38.91, 
26.97, 16.74; 31P NMR 20.00 (d, 1P, J=7.29 Hz), 19.27 (d, 1P, J=8.43 Hz)  
Antibody Generation and Characterization 
Polyclonal antibody production 
Hapten protein conjugates 12a-c were used to immunize rabbits subcutaneously 
by emulsifying 1.5 mg of each conjugate with Freund’s complete adjuvant. This was 
followed by six secondary boosters of the same dose with incomplete Freund adjuvant 
at intervals of 14 days. The rabbits were bled 10 days after each boost. Blood was 
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allowed to coagulate overnight in 50 mL centrifuge tubes and sera was collected and 
stored at 0 º C. 
ELISA Screening 
ELISA plates (96-well polystyrene) were coated with 100 up per well of BSA 
conjugates or BSA (1 ug/mL) in PBS (pH=7.6) and incubated for 1 hr at 37 º C. The 
plates were then washed thoroughly with 10% Tween in PBS buffer (PT) (pH=7.4). 150 
up of serum diluted 1:100 in PT buffer containing casein (PCT) was added and diluted 
1:3 down the plate, then incubated 1 hr at 37 º C. The plates were washed with PT 
buffer and 100 up  of secondary antibody (1:10,000) was added to each well. The plates 
were incubated 1 hr at 37 º C and again washed. 100 up of p-nitrophenylphosphate was 
added to each well (2 pills in 10 ml of Tris buffer ph=9.5). After 20 minutes color began 
to develop and absorbance was read at 405 nm. 
FTase Protein Substrate Modification 
2 µg of recombinant bacterially expressed RDJ2 [200] was incubated with 20 µM 
AGPP 5b or FPP 1b or the other analogs and 5 µg FTase in 50 µL of Tris-HCl buffer 
(pH=7.4) The reactions were incubated for 30 min at 37 º C, boiled with SDS and PAGE 
performed using the protein concentrations indicated on the blots. 
Cell Based Antibody Analysis 
AGOH Labeling and FTI inhibition of label in HEK-293 cells 
Plates were coated with poly-L-Lysine and seeded with HEK-cells in Dulbecco’s 
modified Eagle’s medium with 5% fetal bovine serum. Cells were incubated in medium 
containing 30 µM lovastatin and 10 µM GGOH for 24 hrs. The media was poured off 
then replenished with media without lovastatin and GGOH and were treated with 3 µM 
FTI-277 (calbiochem), 20 µM GGTI-2147 (calbiochem) or no inhibitor and incubated at 
37° C for 1 hour. DMSO as a vehicle, or 100 µM AGOH 5a was then added and 
incubated at 37° C for two hours. Medium was then removed and cells were extracted 
into 300 µL PBS containing Protease Inhibitor cocktail set 1 (Calbiochem). The samples 
were sonicated and centrifuged for 5 minutes. The supernatant was removed and used 
for western blotting. 
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AGOH incorporation into unblocked cells 
Plates were coated with poly-L-Lysine and seeded with HEK-cells in Dulbecco’s 
modified Eagle’s medium with 5% fetal bovine serum. The cells were then treated with 
DMSO as a vehicle, or 30 µM AGOH 5a and incubated at 37° C for the indicated time 
points. Medium was then removed and cells were extracted into 300 µL PBS containing 
Protease Inhibitor cocktail set 1 (Calbiochem). The samples were sonicated and 
centrifuged for 5 minutes. The supernatant was removed and used for western blotting. 
Western Blot Analysis 
Cells were harvested by scraping into 300 µl phosphate buffered saline 
containing protease inhibitor cocktail set 1 (calbiochem), followed by sonication on ice. 
Protein concentration was determined using a Bradford reagent kit (Pierce). The 
proteins from the FTase reaction mixtures or cell lysates were then separated using 
12% SDS-polyacrylamide gels followed by transfer to nitrocellulose membranes. The 
membranes were incubated in blocking buffer PCT (see ELISA) for one hour at room 
temperature, after which the following sequential steps were used: incubation with anti-
AG 1:1000 to 1:10,000 in PCT for one hour; 3X 15 minute washes with vigorous 
shaking in PT buffer (see ELISA); incubation at room temperature one hour with goat 
anti-rabbit horseradish peroxidase-conjugated secondary antibody (Zymed) at a dilution 
of 1:20,000 in PCT buffer; and four 15 minute washes with PT buffer. The membranes 
were then subjected to enhanced chemiluminescence detection by incubation in 20 mL 
of detection buffer (Pierce Super Signal) for one minute. 
Cell Permeant analog Stability 
The time dependent decomposition of 9a and 9b was carried out by analyzing 
the disappearance of the tetraesters and the appearance of the parent alcohols 8a and 
8b by RP-HPLC analysis.  An appropriate amount of either 9a (7 mg, 0.01 mmols) or 9b 
(8 mg, 0.01 mmols) was dissolved in 10 µL of acetonitrile and diluted into 990 µL water 
or 990 µL serum (DMEM + 10% fetal calf serum) adjusted to pH 7.4. The solutions were 
kept at room temperature.  At suitable intervals 10 µL aliquots were withdrawn with the 
autoinjector and analyzed by RP-HPLC. Each sample was eluted with a gradient of 
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water to acetonitrile (9a 70% acetonitrile/water → 100% acetonitrile over 20 min and 9b 
80% acetonitrile/water → 100% acetonitrile over 20 min.) Alternatively the analog was 
placed in dissolved in D2O and the decomposition was monitored by 31P-NMR. 
 
This work has been published under the following citations. 
1. Troutman JM, Chehade KA, Kiegiel K, Andres DA, Spielmann HP. “Synthesis of 
acyloxymethyl ester prodrugs of the transferable protein farnesyl transferase substrate 
farnesyl methylenediphosphonate.” Bioorg Med Chem Lett. 2004 Oct 4;14(19):4979-82 
2. Troutman JM, Roberts MJ, Andres DA, Spielmann HP. “Tools to analyze protein 
farnesylation in cells.” Bioconjug Chem. 2005 Sep-Oct;16(5):1209-17 
Credits:  
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CHAPTER 7 TRANSFERABLE GERANYLGERANYL TRANSFERASE I SUBSTRATE 
ANALOUGES 
 
Introduction 
The major mechanism by which GGTaseI differentiates between a canonical 
FTase target Ca1a2X box and a canonical GGTaseI substrate Ca1a2X sequence is the 
composition of the a2-X binding site of the enzyme [49]. In GGTaseI the a2 binding site 
is made up of Thr49β, Phe53β, Leu320β, the third and forth GGPP 1 isoprenes and the 
target X residue. The X residue binding site is made up of the fourth GGPP isoprene the 
a2 residue, Thr49β, His121β, Ala123β, and Phe174β. Interestingly, in the FTase Ca1a2X 
binding site the third (terminal) isoprene of FPP 2 interacts directly with only the a2 
residue of the target Ca1a2X motif.  
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Figure 7-1 Analogs 
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Analogs of FPP with an aniline moiety replacing the third isoprene of FPP have 
been extremely useful in probing the endogenous activity of proteins modified by FTase 
and in understanding the selectivity of the FTase enzyme. 8-anilinogeranyl diphosphate 
(AGPP 3) is transferable by FTase with kinetics nearly identical to those of FPP [159, 
161]. FTase reactions with AGPP are also highly selective for canonical FTase 
substrates over canonical GGTaseI substrates.(see Chapter 3) Often analogs as 
substrates for FTase verses GGTaseI are designed by extending the FPP analog 
isoprene chain by one isoprenoid to make GGTaseI substrates analogs [166, 239]. In 
this chapter, I will describe how we have utilized this strategy with AGPP 3 and a pNO2 
aniline analog of AGPP in an attempt to design new transferable GGTaseI substrate 
analogs. We have found that anilinofarnesyl diphosphate (AFPP 4a) and pNO2 
anilinofarnesyl diphosphate (NAFPP 4b) analogs can be prepared in a manner 
analogous to the method for preparing the AGPP series of analogs. Both of these 
analogs are substrates for GGTaseI and a CVIL GGTaseI Ca1a2X peptide, and AFPP 
appears to compete very well with the natural substrate of GGTaseI, GGPP. We have 
also found that antibodies designed to detect anilinogeranylated proteins are also useful 
for the detection of anilinofarnesylated proteins. These results suggest that the AFPP 
analogs are substrates and can act as specific probes for the activity of GGTaseI in a 
way analogous to AGPP for FTase. 
Results 
Synthesis of geranylgeranyl diphosphate analogs with substituted aniline moiety 
 The synthetic route shown in figure 7-2 is analogous to the synthesis of AGPP 
with farnesyl acetate 5 as the starting material rather than geranyl acetate. The SeO2 
oxidation of farnesyl acetate 5 was significantly less efficient than geranyl acetate 
oxidation giving maximum yields of 20%. The yield of the reaction was increased slightly 
(30%) using ethereal co-solvents apparently stabilizing the transition state with SeO2. 
Altering the hydroxyl protecting group had no effect on the overall yield of the reaction 
and no further attempts to optimize the reaction were attempted. Following farnesyl 
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acetate oxidation to the α,β-unsaturated aldehyde 6 the aniline moiety was incorporated 
by reductive amination followed by saponification to give the alcohols 9a (AFOH) and 
9b (NAFOH). The alcohols were then halogenated and converted to diphosphate as 
previously described for the AGPP series of FPP analogs giving AFPP 4a and NAFPP 
4b. 
Affects of altering Analogue Structure on Peptide reactivity 
 In order to determine if the anilinofarnesyl diphosphate analogs were substrates 
for GGTaseI we screened the transfer rate of the analogues with two dansylated-
GCaaX peptide substrates utilizing a continuous fluorescence assay. The peptides 
corresponded to a canonical GGTaseI substrate peptide (CVIL) and a peptide that is a 
substrate for both FTase and GGTaseI (CVIM). We confirmed that GGPP was a 
substrate with the CVIM and CVIL peptides (Figure 7-3). We found that AFPP was a 
substrate for GGTaseI and reacted with a rate similar to that of GGPP with both the 
CVIL and CVIM peptides. However, NAFPP was a substrate only with the CVIL peptide 
and no reaction was observed with the CVIM peptide. In addition, AFPP and NAFPP 
were not substrates for FTase with an N-dansyl-GCVIM peptide as the isoprenoid 
acceptor. 
 We have previously observed in the FTase reaction that there are three peptide 
concentration dependent binding states in the steady-state mechanism of FTase. To 
determine if the same was true for GGTaseI we measured initial velocities of a wide 
range of CVIL peptide concentrations with each of the analogues. We found that the 
third peptide binding state was somewhat apparent in the GGPP reaction. However, we 
were unable to reach peptide concentrations sufficient to observe a third peptide 
concentration dependent binding state with the AFPP and NAFPP analogues (Figure 7-
4). In addition, we did not observe peptide inhibition with the NAFPP analogue at the 
concentrations of peptide analyzed. 
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Figure 7-2 synthesis of AFPP and NAFPP 
Reagents: (a) SeO2 DCM 2hrs 0º C; (b) aniline 8a-b HOAc, NaBH(OAc)3, DCE, rt; (c) 
K2CO3 MeOH/Water; (d) PPh3Cl2, MeCN, rt; 10 minutes ((nBu)4N)3HP2O7, MeCN 
overnight. 
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Figure 7-3 Analog reactivity with CVIL and CVIM peptides and GGTaseI catalyst 
 
Reactions were initiated by addition of GGTaseI. Only the compounds shown below 
could be transferred to the peptides. No reaction was detected with any of the analogs 
with CVLS, CVIM or CAHQ peptides as the isoprenoid acceptor and GGTaseI as the 
catalyst. Rates of the reactions are reported in pmols/sec and are based on the 
fluorescence enhancement and RP-HPLC analysis of reactions containing 3µM peptide, 
12 µM analog and 10 nM GGTaseI. Reactions were run in 96 well plate format. All 
reactions were performed in Tris-HCl buffer (pH=7.4) plus detergent and reducing 
agent. Note that AFPP is the only analog that also reacts with the CVIM peptide. 
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Figure 7-4 GGTaseI Steady-State reaction kinetics 
 
GGTaseI Steady-State reaction with a) GGPP b) AFPP c) NAFPP and CVIL. Rates are 
reported as rate per unit enzyme. Note the increase in apparent Ki with each analogue. 
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 In order to determine if the AFPP analogues altered the CVIL peptide reactivity in 
the GGTaseI reaction we measured the apparent kcat, Kmpeptide and kcat /Kmpeptide with 
the analogs, GGPP and FPP (Table 7-1). We found that the catalytic efficiency of the 
CVIL peptide GGTaseI reactions was lowest with FPP and highest with the natural 
substrate GGPP.  The NAFPP analogue increased the Kmpeptide and kcat with the CVIL 
peptide. Interestingly, the catalytic efficiency with NAFPP was five times and three times 
lower than the efficiency with GGPP and AFPP respectively. However, the efficiency of 
the GGTaseI reaction with NAFPP and the CVIL peptide was four times higher than the 
efficiency of GGTaseI with FPP as the donor substrate. Because there was only a small 
contribution of a third peptide binding state we also fit the data to the substrate inhibition 
equation given in equation 1. We found that the Ki of the CaaX peptide was significantly 
higher with AFPP as the substrate therefore peptide inhibition was much more potent 
with GGPP as the substrate (Table 7-2). 
 When the GGTaseI target peptide was replaced with a CVIM peptide we found 
that only GGPP and AFPP were reacted efficiently. Both AFPP and GGPP catalytic 
efficiency were on the same order as with the CVIL peptide, but the value was reduced 
3.6 and 3.2 fold respectively. Surprisingly, no reaction was observed with the NAFPP 
analogue, yet even FPP was utilized to some extent by the enzyme. These results 
suggest that the NAFPP analogue reduces the ability of GGTaseI to catalyze the 
modification of alternative peptide substrates. Interestingly, the reactivity of AFPP with 
the different peptide substrates was similar to the reactivity of GGPP only the catalytic 
efficiency was slightly reduced. In the case of CVIL as the isoprenoid acceptor the 
catalytic efficiency was reduced by an increase in the Kmpeptide while with CVIM both the 
kcat and Kmpeptide were increased. 
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Table 7-1 GGTaseI reaction kinetics  
Steady-state kinetics with the GGTaseI enzyme and substrate analogs.  
All reactions were performed in Tris-HCl buffer (pH=7.4) plus detergent and reducing 
agent with varying concentrations of the peptide,12 µM analog, and 10 nM GGTaseI. 
Note that the transfer kinetics of AFPP are similar to GGPP with CVIL but not CVIM 
 
cmpd # peptide Km
CaaX 
(µM) 
kcat
(s-1) 
kcat/ KmCaaX 
(µM-1• s-1) 
F 2 CVIL 6 ± 1 0.034 ± 0.005 0.0053 ± 0.0002 
GG 1 CVIL 0.31 ± 0.05 0.044 ± 0.002 0.091 ± 0.005 
AF 4a CVIL 0.65 ± 0.06 0.043 ± 0.002 0.054 ± 0.002 
NAF 4b CVIL 30 ± 5 0.64 ± 0.08 0.020 ± 0.001 
F 2 CVIM 4 ± 2 <0.001 <0.0003 
GG 1 CVIM 2.7 ± 0.2 0.086 ± 0.002 0.025 ± 0.001 
AF 4a CVIM 6.4 ± 0.4 0.127 ± 0.004 0.017 ± 0.001 
NAF 4b CVIM NR NR NR 
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Table 7-2 Substrate inhibition data fit with AFPP and GGPP 
 
cmpd # peptide Km
CaaX 
(µM) 
kcat
(s-1) 
KiCaaX 
(µM) 
kcat/ KmCaaX 
(µM-1• s-1) 
GG 1 CVIL 2.4 ± 0.9 0.19 ± 0.06 0.5 ± 0.2 0.08 ± 0.04 
AF 4a CVIL 1.2 ± 0.2 0.066 ± 0.008 5 ± 1 0.06 ± 0.01 
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 The steady-state kinetic results suggest that the CVIL peptide is much more 
readily modified than the CVIM peptide. To test this we mixed the CVIL and CVIM 
peptides 1:1 in competition reactions with excess GGPP or AFPP, and analyzed the 
resulting products by HPLC. We found that the CVIL to CVIM product ratios were 6:1 
and 5:1 with AFPP and GGPP respectively (Figure 7-5). The CVIL to CVIM product ratio 
was slightly higher than expected based on the selectivity factor kcat/Kmpeptide and 
significantly lower than the expected ratio based on the Kmpeptide alone. These results 
were consistent with the model proposed previously for the substrate association 
pathway in FTase giving figure 7-6 as the likely kinetic mechanism for GGTaseI. 
AFPP competes effectively for CVIL modification 
 AGPP is competitive with FPP for FTase catalyzed modification of proteins both 
in vitro and in cell culture [159, 209]. The relative efficiency of peptide modification by an 
alternative isoprenoid substrate over the natural substrate can be determined from the 
ratio of products formed in competition experiments between the transferable 
analogues, the natural substrate and peptide. We measured products ratios from 
competition reactions between transferable AFPP analogues and GGPP for 
modification of the Dns-GCVIL peptide by HPLC separation of the products and 
integration of the dansyl peak absorbance. Reaction of 1:1 ratios of AFPP and GGPP 
with limiting CVIL peptide resulted in a 2:1 ratio of gernaylgeranyl to anilinofarnesyl 
modified CVIL. This was an identical ratio to that found for AGPP with FTase and a 
CVLS peptide (Fiugre 7-7). Surprisingly, when the peptide target was changed to CVIM, 
AFPP was not able to compete with GGPP nearly as well. The product ratio from 
reactions containing 1:1 AFPP:GGPP in excess of the CVIM peptide was 8:1 
geranylgeranyl to anilinofarnesylated peptide. These results suggested that the identity 
of the ability of the analogue to compete with the natural substrate was completely 
dependent on the identity of the peptide target. We also found that the NAFPP analogue 
was not competitive with GGPP for the modification of either GGTaseI substrate 
peptide. 
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Figure 7-5 Peptide competition between CVIL and CVIM peptides with a GGTaseI 
catalyst 
Peptide competition between CVIL and CVIM with GGPP or AFPP as the isoprenoid 
donor. Each competition reaction was prepared with a) GGPP or b) AFPP at 6.7 µM and 
3 µM CVIL and CVIM peptide. Reactions were stopped using a solution of acetic acid 
and isopropanol then analyzed by HPLC. Note that the CVIL outcompetes CVIM with 
both GGPP and AFPP as the isoprenoid donor. 
 
A) GGPP + CVIL + CVIM 
 
 
    B) AFPP + CVIL + CVIM 
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Figure 7-6 GGTaseI proposed reaction mechanism 
Proposed mechanism for the GGTaseI reaction. The mechanism is split into two 
pathways path A representing GGPP stimulated product release and path B 
representing peptide stimulated product release.  E is the GGTaseI enzyme, E-GGPP is 
the GGTaseI•GGPP complex, E•GGPP•CaaX is the GGTaseI•GGPP•CaaX peptide 
complex, E-Product is the GGTaseI bound product complex, E-Product-GGPP is the 
GGTaseI bound to both GGPP and the reaction product, and E-CaaX is the peptide 
bound GGTaseI inhibitory complex, E-Product-CaaX is the peptide bound enzyme 
product complex  
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Figure 7-7 GGPP competition for GGTaseI depends on target peptide. 
Fluorescence HPLC chromatograms of competition reactions between AFPP and 
GGPP for the modification of a CVIL or CVIM peptide Each competition reaction was 
prepared with equimolar GGPP and AFPP at 6.7 µM each and 3 µM CVIL or CVIM 
peptide. Reactions were stopped using a solution of acetic acid and isopropanol then 
analyzed by HPLC. Note that AFPP competes much more effectively for CVIL than 
CVIM. 
 
A) AFPP + GGPP + CVIL 
 
B) AFPP + GGPP + CVIM 
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AFPP and NAFPP are recognized by anti-AG and anti-NAG antibodies 
AGPP as an unnatural probe for the modification of proteins has been extremely 
useful to determine the cellular prenylation status of proteins and for confirming the in 
vitro modification of proteins by FTase. In chapter 6, I described the development of 
antibodies specific for the anilinogeranyl and pNO2anilinogeranyl modification of 
proteins. The antibodies are specific for the aniline isoprenoid of the modified protein. In 
order to determine whether the antibodies could detect anilinofarnesylated or 
pNO2anilinofarnesylated proteins we prepared proteins modified with the AFPP 
analogs. Using a large amount of GGTaseI we were able to obtain bacterially expressed 
H-Ras proteins modified in vitro with the AFPP and NAFPP analogs. Western blot 
analysis of the reaction mixtures indicated that the analog was incorporated into the 
protein and that the antibodies specifically detected the anilinofarnesylated and 
pNO2anilinofarnesylated proteins. (Figure 7-8a) Interestingly, the polyclonal anti 
anilinogeranyl antibody was unable to detect the anilinofarnesylated protein. However, a 
mouse monoclonal antibody raised against the same hapten was able to detect the 
modified protein.  
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Figure 7-8 NAF and AF detection with anti-AG and anti-NAG antibodies 
a) Western blot analysis of anilinofarnesylated and pNO2-anilinofarnesylated Ras 
proteins with anti-AG and anti-NAG polyclonal antibodies and anti-AG monoclonal 
antibody detection (mAG). Equal protein was loaded into each well but the extent of 
modification was not analyzed b) Western blot analysis of H460 and MCF7 cells labeled 
with 30 µM AFOH overnight and lysed then run on SDS-PAGE gel. AG-Ras control is 
an in vitro AGPP modified Ras protein. Note that the mono-clonal but not the polyclonal 
anti-AG antibody can detect the AF modified Ras proteins and that some AF modified 
proteins appear to be labeled in the cell lysates. 
a) 
 
b) 
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Cell labeling with AFOH 
Since the anilinofarnesylated proteins could be detected by the anti-AG 
antibodies we were then interested in whether they could be used to label cellular 
proteins. To test this we treated cells H460 (lung cancer cell line) and MCF7 (breast 
cancer cell line) cells with the AFOH analog or DMSO, lysed the cells and analyzed for 
AFOH incorporation into proteins (Figure 7-8b). The anti-AG antibody did not appear to 
label a large number of proteins, but AFOH did appear to be incorporated into proteins 
with a molecular weight around that of the small molecular weight GTPases. Small 
molecular weight GTPases are most commonly geranylgeranylated which is consistent 
with these results. Low detection of labeled proteins may have been due to poor 
detection by the anti-AG antibody for AF modified proteins, or decreased ability of the 
AFOH due be converted to diphosphate and compete with endogenous GGPP.  
Discussion 
 In this chapter we have found that extending the isoprenoid chain of the FTase 
transferable analogues AGPP and pNO2-AGPP by one isoprenoid unit gives selective 
transferable substrates for the related enzyme GGTaseI. Surprisingly, we found that 
peptide substrate inhibition appeared to be significantly less potent for GGTaseI than 
has previously been observed with FTase, and with NAFPP as the isoprenoid donor 
peptide substrate inhibition was not detected. In addition, the selectivity of the enzyme 
for the different GGTaseI substrate peptides appeared to correlate more closely with 
kcat/Kmpeptide than was observed previously with FTase. These results suggested that 
peptide stimulated release in the GGTaseI mechanism is not nearly as effective as it is 
in the FTase reaction mechanism. 
 AFPP reactivity with CVIL and CVIM peptides were similar to GGPP while the 
addition of the pNO2 group to the aniline moiety resulted in a molecule that only reacted 
with the CVIL peptide. In addition, AFPP did not compete effectively with GGPP when 
the CVIM peptide was the isoprenylation target. The terminal isoprene of GGPP is 
known to interact with more of the surface of a peptide substrate than in the FTase 
reaction. Therefore, GGTaseI substrate analogues may be particularly sensitive to the 
structure of an incoming peptide. Changes in the structure of the isoprenoid result in 
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changes in the kinetics of peptide substrates reactivity and may provides an exogenous 
mechanism for altering the selectivity of the GGTaseI enzyme. 
Experimental 
General 
All RP-HPLC was performed on an Agilent 1100 HPLC system equipped with a 
microplate autosampler, diode array and fluorescence detector. The HPLC analysis was 
performed with a vydac C4 column with 0.01% TFA in water (A) and 0.01% TFA CH3CN 
(B) as the mobile phase. Peptides were purchased from peptidogenics and each 
contained a dansyl group N linked to a glycine linker followed by a C residue then a 
variable aaX sequence (VIL or VIM). Spectrofluorometric analyses were performed in a 
96-well flat bottom, non-binding surface, black polystyrene plate (Excitation wavelength, 
340 nm; emission wavelength 505 nm with a 10 nm cutoff). The plate reader was a 
SpectraMax GEMINI XPS fluorescence well-plate reader. Absorbance readings were 
determined using a Cary UV/Vis spectrophotometer.  
Steady-state peptide kinetics  
The kinetic constants Kmpeptide and kcat with GGPP, and the analogs with each 
peptide were determined in triplicate measurements using a continuous 
spectrofluorometric assay adapted for a 96-well plate. The following assay components 
were assembled in individual wells of a 96-well plate and incubated at 30° C for 20 
minutes: 180 µL of assay buffer (52 mM Tris-HCl, 12 mM MgCl2, 12 µM ZnCl2 pH 7.4), 
40 µL of detergent (0.125% n-dodecyl- β-D-maltoside in assay buffer), 40 µL of 
reducing agent (50 mM DTT in assay buffer) 20uL of GGPP or analog (200 µM in 25 
mM NH4HCO3) and 20 µL of N-dansyl-GCaaX peptide (variable concentration).  
Fluorescence was detected using a time based scan at 30° C for 120 minutes. The 
velocity of each reaction was determined by converting the rate of increase in 
fluorescence intensity units (FLU/s) to µM/s with equation 7-1.  
Equation  7-1: vi=(R·P)/(FMAX-FMIN) 
Where vi is the velocity of the reaction in µM/s. R is the rate of the reaction in FLU/s. P 
is equal to the concentration of modified product in µM (see below). FMAX is the 
fluorescence intensity of fully modified product. FMIN is the fluorescence of a reaction 
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mixture that contained 20 µL of assay buffer in the place of GGTaseI. Complete 
modification of peptides was assumed when fluorescence stabilized for more than 10 
minutes and was confirmed by RP-HPLC analysis of the reaction mixture. 
Final analysis peptide concentrations were chosen based on preliminary 
determination of the Kmpeptide with 0.5, 1, 5 and 10 µM dansyl-GCaaX concentrations 
(see below). The final analysis used 8 peptide concentrations which were: 1/6, 1/5, ¼, 
½, ¾, 1, 2, and 3 times the estimated Kmpeptide. The reaction was then initiated by the 
addition of 20 µL of GGTaseI (final 10  nM). Fluorescence enhancement was 
determined as described above. 
Complete modification of peptides was assumed when fluorescence stabilized for 
more than 10 minutes and was confirmed by RP-HPLC analysis of the reaction mixture. 
If the reactions that contained higher concentrations of peptides did not go to 
completion the Fmax-Fmin value was extrapolated using a linear plot of the Fmax-Fmin 
for each of the lower concentration reactions that did go to completion. Alternatively the 
extent of input peptide modified was determined by RP-HPLC analysis of the dansyl 
moiety peak absorbance corresponding to the unmodified and modified peptides. The 
percent of modified peptide relative to the total input peptide was used to calculate the 
concentration of product in the mixture. 
 The velocities of the reactions were plotted against the concentration of peptide 
and were fit to the Michaelis-Menten equation (Equation 7-2) to give the apparent kcat 
(appkcat) and Kmpeptide (appKmpeptide) values. Where et was the total enzyme 
concentration and [Pep] was the total input peptide. The kcat/Kmpeptide value was derived 
from a Lineweaver-Burke plot of the same data points.  
Equation 7-2: vi/et=(appkcat*[Pep])/(appKmpeptide+[Pep]) 
Peptide competition 
Competition reactions were prepared with the same components given for the 
kcat/Kmpeptide analysis except two peptides were added to the mixture at a single 
concentration. Peptides A and B were diluted to 45 µM in Tris-HCl buffer (pH=7.4) and 
the concentration checked by reading the Abs of the solution at 340 nm (εdansyl=4250 
Abs·M-1·cm-1). 20 µL of peptide A and 20 µL of peptide B were then added to reaction 
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mixtures as described above except only 160 µL of assay buffer was added.  Separate 
reactions were prepared as a standard with GGPP or the analogs and only one peptide 
as described above.  The reactions were then initiated with the addition of GGTaseI (10 
nM final concentration) and analyzed spectrofluorometrically. The reactions were 
stopped prior to consumption of more than 50% of either peptide by adding 20 µL of a 
stop solution (isopropyl alcohol and acetic acid 8:2). HPLC analysis was then performed 
with 100 µL of the reaction mixture loaded onto C18 column and eluted with a linear 
gradient of 0-20 min 50% B to 100% B at a flow rate of 1 mL/min. Peaks on the 340 nm 
trace chromatogram that corresponded to both the standard reactions and fluorescent 
peaks were then integrated. The ratios of products were calculated according to 
equation 7-3. 
Equation  7-3: (IAmod/ IAtot)/(IBmod /IBtot) 
Where IAmod is the integral of the modified peptide A, IAtot is the integral of the 
modified peptide A plus the unmodified peptide A, IBmod is the integral of the modified 
peptide B and IBtot was the integral of the modified peptide B plus the unmodified peptide 
B. Alternatively, the ratios were calculated using the integrals of the standard peptides 
fluorescence relative to competition product fluorescence giving less than a 5% 
difference in the calculated ratio.  
GGPP competition 
Competition reactions were prepared with the same components given for the 
kcat/Kmpeptide analysis except two isoprenoids were added to the mixture and the peptide 
concentration was held constant. GGPP and the analog were diluted to 200 µM in 25 
mM NH4HCO3. 20 µL of GGPP and 20 µL of analog were then added to a 260 µL 
solution of peptide, DTT and detergent in 52 mM Tris-HCl buffer pH=7.4 (final 
concentrations DTT=6.7 mM, DM=0.033%, Peptide=3µM, analog= 13 µM and  FPP=13 
µM). The concentration of peptide was determined by absorbance of the dansyl group 
and isoprenoid diphosphate concentrations were determined using absorbance and the 
extinction coefficient of N-Methyl-aniline (9120 Abs·M-1·cm-1) and N-methyl-p-NO2aniline 
(18,430 Abs·M-1·cm-1). The reactions were initiated with the addition of FTase and 
analyzed spectrofluorometrically (20 nM final GGTaseI concentration). The reactions 
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were stopped after 2 hours with a mixture of acetic acid and iPrOH. HPLC analysis was 
then performed with 100 µL of the reaction mixture loaded onto C18 column and eluted 
with a linear gradient of 0-20 min 50% B to 100% B at a flow rate of 1 mL/min. Peaks on 
the 340 nm trace chromatogram that corresponded to standard reaction fluorescent 
peaks were then integrated. The ratios of products were calculated using Ianalog/IFPP, 
where Ianalog is the integral of the peptide modified with the analog and IFPP is the integral 
of the peptide modified with FPP.  
GGTaseI Protein Substrate Modification 
3 µM recombinant bacterially expressed H-Ras [200] was incubated with 10 µM 
AFPP or NAFPP and  1µM FTase in 300 µL of Tris-HCl buffer (pH=7.4) The reactions 
were incubated for 30 min at 37 º C, boiled with SDS and PAGE performed using 10 µL 
of the reaction mixtures. 
AFOH incorporation into unblocked cells 
Plates were coated with poly-L-Lysine and seeded with in Dulbecco’s modified 
Eagle’s medium with 5% fetal bovine serum. The cells were then treated with DMSO as 
a vehicle, or 30 µM AFOH was added and incubated at 37° C overnight. Medium was 
then removed and cells were extracted into 500 µL of RIPA buffer containing Protease 
Inhibitor cocktail I (calbiochem). The supernatant was removed and used for western 
blotting. 
Western Blot Analysis 
Protein concentration was determined using a Bradford reagent kit (Pierce) with 
1:100 dilutions of the cell lysates. The proteins from the GGTaseI reaction mixtures or 
cell lysates were then separated using 12% SDS-polyacrylamide gels followed by 
transfer to nitrocellulose membranes. The membranes were incubated in blocking buffer 
PBS Casein and Tween buffer for one hour at room temperature, after which the 
following sequential steps were used: incubation with anti-AG or anti-NAG to 1:10,000 
in PCT for one hour; 3 X 15 minute washes with vigorous shaking in PBS Tween buffer; 
incubation at room temperature one hour with goat anti-rabbit horseradish peroxidase-
conjugated secondary antibody (Zymed) at a dilution of 1:20,000 in PCT buffer; and four 
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15 minute washes with PT buffer. The membranes were then subjected to enhanced 
chemiluminescence detection by incubation in 20 mL of detection buffer (Pierce Super 
Signal) for one minute. 
Credits: 
Post-doctoral researcher Zhongwen Wang was responsible for the synthesis of AFPP 
and NAFPP 
Post-doctoral researcher Thangiah Subramanian was responsible for finding that 
ethereal solvents improved α,β-unsaturated aldehyde formation 
Post-doctoral researcher David Dremmer in the department of pharmacy practice and 
science laboratory of Val Adams was responsible for cell treatments with AFOH. 
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CHAPTER 8 SUMMARY, DISCUSSION AND FUTURE DIRECTIONS 
 
The results presented in this dissertation describe the development of and 
biochemical analysis of lipid analogs of isoprenoid diphosphate prenyltransferase 
substrates. In chapter 2, I described the synthesis of a small library and a few 
exploratory FPP analogs and the finding that FTase accepts a wide variety of ω-
isoprene substituted analogs as substrates, and that many of these substrates disrupt 
the function of oncogenic H-Ras in a whole cell model system. The structural 
parameters of the analogs that affected the ability of the analog to transfer to protein 
targets did not appear to be the same structural parameters important for the function of 
the lipid group on the protein target. The results strongly support the hypothesis that the 
relationship of lipid structure of FTase transfer is orthogonal to that of lipid structure on 
function. Specifically, the hydrophobicity of the analog did not appear to affect analog 
transferability, but was the central property important for the function of the lipid.  
The major limitation with using the isoprenoid analogs was the fact that there 
were no efficient methods to observe cellular prenylation of proteins with the analogs. It 
was possible that the highly charged diphosphate anion of the lipid diphosphate 
molecules would prevent cellular uptake of the farnesyl diphosphate analogs. The 
Xenopus studies avoided this problem because the analogs were directly injected into 
the relatively large oocyte cells. However, such microinjection would not be feasible for 
cell culture studies or in vivo studies with the analogs. In chapter 6, I have described the 
development of antibodies directed towards the modification of proteins with two of the 
unnatural prenyl lipid analogs. Utilizing these antibodies we found that the parent 
alcohol of AGPP could traverse a cell membrane and apparently was endogenous 
converted to diphosphate and utilized by cellular FTase. AGPP was even competitive 
with endogenous pools of FPP for the modification of proteins. In chapter 4 I described 
the factors of the analogs affecting FPP competitiveness and found that numerous 
transferable analogs were even more competitive that AGPP in vitro. It would be 
interesting to see if this was the case in whole cells. It would be possible to test the 
competitiveness of a number of the analogs in cells using the reagents developed for 
this dissertation since numerous analogs cross-react with the anti-anilinogeranyl 
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antibodies. In addition, the antibodies could be very useful for the study of protein 
prenylation in multi-cellular organisms and potentially provide a method for studying the 
affect of FTIs in such organisms. Collaborators in the laboratory of Professor Daret St. 
Clair at the University of Kentucky have treated mice with the anilinogeraniol and 
pNO2anilinogeraniol compounds. However, western blot analysis of tissue samples from 
these animals have been inconclusive. Importantly, we are also developing methods to 
utilize the anti-anilinogeranyl antibodies to isolate prenylated proteins from cell lysates. 
The anti-anilinogeranyl antibodies have proved useful for our laboratory as well as a 
number of others around the world. Dr. Carol Fierke’s laboratory at the University of 
Michigan has made use of them for the purposes of studying the in vitro prenylation of 
unusual Ca1a2X containing proteins. The laboratory of Dr. Michael Morgan at Hanover 
Medical School in Germany has also made use of these antibodies in studying the 
targets of FTIs in hematologic malignancies. 
Chapters 3 through 5 are extremely important for understanding the mechanism 
of the FTase enzyme and how the kinetic mechanism can be exploited with analogs of 
the natural substrate of FTase. In chapter 3, I describe the kinetic mechanism by which 
FTase chooses between different Ca1a2X sequence targets. We found that un-
farnesylated Ca1a2X peptide binding to the E•product complex had a major affect on the 
selectivity of the enzyme for different Ca1a2X substrates. One of the most important 
results of this chapter with regards to future studies was the fact that the selectivity of 
the enzyme could not be predicted by the classic Michaelis-Menten “selectivity 
constant” kcat/Kmpeptide. Instead FTase selectivity was much more dependent on the 
Kmpeptide alone. This result gives a key parameter of the steady-state FTase reaction 
that is central to predicting the Ca a X1 2  selectivity of the enzyme with different isoprenoid 
donors. In addition, I described the ability of the analog to alter the Ca a X1 2  selectivity of 
the FTase enzyme. Later in chapter 5, I described how we could take advantage of the 
lipid interaction between the isoprenoid and peptide target of the FTase reaction to 
create Ca a X1 2  selective analogs that converted FTase from a relatively promiscuous 
enzyme to one with much more limited target selectivity. The next logical extension of 
this work would be to determine if these factors were equally important in a whole cell 
system. Unfortunately, the antibodies development thus far cannot detect the 
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modification of proteins with the selective analogs. However, the methods used for 
developing the anti-anilinogeranyl antibodies could easily be adapted to other lipid 
modifications. 
Taken together the results I have described in this dissertation indicate that it will 
be possible to develop selective, FPP or GGPP competitive, prenyl function inhibitors of 
proteins. Such prenyl function inhibitors would be a major step forward for the 
development of new therapeutics for diseases ranging from cancer to hepatitis delta 
infections. Selectivity would allow specific targeting of only certain proteins for inhibition 
of function and likely greatly reduce toxicity associated with the use of a FTI. Selectivity 
would be especially important for diseases like hepatitis delta infection. The large 
antigen of the hepatitis delta protein that must be farnesylated for the virus to function 
has a highly unusual C-terminal Ca a X1 2  sequence, CRPQ. Analogs designed to only 
target that particular sequence would likely not affect the prenylation of any proteins 
other than the hepatitis delta protein. In conclusion, there is still a great deal of work that 
needs to be done to reach the development of Ca a X1 2  protein selective prenyl function 
inhibitors. The work in this dissertation however lays significant ground work for 
understanding the properties important for such an inhibitor and the properties that are 
important for Ca a X1 2  selectivity. This work also describes the development of an 
important novel reagent that could be used to study prenylation in cells and possibly 
large organisms.  
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